| Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial 2024 · Marine n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses | 1 g | 1936 days | 12,933 |
| Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis 2007 · EPA group · Japanese hypercholesterolaemic patients with total cholesterol of 6.5 mmol/L or greater | 1.8 g | 5 years | 9,326 |
| Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial 2025 · icosapent ethyl group · Adults aged 45 years or older with cardiovascular disease, or aged 50 years or older with diabetes and at least one cardiovascular risk factor; statin-treated with elevated triglycerides and high cardiovascular risk | 4 g | — | 4,089 |
| Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial 2008 · n-3 PUFA group · Patients with chronic heart failure, New York Heart Association class II–IV | 1 g | 1424 days | 3,494 |
| Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT 2024 · icosapent ethyl group · Adults with established atherosclerotic cardiovascular disease and elevated triglycerides, receiving stable statin therapy | 4 g | 1752 days | 2,892 |
| Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 1999 · n-3 PUFA · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified | 1 g | 1278 days | 2,836 |
| Identifying women who may benefit from higher dose omega-3 supplementation during pregnancy to reduce their risk of prematurity: exploratory analyses from the ORIP trial 2023 · n-3 arm · Pregnant women with singleton pregnancies; age range and condition other than pregnancy not specified | 900 mg | — | 2,654 |
| Predictors of compliance with higher dose omega-3 fatty acid supplementation during pregnancy and implications for the risk of prematurity: exploratory analysis of the ORIP randomised trial 2023 · intervention group · Pregnant women enrolled before 20 weeks’ gestation; analysis restricted to singleton pregnancies with known gestational age at birth | 900 mg | — | 2,654 |
| Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI 2022 · Icosapent ethyl · Adults with prior percutaneous coronary intervention, elevated triglycerides despite statin therapy, and established cardiovascular disease or diabetes with additional risk factors; at least 45 years old with established cardiovascular disease or at least 50 years old with diabetes | 4 g | 1752 days | 1,737 |
| Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States 2024 · icosapent ethyl (IPE) · Adults with elevated triglycerides and controlled LDL-C who had cardiovascular disease or diabetes plus additional cardiovascular risk factors; statin-stabilized | 4 g | 1789 days | 1,548 |
| Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG 2021 · icosapent ethyl · Statin-treated patients with a history of coronary artery bypass grafting, controlled low-density lipoprotein cholesterol, and mild to moderate hypertriglyceridemia | 4 g | 1752 days | 897 |
| Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking 2023 · Icosapent ethyl (current smokers) · Adults with hypertriglyceridaemia and high cardiovascular risk receiving statin treatment; current cigarette smokers | 4 g | 1789 days | 628 |
| Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial 2022 · EPA/DHA · Elderly patients with a recent acute myocardial infarction | 1.8 g | 2 years | 438 |
| Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth 2014 · omega-3 supplements · Pregnant women with a singleton gestation and a prior spontaneous preterm birth | 2 g | — | 434 |
| Atopic and non-atopic effects of fish oil supplementation during pregnancy 2023 · n-3 LCPUFA · Pregnant women enrolled at pregnancy week 24; age and specific health conditions not stated | 2.4 g | — | 368 |
| Effect of six month's treatment with omega-3 acid ethyl esters on long-term outcomes after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial 2024 · O3-FA · Patients with acute myocardial infarction; age and sex range not specified | 4 g | 26 weeks | 180 |
| Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes 2026 · low-dose fish oil · Adults aged 40–75 with type 2 diabetes | 1.5 g | 426 days | 140 |
| Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes 2026 · high-dose fish oil · Adults aged 40–75 with type 2 diabetes | 3 g | 426 days | 137 |
| Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial 2023 · Aspirin & EPA · Adults aged 55–73 years with high-risk colorectal polyp findings at screening colonoscopy | 2 g | 1 year | 136 |
| Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial 2024 · Aspirin and EPA · Predominantly White European adults, median age about 65 years, mostly men, at high risk of colorectal polyps after removal of multiple sporadic polyps | 2 g | 1 year | 131 |
| Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial 2023 · EPA only · Adults aged 55–73 years with high-risk colorectal polyp findings at screening colonoscopy | 2 g | 1 year | 126 |
| Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial 2024 · EPA only · Predominantly White European adults, median age about 65 years, mostly men, at high risk of colorectal polyps after removal of multiple sporadic polyps | 2 g | 1 year | 123 |
| Omega-3 polyunsaturated Fatty acids reduce the incidence of postoperative atrial fibrillation in patients with history of prior myocardial infarction undergoing isolated coronary artery bypass grafting 2014 · omega-3 PUFA treatment group · Patients with recent myocardial infarction (within 3 months) undergoing isolated coronary artery bypass grafting | 2 g | — | 99 |
| N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing "on-pump" coronary artery bypass graft surgery 2011 · n-3 polyunsaturated fatty acids 2 g/day group · Patients undergoing coronary artery bypass graft surgery; age and sex not specified; included on-pump and off-pump surgery | 2 g | — | 96 |
| Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion 2012 · omega-3 group · Patients with persistent atrial fibrillation lasting more than 1 month | 6 g | 1 year | 91 |
| A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study 2014 · EPA group · Patients with subarachnoid hemorrhage who underwent surgical clipping within 72 hours of onset; age and sex not specified | 2.7 g | 30 days | 81 |
| N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial 2005 · PUFAs 2 g/day · Adults undergoing elective coronary artery bypass graft surgery; mean age 66.2 years; 11 female; patients with coronary artery disease requiring CABG | 2 g | — | 79 |
| Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study 2014 · EPA group · Patients with acute myocardial infarction; age range and sex not reported | 1.8 g | 30 days | 57 |
| Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial 2010 · omega-3 group · Adolescents and young adults aged 13 to 25 years at ultra-high risk of psychotic disorder with subthreshold psychosis | 1.2 g | 12 weeks | 41 |
| Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial 2012 · omega-3 supplemented group · Women aged 30–70 with node-positive breast cancer receiving paclitaxel chemotherapy | 1.92 g | 93 days | 30 |
| Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis 2010 · EPA-FFA · Patients with familial adenomatous polyposis undergoing endoscopic surveillance of the retained rectum after colectomy | 2 g | 26 weeks | 28 |
| The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial 2021 · intervention group · Critically ill adults aged 35–85 with COVID-19 admitted to ICU and indicated for enteral nutrition | 1 g | 2 weeks | 28 |
| Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study 1995 · 9 g EPA (low-dose EPA) · Cadaveric renal transplant recipients receiving cyclosporine A, prednisone and azathioprine; age and sex not reported | 9 g | 26 weeks | 22 |
| Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study 2005 · Group I · Children aged 5–16 years with Crohn's disease in remission | 3 g | 1 year | 18 |
| Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study 1995 · 18 g EPA (high-dose EPA) · Cadaveric renal transplant recipients receiving cyclosporine A, prednisone and azathioprine; age and sex not reported | 18 g | 26 weeks | 18 |
| Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial 2015 · N-3 group · Adults aged 25–72 with biopsy-confirmed non-alcoholic steatohepatitis (NASH) | 3 g | 1 year | 17 |
| Omega-3 Intake Improves Clinical Pregnancy Rate in Polycystic Ovary Syndrome Patients: A Double-Blind, Randomized Study 2023 · omega-3 supplements · Women with PCOS-related oligo/anovulation and infertility; mean age 33.9 years. The subgroup analysis included overweight/obese women with BMI 25–35. | 1.8 g | — | 17 |
| Oral eicosapentaenoic acid for complications of bone marrow transplantation 2001 · EPA group · Patients undergoing bone marrow transplantation with unrelated donors | 1.8 g | 201 days | 7 |
| Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol 2001 · n-3 group · Adults with acute myocardial infarction | 4 g | 2 years | — |
| Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione 2002 · n-3 PUFAs · Patients who survived a recent myocardial infarction (<3 months) | 1 g | — | — |
| Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease 2009 · EPA group · Patients with established coronary artery disease and total cholesterol ≥250 mg/dL; age and sex not reported | 1.8 g | 1679 days | — |
| A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk 2010 · n-3 PUFA supplementation without diet counseling · Norwegian men aged 64–76 at high cardiovascular risk; 72% of the trial population had no overt cardiovascular disease | 2.4 g | 3 years | — |
| A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk 2010 · n-3 PUFA supplementation with diet counseling · Norwegian men aged 64–76 at high cardiovascular risk; 72% of the trial population had no overt cardiovascular disease | 2.4 g | 3 years | — |
| A low-fat high-carbohydrate diet supplemented with long-chain n-3 PUFA reduces the risk of the metabolic syndrome 2011 · LFHCC n-3 · Adults with MetS risk criteria; age and sex not specified | 1.24 g | 12 weeks | — |
| n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study 2011 · n-3 PUFAs · Patients with persistent atrial fibrillation and at least one relapse after cardioversion, treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor; age and sex not stated | 2 g | — | — |
| Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction 2012 · EPA-DHA · Adults with a history of myocardial infarction; statin users and non-users | 400 mg | — | — |
| Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use 2015 · FO group · DMARD-naïve patients with rheumatoid arthritis of less than 12 months' duration | 5.5 g | — | — |
| Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use 2015 · control group · DMARD-naïve patients with rheumatoid arthritis of less than 12 months' duration | 400 mg | — | — |
| The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients - A pilot study 2016 · omega-3 fish oil supplementation · ΔF508-homozygous patients with cystic fibrosis undergoing chronic azithromycin | 60 mg/kg | 1 year | — |
| Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study 2017 · EPA group · Patients with acute coronary syndrome; age and sex not specified | 1.8 g | 1 year | — |
| The Efficacy of Omega-3 Supplement on Prevention of Retinopathy of Prematurity in Premature Infants: A Randomized Double-blinded Controlled trial 2018 · intervention group · Premature infants with gestational age under 32 weeks and birth weight under 1500 g, at risk of retinopathy of prematurity | 300 mg | — | — |
| Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia 2019 · icosapent ethyl group · Patients with established cardiovascular disease or diabetes and other cardiovascular risk factors, elevated triglycerides, and receiving statin therapy | 4 g | 1789 days | — |
| Fish Oil Supplementation in Pregnancy Increases Gestational Age, Size for Gestational Age, and Birth Weight in Infants: A Randomized Controlled Trial 2019 · n-3 LCPUFA group · Pregnant women recruited at 22–26 weeks of gestation | 2.4 g | — | — |
| Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT 2019 · icosapent ethyl · Statin-treated patients with elevated triglycerides and a history of atherosclerosis or diabetes | 4 g | 1789 days | — |
| Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder 2019 · EPA group · Adults with major depressive disorder | 3 g | 12 weeks | — |
| REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States 2020 · icosapent ethyl · Adults aged 45 years or older with established cardiovascular disease, or adults aged 50 years or older with diabetes and at least one additional cardiovascular risk factor; statin-treated with elevated triglycerides | 4 g | 1789 days | — |
| Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure 2020 · n-3 group · older adults; mean age 67.1 years, 50.6% women; no condition specified | 1 g | 1935 days | — |
| Omega-3 fatty acids reduce post-operative risk of deep vein thrombosis and pulmonary embolism after surgery for elderly patients with proximal femoral fractures: a randomized placebo-controlled, double-blind clinical trial 2020 · omega-3 fatty acids · elderly patients over 60 years of age with proximal femoral fractures after surgery | 1 g | 30 days | — |
| Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses 2021 · icosapent ethyl · Statin-treated adults with elevated triglycerides and high cardiovascular risk, with established cardiovascular disease or diabetes plus additional cardiovascular risk factors | 4 g | 1789 days | — |
| Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial 2020 · Marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry | 1 g | 1937 days | — |
| Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study 2021 · EPA + DHA group · Adults with first-episode schizophrenia | 2.2 g | 26 weeks | — |
| Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL 2021 · Icosapent ethyl · Adults aged 50 years or older with established cardiovascular disease, or with medically treated type 1 or type 2 diabetes and at least one other major cardiovascular risk factor; on statin therapy with elevated triglycerides | 4 g | 1789 days | — |
| Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial 2022 · Marine omega-3 supplementation (with or without vitamin D supplementation; exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years | 1 g | 3 years | — |
| Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization 2022 · marine omega-3 fatty acids group · Adults enrolled in VITAL; mean age 67.1 years, 50.6% women, with and without type 2 diabetes | 1 g | 1935 days | — |
| Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction 2022 · icosapent ethyl (IPE) · Statin-treated patients with prior myocardial infarction, controlled low-density lipoprotein cholesterol, and moderately elevated triglycerides | 4 g | — | — |
| Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT 2023 · icosapent ethyl (IPE) · Statin-treated adults with controlled LDL cholesterol, elevated triglycerides, and cardiovascular risk, with or without a history of atrial fibrillation | 4 g | 1789 days | — |
| Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': A secondary analysis from the OMEMI trial 2023 · n-3 PUFA group · Adults aged 70–82 with a recent myocardial infarction | 1.8 g | 2 years | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes 2023 · n−3 fatty acid supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population | 1 g | 1935 days | — |
| Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial 2024 · icosapent ethyl (IPE) · Statin-treated patients with recent acute coronary syndrome (MI or unstable angina within 12 months before randomization) and controlled LDL cholesterol and moderately elevated triglycerides; age and sex not specified | 4 g | 1734 days | — |
| Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl 2024 · icosapent ethyl (IPE) · Participants receiving statin therapy with established cardiovascular disease, or aged 50 years or older with diabetes and at least one additional cardiovascular risk factor; fasting triglycerides 1.69 to 5.63 mmol/L and LDL cholesterol 1.06 to 2.59 mmol/L | 4 g | — | — |
| A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events 2025 · ω-3 fatty acid supplementation · Older adults in the United States enrolled in a primary-prevention trial; age range and sex distribution are not stated in the abstract. | 840 mg | 1935 days | — |
| [n-3 polyunsaturated fatty acids, heart rate variability and ventricular arrhythmias in post-AMI-patients. A clinical controlled trial] 1997 · n-3 PUFA group · Patients with a previous myocardial infarction; age and sex not reported | 5.2 g | 12 weeks | — |
| Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL 2025 · omega-3 FA supplementation arm · US men aged 50 years or older and women aged 55 years or older in a primary-prevention trial | 840 mg | 5 years | 12,933 |
| Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 1999 · n-3 PUFA and vitamin E · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified | 1 g | 1278 days | 2,830 |
| The impact of pre- and postnatal exposures on allergy related diseases in childhood: a controlled multicentre intervention study in primary health care 2013 · intervention cohort · Pregnant women and their children in the general population of Trondheim; no age range or sex restriction stated | 1.2 g | — | 1,374 |
| Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis 2026 · fish-oil group · Adults receiving maintenance hemodialysis | 4 g | 1278 days | 610 |
| The effect of omega-3 supplementation on pregnancy outcomes by smoking status 2017 · omega-3 supplementation · Pregnant women enrolled at 16 0/7 to 21 6/7 weeks of gestation with a singleton pregnancy and a prior spontaneous preterm delivery; included smokers and nonsmokers | 2 g | — | 434 |
| Fish oil intake compared with olive oil intake in late pregnancy and asthma in the offspring: 16 y of registry-based follow-up from a randomized controlled trial 2008 · fish oil · Women with normal pregnancies, recruited around gestation week 30 | 2.7 g | — | 266 |
| n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes 2011 · EPA-DHA · Adults aged 60–80 with diabetes and a previous myocardial infarction | 400 mg | 1217 days | 262 |
| n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes 2011 · EPA-DHA plus ALA · Adults aged 60–80 with diabetes and a previous myocardial infarction | 400 mg | 1217 days | 245 |
| CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study 2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye | 270 mg | 3 years | 127 |
| Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT) 2002 · omega-3 FA group · Patients undergoing balloon-only percutaneous transluminal coronary angioplasty (PTCA) | 3 g | 240 days | 125 |
| A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement 2013 · supplemented group · Patients scheduled for on-pump cardiac surgery; age and sex not specified | 2 g | — | 103 |
| Effect of dietary fish oil on atrial fibrillation after cardiac surgery 2011 · fish oil group · Adults undergoing CABG or valve cardiac surgery; age and sex not reported | 4.6 g | 3 weeks | 97 |
| Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation 2011 · ω-3-supplemented group · Pregnant women at risk of having an allergic infant, starting in the 25th gestational week and continuing through breastfeeding | 1.6 g | — | 54 |
| Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy 2009 · omega-3 group · Pregnant and breastfeeding women with an allergy themselves or a husband or previous child with allergies | 1.6 g | — | 52 |
| Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study 2015 · omega-3 PUFA group · People aged 13–25 years at ultrahigh risk for psychosis | 1.18 g | 12 weeks | 41 |
| Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease 1996 · fish-oil group · Patients with Crohn's disease in remission at high risk of relapse; age and sex not specified | 2.7 g | 1 year | 39 |
| Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial 1998 · fish oil · Adults with generalized solid tumors, including well-nourished and malnourished patients | 18 g | — | 30 |
| Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial 2020 · juice-based TMN · Patients with non-small-cell lung cancer receiving first-line chemotherapy, with weight loss or low BMI | 2 g | 12 weeks | 26 |
| Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo 2021 · ω-3-FA · Peri- and postmenopausal women younger than 70 with BMI ≥28 and increased breast-cancer risk | 2.2 g | 1 year | 23 |
| The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial 2025 · n-3 PUFAs group · Patients with late-life depression who were euthymic at enrollment; ages and sex not reported | 1.2 g | 52 weeks | 19 |
| Perioperative immunonutrition and outcomes in head and neck cancer surgery - a randomized clinical trial: Effects of perioperative immunonutrition in patients with head and neck cancer 2026 · IN (intervention group) · Adults aged 18–75 with newly diagnosed head and neck cancer undergoing first-line surgery; predominantly men; body-weight loss was common | 3 g | 15 days | 17 |
| Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration 1992 · fish oil · Healthy Danish women in week 30 of pregnancy | 2.7 g | — | — |
| Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction 2012 · EPA-DHA plus ALA · Adults with a history of myocardial infarction; statin users and non-users | 400 mg | — | — |
| Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial 2013 · 1 capsule daily, ages 2–4 years · Children aged 2–4 years with homozygous sickle cell disease | 317 mg | 1 year | — |
| Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial 2013 · 2 capsules daily, ages 5–10 years · Children aged 5–10 years with homozygous sickle cell disease | 634 mg | 1 year | — |
| Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial 2013 · 3 capsules daily, ages 11–16 years · Adolescents aged 11–16 years with homozygous sickle cell disease | 833 mg | 1 year | — |
| Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial 2013 · 4 capsules daily, ages 17 years and older · People aged 17 years or older with homozygous sickle cell disease | 1.27 g | 1 year | — |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 650 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 1 g | 1789 days | — |
| Maternal obesity, fish intake, and recurrent spontaneous preterm birth 2019 · study drug · Pregnant women recruited at 16–22.9 weeks’ gestation with one or more prior spontaneous preterm births | 2 g | — | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 840 mg | 1936 days | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 840 mg | 1936 days | — |
| Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder 2019 · EPA + DHA group · Adults with major depressive disorder | 1.5 g | 12 weeks | — |
| No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 2019 · Omega-3 fatty acids addition · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye | 1 g | 5 years | — |
| Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial 2020 · Vitamin D3 and marine omega-3 fatty acids active · Men aged 50 years or older and women aged 55 years or older without cancer or cardiovascular disease at study entry | 1 g | 1937 days | — |
| Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial 2022 · Vitamin D plus marine omega-3 supplementation (exercise assignment varied) · Community-dwelling adults aged 70 years and older, generally healthy and active, without major health events in the prior 5 years | 1 g | 3 years | — |
| Effect of a collagen-enriched beverage with or without omega-3 fatty acids on wound healing, metabolic biomarkers, and adipokines in patients with major burns 2023 · collagen plus omega-3 · Patients with 20–45% deep partial- or full-thickness burns | 3 g | 4 weeks | — |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + placebo · Women in early pregnancy | 220 mg | — | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes 2023 · combination supplementation group · Men aged 50 years or older and women aged 55 years or older, free of known cardiovascular disease or cancer, from the general US population | 1 g | 1935 days | — |
| Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial 2024 · Vitamin D and n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses | 1 g | 1936 days | — |
| Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial 2025 · Marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults | 840 mg | 1935 days | — |
| Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial 2025 · Vitamin D plus marine omega-3 · Men aged 50 years or older and women aged 55 years or older, without type 2 diabetes at baseline; older US adults | 840 mg | 1935 days | — |
| A randomized clinical trial of omega-3 fatty acid and vitamin D supplementation on electrocardiographic risk profiles 2023 · EPA/DHA active treatment · Men aged 50 years or older and women aged 55 years or older in the VITAL ECG substudy; no specific disease required | 1 g | 2 years | 457 |
| Effect of fish oil supplementation in pregnancy on bone, lean, and fat mass at six years: randomised clinical trial 2018 · n-3 LCPUFA supplementation group · Pregnant women, randomised at pregnancy week 24; offspring followed through age 6 years | 2.4 g | — | 368 |
| Effects of food supplementation on cognitive function, cerebral blood flow, and nutritional status in young children at risk of undernutrition: randomized controlled trial 2020 · NEWSUP · Children aged 15 months to 7 years living in rural Guinea-Bissau and considered at risk of undernutrition; both sexes | 534 mg | 23 weeks | 359 |
| The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: A secondary analysis of a randomized clinical trial 2018 · Lovaza · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk criteria | 3.36 g | 1 year | 147 |
| Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927 2015 · O3-FA arm · Women with early-stage breast cancer receiving an aromatase inhibitor and with a worst joint pain/stiffness score of at least 5/10 | 3.3 g | 24 weeks | 122 |
| Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer 2020 · ω-3 PUFAs group · Adults with stage III or IV colon cancer receiving oxaliplatin and capecitabine chemotherapy | 1.92 g | 22 weeks | 98 |
| Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial 2003 · Experimental (E) · Patients with advanced pancreatic cancer and cachexia; age and sex not reported | 2.2 g | 8 weeks | 95 |
| Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia 2008 · Group A · Patients with nonalcoholic fatty liver disease associated with hyperlipidemia; age and sex not reported | 6 g | 24 weeks | 72 |
| The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial 2016 · n-3 PUFA group · Adults older than 18 years with psoriatic arthritis | 3 g | 24 weeks | 72 |
| Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial 2021 · n-3 PUFA group · Adults with psoriatic arthritis; age and sex ranges not specified | 3 g | 24 weeks | 71 |
| Evaluation of the effect of omega-3 fatty acids in the treatment of premenstrual syndrome: "a pilot trial" 2013 · omega-3 group (group A) · Women with premenstrual syndrome (PMS); age range not stated | 2 g | 90 days | 70 |
| The comparison of the effect of soybean and fish oil on supplementation on menopausal symptoms in postmenopausal women: A randomized, double-blind, placebo-controlled trial 2020 · Omega-rex · Postmenopausal women; age range and specific condition not reported | 1 g | 12 weeks | 60 |
| High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels 2019 · n-3 PUFAs (EPA) group · Children and adolescents aged 6–18 years with ADHD; participants were stratified by baseline EPA level, including a low-EPA subgroup. | 1.2 g | 12 weeks | 48 |
| Efficacy of omega 3 fatty acid as an adjunct in the management of chronic periodontitis: A randomized controlled trial 2020 · test group · Patients with chronic moderate periodontitis; age and sex not reported | 1 g | 30 days | 48 |
| Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome 2009 · EPA-treated group · Obese Japanese subjects with metabolic syndrome; age and sex not reported | 1.8 g | 90 days | 46 |
| Omega-3 fatty acids reduce depressive symptoms only among the socially stressed: A corollary of the social signal transduction theory of depression 2023 · 1.25 grams per day (g/d) omega-3 supplementation group · Healthy, sedentary, generally overweight and obese middle-aged and older adults | 1.25 g | 120 days | 46 |
| Omega-3 fatty acids reduce depressive symptoms only among the socially stressed: A corollary of the social signal transduction theory of depression 2023 · 2.5 g/d omega-3 supplementation group · Healthy, sedentary, generally overweight and obese middle-aged and older adults | 2.5 g | 120 days | 46 |
| Efficacy of omega-3 in the treatment of polycystic ovary syndrome 2013 · omega-3 · Non-obese women with polycystic ovary syndrome | 1.5 g | 26 weeks | 45 |
| Effect of omega-3 and vitamin D co-supplementation on psychological distress in reproductive-aged women with pre-diabetes and hypovitaminosis D: A randomized controlled trial 2021 · Group 2 Omega-3 group · Women aged 15–50 with pre-diabetes and hypovitaminosis D | 2 g | 8 weeks | 42 |
| Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease 2014 · EPA group · Adults with established coronary artery disease, impaired flow-mediated dilation, and LDL-C below 100 mg/dl while receiving statin treatment | 1.8 g | 158 days | 40 |
| Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients: A cross-over randomized clinical trial 2022 · Omega-3 treatment period · Hemodialysis patients with pruritus; age and sex not reported | 3 g | 4 weeks | 40 |
| The Role of Omega-3 Polyunsaturated Fatty Acids in Patients with Metabolic Syndrome and Endothelial Dysfunction 2024 · n-3 PUFAs group · Adults aged 31–81 years, both sexes, with metabolic syndrome | 2.4 g | 90 days | 40 |
| Untitled 2012 · A1 (Al) · Men aged 52.5 ± 1.3 years with Q-wave myocardial infarction and I–III grade ventricular heart rhythm disturbances | 1 g | 26 weeks | 39 |
| Omega-3 versus isoflavones in the control of vasomotor symptoms in postmenopausal women 2017 · omega-3 · Healthy postmenopausal women aged 45–65 | 850 mg | 16 weeks | 38 |
| A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia 2016 · n-3 PUFA group · Patients aged 16–35 with first-episode schizophrenia | 2.2 g | 26 weeks | 36 |
| Effect of Eicosapentaenoic Acid on Body Composition and Inflammation Markers in Patients with Head and Neck Squamous Cell Cancer from a Public Hospital in Mexico 2018 · EPA group · Patients with head and neck squamous cell cancer; age and sex not reported | 2 g | 6 weeks | 32 |
| Untitled 2012 · A2 · Men aged 52.5 ± 1.3 years with Q-wave myocardial infarction and IV–V grade ventricular heart rhythm disturbances | 1 g | 26 weeks | 31 |
| Effect of oral omega-3 Fatty Acid supplementation on contrast sensitivity in patients with moderate meibomian gland dysfunction: a prospective placebo-controlled study 2015 · Treatment group · Patients with moderate meibomian gland dysfunction; age and sex not reported | 1.2 g | 12 weeks | 30 |
| Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients 2016 · omega-3 fatty acid + alpha-tocopherol placebo · Chronic hemodialysis patients; age and sex not specified | 1.25 g | 12 weeks | 30 |
| Oral Omega-3 Fatty Acid Supplementation for Laser In Situ Keratomileusis-Associated Dry Eye 2017 · treatment group · Patients undergoing LASIK | 1.2 g | 13 weeks | 30 |
| Clinical and metabolic response to flaxseed oil omega-3 fatty acids supplementation in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial 2017 · omega-3 fatty acids supplementation · Adults aged 40–85 with grade 3 diabetic foot ulcer | 2 g | 12 weeks | 30 |
| Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia 2022 · group I · Children with newly diagnosed acute lymphoblastic leukemia receiving chemotherapy including doxorubicin | 1 g | 26 weeks | 30 |
| A Randomized Trial of the Effects of Dietary n3-PUFAs on Skeletal Muscle Function and Acute Exercise Response in Healthy Older Adults 2022 · n3-PUFA group · Adults aged 65–85 years, male and female, independently living and without a known chronic debilitating disease | 3.9 g | 26 weeks | 30 |
| Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial 2017 · MPL group · Adults aged 18 years or older with pancreatic carcinoma and tumor-associated weight loss of at least 5% since diagnosis | 300 mg | 6 weeks | 29 |
| The Effect of Omega-3 Fatty Acids on Thromboxane, Brain-Derived Neurotrophic Factor, Homocysteine, and Vitamin D in Depressive Children and Adolescents: Randomized Controlled Trial 2021 · Om3 group · Children and adolescents with depressive disorder or mixed anxiety and depressive disorder, alongside standard antidepressant therapy | 2.4 g | 12 weeks | 29 |
| Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial 2009 · EPA-enriched enteral nutrition · Patients undergoing esophagectomy for esophageal cancer; age and sex not stated | 2.2 g | 26 days | 28 |
| The effect of omega-3 fatty acids supplementation on social and behavioral disorders of children with autism: a randomized clinical trial 2021 · intervention group · Children aged 5–15 years with moderate or severe autism spectrum disorder | 1 g | 8 weeks | 28 |
| Effects of Omega-3 PUFAs on lipid profiles and antioxidant response in depressed adolescents: A metabolomic and lipidomic study 2025 · ω3 + Paxil group · Adolescents aged 13–24 years with depression | 2.7 g | 12 weeks | 27 |
| Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes 2009 · n-3 PUFA · Healthy adults aged 29.9 ± 6.2 years, men and women, with at least one parent diagnosed with type 2 diabetes; included participants with normal or impaired glucose tolerance | 2 g | 12 weeks | 26 |
| Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study 2012 · low-dose treatment · Adults aged 21–65 with moderate hypertriglyceridemia; 23 men and three postmenopausal women in the study population | 850 mg | 8 weeks | 26 |
| Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study 2012 · high-dose treatment · Adults aged 21–65 with moderate hypertriglyceridemia; 23 men and three postmenopausal women in the study population | 3.4 g | 8 weeks | 26 |
| Effects of n-3 polyunsaturated fatty acids on depressive symptoms, anxiety and emotional state in patients with acute myocardial infarction 2013 · group P · Patients with acute myocardial infarction and no history of mental disorders | 1 g | 30 days | 26 |
| Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia 2013 · Low-dose EPA + DHA · Men and postmenopausal women aged 21–65 with moderate hypertriglyceridemia (150–500 mg/dl) | 850 mg | 8 weeks | 26 |
| Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia 2013 · High-dose EPA + DHA · Men and postmenopausal women aged 21–65 with moderate hypertriglyceridemia (150–500 mg/dl) | 3.4 g | 8 weeks | 26 |
| Gallstone Dissolution Effects of Combination Therapy with n-3 Polyunsaturated Fatty Acids and Ursodeoxycholic Acid: A Randomized, Prospective, Preliminary Clinical Trial 2024 · Combination group · Adults aged 19 years or older with gallbladder stones 15 mm or smaller and no or mild symptoms | 3 g | 26 weeks | 26 |
| Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study 2006 · 2 g/day ethyl-EPA · People with bipolar depression | 2 g | 12 weeks | 25 |
| Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study 2011 · EPA-plus-statin group (combined-therapy group) · Patients with coronary artery disease and dyslipidemia receiving statin therapy | 1.8 g | 48 weeks | 25 |
| Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study 2006 · 1 g/day ethyl-EPA · People with bipolar depression | 1 g | 12 weeks | 24 |
| The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial 2024 · group 1: omega-3 supplementation (ω3) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment | 600 mg | 9 weeks | 24 |
| Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial 2010 · n-3 group · Depressed women aged 66–95 years living in a nursing home | 2.5 g | 8 weeks | 22 |
| Comparison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters 2012 · Omega-3 group · Women aged 65–95 with depression, institutionalized in a nursing home | 2.5 g | 8 weeks | 22 |
| Impact of Omega-3 Fatty Acid Supplementation on Memory Functions in Healthy Older Adults 2016 · LC-n3-FA · Cognitively healthy adults aged 50–75 years | 2.2 g | 26 weeks | 22 |
| Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain 2018 · n-3 PUFA group · Postmenopausal women aged 43–76 with stage I–III hormone-receptor-positive breast cancer, starting aromatase inhibitor therapy | 4.3 g | 24 weeks | 22 |
| Variable effects of 12 weeks of omega-3 supplementation on resting skeletal muscle metabolism 2014 · omega-3 supplementation · Recreationally active, healthy young men | 3 g | 12 weeks | 21 |
| Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡) 2020 · omega-3 LCPUFA (OM) · Children aged 2.5–8 years with autism spectrum disorder | 722 mg | 1 year | 21 |
| omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study 2003 · E-EPA · Women with moderately severe borderline personality disorder meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria | 1 g | 8 weeks | 20 |
| N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction 2011 · study group (group P) · Adults with acute myocardial infarction who had successful percutaneous coronary intervention; age and sex not reported | 1 g | 30 days | 20 |
| Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy 2016 · ω3-FA supplementation · Adults with familial hypercholesterolaemia on optimal cholesterol-lowering therapy | 4 g | 8 weeks | 20 |
| The effect of omega-3 fatty acid supplementation on weight loss and cognitive function in overweight or obese individuals on weight-loss diet 2022 · omega-3 group · Adults aged 30–60 years with overweight or obesity (BMI 27.0–35.0 kg/m²) on a weight-loss diet | 1.02 g | 12 weeks | 20 |
| Effect of omega-3 fatty acid ethyl esters on postprandial arterial elasticity in patients with familial hypercholesterolemia 2023 · ω-3FAEE · Adults with familial hypercholesterolemia | 4 g | 8 weeks | 20 |
| Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia 2020 · 4-g group · Men or postmenopausal women aged 20 years or older with dyslipidemia and hypertriglyceridemia, receiving an HMG-CoA reductase inhibitor | 4 g | 8 weeks | 19 |
| Dietary Intake of n-3 PUFA-Enriched Hen Eggs Changes Inflammatory Markers' Concentration and Treg/Th17 Cells Distribution in Blood of Young Healthy Adults-A Randomised Study 2021 · n-3 PUFAs group · Healthy adults aged 19–28 years, both sexes | 1.05 g | 3 weeks | 19 |
| Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia 2020 · 2-g group · Men or postmenopausal women aged 20 years or older with dyslipidemia and hypertriglyceridemia, receiving an HMG-CoA reductase inhibitor | 2 g | 8 weeks | 18 |
| A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs 2002 · 1 g/d ethyl-eicosapentaenoate · Adults with persistent depression despite ongoing adequate-dose standard antidepressant treatment | 1 g | 12 weeks | 17 |
| A high-fat meal enriched with eicosapentaenoic acid reduces postprandial arterial stiffness measured by digital volume pulse analysis in healthy men 2008 · EPA plus high-oleic sunflower oil (HOS) · 17 healthy men | 5 g | 1 day | 17 |
| A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder 2009 · EPA · Adults aged 18–80 with major depressive disorder, with baseline HAM-D-17 score of at least 18 | 1 g | 8 weeks | 17 |
| The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans 2012 · EPA+DHA · Healthy men and women aged 18–50 years | 3.4 g | 1 day | 16 |
| The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans 2012 · Aspirin plus EPA+DHA · Healthy men and women aged 18–50 years | 3.4 g | 1 day | 16 |
| Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia 2000 · omega-3 fatty acids · Hypercholesterolemic subjects with no other known cause for endothelial dysfunction; age and sex not reported | 4 g | 120 days | 15 |
| Untitled 2012 · group SE (statin plus EPA) · Adults with type 2 diabetes and dyslipidemia, receiving statin therapy | 1.8 g | 26 weeks | 15 |
| Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study 2011 · 1 g/d n3-PUFA · Patients with severe, nonischemic chronic heart failure | 1 g | 90 days | 14 |
| n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers 2006 · n-3 PUFA group · Patients with substance use disorders | 3 g | 90 days | 13 |
| Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study 2011 · 4 g/d n3-PUFA · Patients with severe, nonischemic chronic heart failure | 4 g | 90 days | 13 |
| Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis 2021 · EPA · Adults with major depressive disorder meeting DSM-IV criteria and baseline 21-item Hamilton Rating Scale for Depression scores of at least 18; sex and age range not reported | 3 g | 12 weeks | 11 |
| Acute ingestion of a meal rich in n-3 polyunsaturated fatty acids results in rapid gastric emptying in humans 2002 · n-3 PUFA meal · Healthy women aged 50–62 years | 40 g | 1 day | 10 |
| The effects of omega-3 supplementation on pulmonary function of young wrestlers during intensive training 2010 · experimental group · Healthy young male wrestlers | 1 g | 12 weeks | 10 |
| Nonsurgical Treatment of Periodontitis in Menopausal Patients: A Randomized Control Trial 2024 · Group II (SRP + omega-3FAs) · Menopausal women aged 45–55 with generalized chronic periodontitis and periodontal pockets of at least 5 mm | 1 g | 1 year | 10 |
| Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis 2006 · low-dose group · Patients with ankylosing spondylitis | 1.95 g | 21 weeks | 9 |
| Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis 2006 · high-dose group · Patients with ankylosing spondylitis | 4.55 g | 21 weeks | 9 |
| Incorporation and washout of n-3 PUFA after high dose intravenous and oral supplementation in healthy volunteers 2015 · oral n-3PUFA · healthy volunteers | 600 mg/kg | 3 days | 8 |
| Long-Chain Omega-3 Fatty Acid Supplementation and Exercise-Induced Muscle Damage: EPA or DHA? 2024 · EPA + DHA · Males; age and health status not reported | 4 g | 52 days | 8 |
| Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression 2006 · 2.8 g/day group · Women with postpartum depression; ages and sex details beyond postpartum mothers not reported | 2.8 g | 8 weeks | 7 |
| The effect of Omega-3 polyunsaturated fatty acid supplementation on exercise-induced muscle damage 2021 · N-3 · Healthy, physically active males aged 18–35 years without a stated disease | 3 g | 4 weeks | 7 |
| Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression 2006 · 0.5 g/day group · Women with postpartum depression; ages and sex details beyond postpartum mothers not reported | 500 mg | 8 weeks | 6 |
| Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression 2006 · 1.4 g/day group · Women with postpartum depression; ages and sex details beyond postpartum mothers not reported | 1.4 g | 8 weeks | 3 |
| Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial 1999 · omega3 fatty acids · Patients with bipolar disorder | 9.6 g | 120 days | — |
| Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids 1999 · 6.6 g n-3 PUFA group · Healthy volunteers | 6.6 g | 12 weeks | — |
| Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids 1999 · 2.0 g n-3 PUFA group · Healthy volunteers | 2 g | 12 weeks | — |
| Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men 2000 · EPA · Overweight, mildly hyperlipidemic men | 4 g | 6 weeks | — |
| A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms 2002 · 1 g/day E-E · Adults with DSM-IV-defined schizophrenia receiving typical antipsychotics, new atypical antipsychotics, or clozapine | 1 g | 12 weeks | — |
| A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms 2002 · 2 g/day E-E · Adults with DSM-IV-defined schizophrenia receiving typical antipsychotics, new atypical antipsychotics, or clozapine | 2 g | 12 weeks | — |
| A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms 2002 · 4 g/day E-E · Adults with DSM-IV-defined schizophrenia receiving typical antipsychotics, new atypical antipsychotics, or clozapine | 4 g | 12 weeks | — |
| A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs 2002 · 2 g/d ethyl-eicosapentaenoate · Adults with persistent depression despite ongoing adequate-dose standard antidepressant treatment | 2 g | 12 weeks | — |
| A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs 2002 · 4 g/d ethyl-eicosapentaenoate · Adults with persistent depression despite ongoing adequate-dose standard antidepressant treatment | 4 g | 12 weeks | — |
| Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers 2003 · EPA group · Healthy subjects; age and sex not stated | 4 g | 90 days | — |
| Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial 2003 · omega-3 PUFA group · Patients with major depressive disorder | 6.6 g | 8 weeks | — |
| The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized, double blind trial 1992 · n-3 PUFA · Patients with active rheumatoid arthritis | 3.6 g | 12 weeks | — |
| Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans 2005 · n-3 fatty acids group · Patients with at least 1440 premature ventricular complexes per 24 hours on a previous Holter recording | 1.5 g | 14 weeks | — |
| Supplementation of fish oil and olive oil in patients with rheumatoid arthritis 2005 · G2 · Adults with rheumatoid arthritis; 34 women and 9 men across the study, mean age 49 years | 3 g | 24 weeks | — |
| A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus 2008 · fish oil group · Patients with systemic lupus erythematosus; age and sex not specified | 3 g | 24 weeks | — |
| Tolerability of omega-3 fatty acid supplements in perinatal women 2007 · omega-3 fatty acids · Pregnant and postpartum women with major depressive disorder | 1.84 g | 8 weeks | — |
| Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial 2007 · E-EPA · Patients with first-episode psychosis | 2 g | 12 weeks | — |
| Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder 2008 · EPA · Outpatients with major depressive disorder, age and sex not reported | 1 g | 8 weeks | — |
| Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder 2008 · EPA + fluoxetine · Outpatients with major depressive disorder, age and sex not reported | 1 g | 8 weeks | — |
| Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial 2008 · omega-3 PUFAs · Pregnant women with major depressive disorder | 3.4 g | 8 weeks | — |
| The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study 2008 · omega-3 PUFAs · People with mild or moderate Alzheimer's disease or mild cognitive impairment | 1.8 g | 24 weeks | — |
| Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus 1991 · MaxEPA · Patients with active systemic lupus erythematosus | 20 g | 34 weeks | — |
| The effects of ingestion of omega-3 fatty acids on perceived pain and external symptoms of delayed onset muscle soreness in untrained men 2009 · experimental group · Untrained men who had not participated in a training program in the preceding 60 days | 1.8 g | — | — |
| EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD 2010 · EPA · Children aged 7–12 years with ADHD | 500 mg | 15 weeks | — |
| Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy 2011 · n-3 PUFAs group · Patients with chronic heart failure due to nonischemic dilated cardiomyopathy and minimal symptoms receiving standard therapy; age and sex not specified | 2 g | 1 year | — |
| Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study 2011 · EPA and DHA group · Infertile men with idiopathic oligoasthenoteratospermia (OAT) | 1.84 g | 32 weeks | — |
| Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial 2012 · n-3FA (Lovaza) 4 g · Postmenopausal women at increased risk for breast cancer (breast density ≥ 25%) | 4 g | 2 years | — |
| Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial 2012 · Lovaza 4 g+Ral 30 mg · Postmenopausal women at increased risk for breast cancer (breast density ≥ 25%) | 4 g | 2 years | — |
| Untitled 2012 · ω-3 PUFA group · Patients with ischemic heart disease and ventricular arrhythmias | 1 g | 26 weeks | — |
| Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial 2013 · EPA group · Adults with mild-to-moderate depression receiving maintenance medication | 1 g | 12 weeks | — |
| Randomized controlled trial of oral omega-3 PUFA in solar-simulated radiation-induced suppression of human cutaneous immune responses 2013 · n-3 PUFA group · Nickel-allergic women aged 22–60 years with phototype I or II | 5 g | 90 days | — |
| Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective? 2013 · ω-3 PUFA group · Young patients at ultra-high risk for psychosis | 1.2 g | 12 weeks | — |
| Long-chain omega-3 fatty acids improve brain function and structure in older adults 2014 · fish oil · Healthy adults aged 50–75 years | 2.2 g | 26 weeks | — |
| Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial 2013 · n-3 PUFA group · Adolescents with borderline personality disorder who also met ultra-high-risk criteria for psychosis; mean age 16.2 years | 1.2 g | 12 weeks | — |
| Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial 2013 · 0.45 g/day n-3 PUFA group · Non-smoking men and women aged 45–70 years, healthy and at moderate cardiovascular risk | 450 mg | 1 year | — |
| Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial 2013 · 0.9 g/day n-3 PUFA group · Non-smoking men and women aged 45–70 years, healthy and at moderate cardiovascular risk | 900 mg | 1 year | — |
| Effect of low doses of long chain n-3 polyunsaturated fatty acids on sleep-time heart rate variability: a randomized, controlled trial 2013 · 1.8 g/day n-3 PUFA group · Non-smoking men and women aged 45–70 years, healthy and at moderate cardiovascular risk | 1.8 g | 1 year | — |
| Efficacy of omega-3 in treatment of recurrent aphthous stomatitis and improvement of quality of life: a randomized, double-blind, placebo-controlled study 2014 · omega-3 · Participants with recurrent aphthous stomatitis; age and sex not specified | 3 g | 26 weeks | — |
| B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial 2014 · n-3 fatty acids only · Adults aged 45–80 with a recent history of myocardial infarction, unstable angina, or ischemic stroke | 600 mg | 1716 days | — |
| Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial 2014 · omega-3 fatty acid group · Participants with mild to moderate acne; age and sex not reported | 2 g | 10 weeks | — |
| Omega-3 supplementation and loneliness-related memory problems: secondary analyses of a randomized controlled trial 2014 · 1.25 g/d omega-3 supplementation group · Healthy, overweight, sedentary adults aged 40–85 | 1.25 g | 120 days | — |
| Omega-3 supplementation and loneliness-related memory problems: secondary analyses of a randomized controlled trial 2014 · 2.50 g/d omega-3 supplementation group · Healthy, overweight, sedentary adults aged 40–85 | 2.5 g | 120 days | — |
| Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial 2014 · omega-3 fatty acids supplementation · Healthy volunteers; age and sex not reported. | 4 g | 4 weeks | — |
| Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss 2015 · EPA · Healthy overweight or obese women following an energy-restricted diet | 1.3 g | 10 weeks | — |
| Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo controlled trial 2015 · LCPUFAs group · Young adults with depressive symptoms (BDI score greater than 10); mean age 20.2 years, 78% female | 1.4 g | 3 weeks | — |
| Omega-3 fatty acids supplementation improves endothelial function and arterial stiffness in hypertensive patients with hypertriglyceridemia and high cardiovascular risk 2017 · omega-3 fatty acids · Adults with hypertriglyceridemia (triglycerides 150–499 mg/dL), including low- and high-cardiovascular-risk hypertensive patients | 1.8 g | 12 weeks | — |
| Beneficial effect of n-3 polyunsaturated fatty acids on inflammation and analgesic use in psoriatic arthritis: a randomized, double blind, placebo-controlled trial 2018 · n-3 PUFA group · Patients with established psoriatic arthritis; age and sex not specified | 3 g | 24 weeks | — |
| Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) 2017 · study group · Men aged 50–70 with LUTS and BPH and no other comorbidities | 900 mg | 26 weeks | — |
| The effect of omega 3 fatty acid supplementation on premenstrual syndrome and health-related quality of life: a randomized clinical trial 2018 · omega-3 supplement group · Iranian women aged 20–35 years with premenstrual symptoms | 1 g | — | — |
| Effects of n-3 Polyunsaturated Fatty Acid Supplementation on Serum Leptin Levels, Appetite Sensations, and Intake of Energy and Macronutrients in Obese People: A Randomized Clinical Trial 2018 · intervention group · Obese adults with BMI 30 kg/m² or above; age range and sex distribution not reported | 1 g | 4 weeks | — |
| Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate 2018 · omega-3 fatty acid group · Patients with schizophrenia taking clozapine and sodium valproate | 4 g | 8 weeks | — |
| Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children 2018 · Group B · Children aged 7–15 with nocturnal enuresis | 1 g | 60 days | — |
| Effects of omega-3 polyunsaturated fatty acids on fibrosis, endothelial function and myocardial performance, in ischemic heart failure patients 2019 · intervention arm · Patients with ischemic heart failure; age and sex not specified | 2 g | 8 weeks | — |
| Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927) 2018 · O3-FA · Post-menopausal women with stage I–III breast cancer taking an aromatase inhibitor for at least 90 days and with aromatase inhibitor-related arthralgia; results were analysed separately for BMI <30 and BMI ≥30 kg/m². | 3.3 g | 24 weeks | — |
| Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study) 2018 · PE group (pitavastatin with EPA) · Patients with type 2 diabetes mellitus | 1.8 g | 1 year | — |
| Omega-3 fatty acid supplementation attenuates skeletal muscle disuse atrophy during two weeks of unilateral leg immobilization in healthy young women 2019 · n-3 fatty acid group · Healthy women aged 22 ± 3 years | 5 g | 8 weeks | — |
| Effect of n-3 fatty acids supplementation during life style modification in women with overweight 2018 · LSM & n-3 · Women with overweight | 1.5 g | 12 weeks | — |
| Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women 2020 · omega-3 group · Pregnant women at 12–24 weeks of gestation with Edinburgh Postnatal Depression Scale scores ≥9 | 1.8 g | 12 weeks | — |
| Fish oil decreases the severity of treatment-related adverse events in gastrointestinal cancer patients undergoing chemotherapy: A randomized, placebo-controlled, triple-blind clinical trial 2019 · Fish oil group (FOG) · Gastrointestinal cancer patients undergoing chemotherapy; age and sex not specified | 1.55 g | 9 weeks | — |
| Effects of n-3 PUFA on endothelial function in patients with peripheral arterial disease: a randomised, placebo-controlled, double-blind trial 2019 · n-3 PUFA · Adults with stable peripheral arterial disease, Rutherford stage 2 or 3 | 4 g | 90 days | — |
| Efficacy of ω-3 supplementation on nutritional status, skeletal muscle, and chemoradiotherapy toxicity in cervical cancer patients: A randomized, triple-blind, clinical trial conducted in a middle-income country 2019 · intervention group · Women with cervical cancer undergoing chemoradiotherapy; average age 44.53 years | 2.5 g | 45 days | — |
| Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction-Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial 2019 · O-3FA · Adults with acute myocardial infarction, treated 2–4 weeks after the event; mean age 59 years and 19% female in the overall cohort | 4 g | 26 weeks | — |
| The Effect of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability in Renal Transplant Recipients: A Randomized Controlled Trial 2019 · marine n-3 PUFA · Adults older than 18 years with a functional kidney graft, 6–8 weeks after renal transplantation | 3 g | 44 weeks | — |
| Efficacy of omega-3 fatty acids and punctal plugs in the prevention of isotretinoin-associated ocular surface disease 2021 · O3FAs/PPs group · Patients receiving systemic isotretinoin therapy; age and sex not specified | 1.04 g | 26 weeks | — |
| ω-3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial 2021 · EPA and DHA · Cognitively healthy older adults with stable coronary artery disease receiving statin treatment | 3.36 g | 900 days | — |
| Nutritional Status Predicts Fatty Acid Uptake from Fish and Soybean Oil Supplements for Treatment of Cancer-Related Fatigue: Results from a Phase II Nationwide Study 2021 · 6 g fish oil · Adult female breast cancer survivors aged 18 or older, with stage 0–III cancer, 4–36 months post-treatment and self-reported fatigue | 6 g | 6 weeks | — |
| Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial 2025 · EPA group · Adults with chronic migraine; most participants were female | 2 g | 8 weeks | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Omega-3s, without vitamin D3 · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 1 g | 3 years | — |
| Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates 1995 · fish oil group · Patients with rheumatoid arthritis | 130 mg/kg | 30 weeks | — |
| Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study 1994 · 2.6 gm of omega 3 · People with active rheumatoid arthritis; age and sex not stated | 2.6 g | 1 year | — |
| [Fish oils and rheumatoid arthritis. A randomized and double-blind study] 1994 · n-3 PUFA · Patients with active rheumatoid arthritis | 3.6 g | 12 weeks | — |
| Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4 1993 · EPA · Patients with cystic fibrosis colonised with Pseudomonas aeruginosa; age and sex not reported | 2.7 g | 6 weeks | — |
| Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans 1998 · EPA group · Healthy, nonsmoking men aged 36–56 years | 4 g | — | — |
| The effect of prenatal docosahexaenoic acid supplementation on infant outcomes in African American women living in low-income environments: A randomized, controlled trial 2016 · Active supplement (groups B and C; identical doses) · African American pregnant women aged 20–30 living in low-income environments, with sea fish consumption below 2 servings per week | 90 mg | — | 43 |
| Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial 2018 · TMN · Adults aged 50 years or older with moderate-to-severe COPD and pre-cachexia or cachexia | 4 g | 12 weeks | 22 |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 650 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 1 g | 1789 days | — |
| No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye | 1 g | 5 years | — |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + probiotics · Women in early pregnancy | 220 mg | — | — |
| The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT) 2021 · Omega 3 Polyunsaturated Fatty Acids · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait | 113 mg | 3 years | 381 |
| The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT) 2021 · Combined intervention · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait | 113 mg | 3 years | 374 |
| The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial 2021 · DHA-rich fish oil · Pregnant women with singleton pregnancies enrolled before 21 weeks’ gestation; no specific diagnosed condition stated | 100 mg | — | 351 |
| Effect of Omega-3 on HLA-DR Expression by Conjunctival Cells and Tear Cytokine Concentrations in the Dry Eye Assessment and Management Study 2022 · active supplement group (ω3) · Adults with moderate to severe dry eye disease | 2 g | 1 year | 349 |
| Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye 2015 · O3FA group · Symptomatic computer users using computers more than 3 hours per day for at least 1 year; sex and age not specified; computer vision syndrome-related dry eye | 360 mg | 90 days | 220 |
| Omega-3 Supplementation for the Prevention of Cognitive Decline in Older Adults: Does It Depend on Homocysteine Levels? 2022 · Omega-3 fatty acid supplementation · Community-dwelling men and women aged 70 years or older without dementia, with spontaneous memory complaints, slow gait speed, or limitations in instrumental activities of daily living | 513 mg | 3 years | 187 |
| Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial 2023 · Multidomain plus omega 3 · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed | 400 mg | 3 years | 129 |
| Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials 2021 · DHA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use | 270 mg | 26 weeks | 113 |
| Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials 2021 · EPA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use | 900 mg | 26 weeks | 112 |
| Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial 2023 · Omega 3 alone · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed | 400 mg | 3 years | 112 |
| Cognitive Changes with Omega-3 Polyunsaturated Fatty Acids in Non-Demented Older Adults with Low Omega-3 Index 2017 · n-3 PUFA supplementation group · Men and women aged 70 or older without dementia, with low omega-3 index (≤4.83%) and at least one risk criterion for dementia: subjective memory complaints, limitation in an instrumental activity of daily living, or slow gait speed | 513 mg | 3 years | 98 |
| Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial 2009 · fish oil · Thai schoolchildren aged 9 to 12 years | 200 mg | 26 weeks | 94 |
| Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study 2009 · Omega-3/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease | 600 mg | 1 year | 89 |
| Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study 2019 · omega-3 fatty acid supplementation · Community-based patients with mild to moderate Alzheimer's disease, MMSE ≥15; 88 participants received supplementation | 600 mg | 26 weeks | 88 |
| Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development 2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required | 300 mg | 26 weeks | 87 |
| Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study 2009 · Placebo/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease | 600 mg | 26 weeks | 85 |
| Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension 2011 · PS-DHA treatment group (double-blind phase) · Men and women aged 50–90 years with memory complaints and without dementia | 79 mg | 15 weeks | 79 |
| Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial 2024 · ω-3 group · Korean adults aged 20–75 with dry eye disease and concurrent meibomian gland dysfunction; both sexes | 1.68 g | 12 weeks | 66 |
| The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients 2008 · low-dose medical food emulsion (Trial 2) · Adults with asthma | 500 mg | 4 weeks | 65 |
| The Effect of Dietary Supplementation on Aggressive Behaviour in Australian Adult Male Prisoners: A Feasibility and Pilot Study for a Randomised, Double Blind Placebo Controlled Trial 2020 · omega-3 group · Adult male prisoners over 18 years at the South Coast Correctional Centre | 960 mg | 16 weeks | 65 |
| Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA) 2023 · MAG-EPA intervention group · Adult men with aggressive localized prostate cancer (Gleason score ≥ 7, ISUP Grade group ≥ 2) treated by radical prostatectomy | 3.3 g | 1 year | 65 |
| l-Serine and EPA Relieve Chronic Low-Back and Knee Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2020 · l-Ser + EPA supplementation group · Adults aged 20 years or older with chronic pain in at least the low back and knee for at least 3 months | 149 mg | 8 weeks | 60 |
| Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin 2008 · CLA plus n-3 LC-PUFA · Young and older men, ages about 31 and 57 years, both lean and obese | 3 g | 12 weeks | 59 |
| Effect of Omega-3 fatty acid supplementation on sexual function of pregnant women: a double blind randomized controlled trial 2024 · intervention group · Pregnant women aged 18–42, at 16–22 weeks’ gestation, with sexual dysfunction and low dietary PUFA intake | 600 mg | 8 weeks | 59 |
| Effects of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability and Heart Rate in Patients on Chronic Dialysis: A Randomized Controlled Trial 2018 · n-3 PUFA group · Adults over 18 years receiving chronic dialysis for more than 3 months | 2 g | 90 days | 56 |
| Long-chain Polyunsaturated Fatty Acid Supplementation Improves Mood in Elderly Japanese Men 2017 · LCPUFA group · Japanese men aged 55–64 years | 100 mg | 4 weeks | 51 |
| Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis 2008 · cod liver oil group · Adults with rheumatoid arthritis; age and sex not specified | 2.2 g | 39 weeks | 49 |
| The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial 2017 · n-3 PUFA · Chinese adults aged 60 years or older with mild cognitive impairment | 720 mg | 26 weeks | 44 |
| Effect of omega-3 and vitamin D co-supplementation on psychological distress in reproductive-aged women with pre-diabetes and hypovitaminosis D: A randomized controlled trial 2021 · Group 4 Vitamin D + Omega-3 group · Women aged 15–50 with pre-diabetes and hypovitaminosis D | 2 g | 8 weeks | 42 |
| Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial 2013 · Fish + S · Adults aged 18–60 years with overweight or obesity (BMI 25–37 kg/m²), otherwise healthy | 420 mg | 1 year | 40 |
| Untitled 2012 · omega-3 PUFA · Healthy adults aged 51–72 years, women and men, with BMI 20–30 kg/m² and no known metabolic disease or cognitive decline | 3 g | 5 weeks | 38 |
| Does supplementation with leucine-enriched protein alone and in combination with fish-oil-derived n-3 PUFA affect muscle mass, strength, physical performance, and muscle protein synthesis in well-nourished older adults? A randomized, double-blind, placebo-controlled trial 2021 · LEU-PRO plus LC n−3 PUFAs · Men and women aged 65 years or older at increased risk of sarcopenia | 4.8 g | 24 weeks | 38 |
| Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease 2010 · omega-3 arm · Adults with documented coronary heart disease and current major depressive episode | 1.68 g | 10 weeks | 36 |
| A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine 2024 · EPA group · Adults with episodic migraine; age and sex range not reported | 1.8 g | 12 weeks | 35 |
| Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial 2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years | 1.1 g | — | 33 |
| Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome 2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation | 242 mg/kg | 1 year | 33 |
| Effects of the re-esterified triglyceride (rTG) form of omega-3 supplements on dry eye following cataract surgery 2021 · omega-3 group · Adults with newly developed dry-eye symptoms one month after uncomplicated cataract surgery; mean age 65.47 years, 63.6% women | 2.19 g | 8 weeks | 32 |
| The effects of Omega-3 supplementation on stress, anxiety, depression, sleep quality, and everyday memory in individuals with psychological distress: A randomized, double-blind, placebo-controlled trial 2026 · intervention group · Participants with high levels of stress, anxiety and depression, memory issues, and poor sleep quality | 750 mg | 90 days | 32 |
| Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial 2017 · FO group · Adults aged 18 years or older with pancreatic carcinoma and tumor-associated weight loss of at least 5% since diagnosis | 300 mg | 6 weeks | 31 |
| Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients 2016 · omega-3 fatty acids + vitamin E · Chronic hemodialysis patients; age and sex not specified | 1.25 g | 12 weeks | 30 |
| The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial 2015 · omega-3 group · Adults aged 20-70 with newly diagnosed active rheumatoid arthritis; 49 women and 11 men were enrolled across the study | 3.9 g | 12 weeks | 30 |
| Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients 2016 · omega-3 fatty acids + alpha-tocopherol · Chronic hemodialysis patients; age and sex not specified | 1.25 g | 12 weeks | 30 |
| The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study 2024 · n-3 PUFAs group · Adults aged 18–65 with major depressive disorder and HRSD-21 score >18 | 3.2 g | 12 weeks | 30 |
| Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial 2021 · DHA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week | 270 mg | 26 weeks | 29 |
| Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial 2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day | 900 mg | 90 days | 27 |
| Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial 2021 · EPA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week | 900 mg | 26 weeks | 27 |
| Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial 2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder | 2.13 g | 12 weeks | 27 |
| Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment 2018 · FO + BB · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment | 1.6 g | 24 weeks | 26 |
| An Oral Polyphenol Formulation to Modulate the Ocular Surface Inflammatory Process and to Improve the Symptomatology Associated with Dry Eye Disease 2022 · group A · Adults aged 18–55 with mild to moderate dry eye disease and visual strain who worked looking at a screen for more than 8 hours per day | 250 mg | 12 weeks | 26 |
| Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus 2015 · fish oil · Adults aged 18–64 with systemic lupus erythematosus | 4.5 g | 26 weeks | 25 |
| A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone 2019 · omega-3 · People aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum disorders or bipolar I disorder with psychotic features | 1.14 g | 16 weeks | 25 |
| Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial 2020 · TG1 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis | 900 mg | 60 days | 25 |
| Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial 2020 · TG2 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis | 900 mg | 60 days | 25 |
| Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial 2021 · Risperidone + fish oil (FO) · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum and bipolar disorder with psychosis | 740 mg | 16 weeks | 25 |
| An Oral Polyphenol Formulation to Modulate the Ocular Surface Inflammatory Process and to Improve the Symptomatology Associated with Dry Eye Disease 2022 · group A + L · Adults aged 18–55 with mild to moderate dry eye disease and visual strain who worked looking at a screen for more than 8 hours per day | 250 mg | 12 weeks | 25 |
| Effect of Omega-3 Supplementation in Pregnant Women with Obesity on Newborn Body Composition, Growth and Length of Gestation: A Randomized Controlled Pilot Study 2021 · n-3 PUFA group · Pregnant women with BMI >25 kg/m², aged about 26.9 years on average, with a singleton pregnancy and no stated pre-existing metabolic disorder | 2 g | 25 weeks | 24 |
| Clinical Assessment of Efficacy of Omega 3 in Oral Submucous Fibrosis Patients - A Randomized Controlled Trial 2022 · Group B · Adults aged 19–52 with grade II or III oral submucous fibrosis; all consumed areca nut | 3 g | 90 days | 24 |
| The Effects of Omega-3 Fatty Acids and Vitamin D Supplementation on the Nutritional Status of Women with Breast Cancer in Palestine: An Open-Label Randomized Controlled Trial 2024 · group 3: both omega-3 and vitamin D supplementation (ω3+VitD) · Women aged 28–64 with newly diagnosed stage II or III breast cancer, before first chemotherapy treatment | 600 mg | 9 weeks | 24 |
| Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials 2018 · Ω3 monotherapy · Children aged 7–14 with a depressive disorder, cyclothymic disorder, or bipolar disorder not otherwise specified | 2 g | 12 weeks | 23 |
| Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial 2007 · n-3 EFA group · Patients presenting after recurrent self-harm | 1.2 g | 12 weeks | 22 |
| Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials 2018 · Combined intervention · Children aged 7–14 with a depressive disorder, cyclothymic disorder, or bipolar disorder not otherwise specified; also received PEP therapy | 2 g | 12 weeks | 22 |
| Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment 2018 · FO · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment | 1.6 g | 24 weeks | 21 |
| Emotion-Related Network Reorganization Following Fish Oil Supplementation in Depressed Bipolar Offspring: An fMRI Graph-Based Connectome Analysis 2021 · Fish oil · Patients aged 9–21 with a depressive disorder and a biological parent with bipolar I disorder | 1.47 g | 12 weeks | 21 |
| The Influence of Vitamin E and Omega-3 Fatty Acids on Reproductive Health Indices Among Male Workers Exposed to Electromagnetic Fields 2022 · Omega-3 group · Male workers aged 20–50 years employed for at least 2 years and exposed to electromagnetic fields; no stated fertility diagnosis | 300 mg | 90 days | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea | 1.08 g | 60 days | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea | 1.08 g | 60 days | 21 |
| Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure 2006 · omega-3 fatty acid · Adults aged 65 years or older with grade II or III chronic heart failure | 1.8 g | 6 weeks | 20 |
| Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder 2012 · citalopram + omega-3 treatment group · Adults aged 18–65 with major depressive disorder and HAM-D score greater than 17 | 1 g | 8 weeks | 20 |
| Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects 1990 · low-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified | 27 mg/kg | 24 weeks | 20 |
| The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome 2018 · omega-3 fatty acids plus vitamin E · Women with polycystic ovary syndrome (PCOS) | 1 g | 12 weeks | 20 |
| Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial 2023 · n-3 PUFAs group · Adults with cardiovascular diseases comorbid with major depressive disorder; mean age 60 ± 9 years, 58% male | 2 g | 12 weeks | 20 |
| The Influence of Vitamin E and Omega-3 Fatty Acids on Reproductive Health Indices Among Male Workers Exposed to Electromagnetic Fields 2022 · Vitamin E + Omega-3 group · Male workers aged 20–50 years employed for at least 2 years and exposed to electromagnetic fields; no stated fertility diagnosis | 300 mg | 90 days | 19 |
| Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial 2012 · DHA-rich supplement · Adults older than 65 years with mild cognitive impairment | 400 mg | 26 weeks | 18 |
| The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial 2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery | 940 mg | 30 days | 18 |
| Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial 2018 · n-3 PUFA (ω-3) group · Adult women aged 27–45 with primary antiphospholipid syndrome | 3.1 g | 16 weeks | 18 |
| [Polyunsaturated omega-3 fatty acids in the treatment of experimental human gingivitis] 1996 · treatment group · Healthy volunteers; age and sex not specified; no stated condition | 1.8 g | 7 days | 18 |
| Pilot study on n-3 polyunsaturated fatty acids in the treatment of human experimental gingivitis 1997 · drug (fish oil) group · Healthy volunteers with experimentally induced gingivitis; age and sex not stated | 1.8 g | 8 days | 18 |
| Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial 2012 · EPA-rich supplement · Adults older than 65 years with mild cognitive impairment | 1.67 g | 26 weeks | 17 |
| Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects 1990 · high-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified | 54 mg/kg | 24 weeks | 17 |
| Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: a parallel randomised controlled trial 2016 · Fish oil (FO) · Adults with impaired glucose regulation; age and sex not reported | 3.9 g | 270 days | 16 |
| Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment 2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified | 1.6 g | 24 weeks | 15 |
| Inflammation (IL-1β) Modifies the Effect of Vitamin D and Omega-3 Long Chain Polyunsaturated Fatty Acids on Core Symptoms of Autism Spectrum Disorder-An Exploratory Pilot Study(‡) 2020 · vitamin D and omega-3 LCPUFA (VIDOM) · Children aged 2.5–8 years with autism spectrum disorder | 722 mg | 1 year | 15 |
| Long Chain Omega-3 Polyunsaturated Fatty Acids Improve Vascular Stiffness in Abdominal Aortic Aneurysm: A Randomized Controlled Trial 2020 · LC n-3 PUFA capsules · Men aged 60–86 with a small abdominal aortic aneurysm (<5 cm) | 1.8 g | 12 weeks | 15 |
| Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial 2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis | 300 mg | 90 days | 15 |
| Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers 2008 · PUFA group · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders | 250 mg | 90 days | 13 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 1 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 1 g | 12 weeks | 13 |
| Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise 2008 · DHA + EPA · Healthy adult men and women; ages not reported | 3 g | 6 weeks | 12 |
| Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females 2015 · fish oil (FO) · Community-dwelling females aged 60–76 years in generally good health, with low fish intake and no omega-3 supplement use | 3 g | 12 weeks | 12 |
| Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial 2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition | 600 mg | 62 days | 12 |
| Psychoeducational Psychotherapy and Omega-3 Supplementation Improve Co-Occurring Behavioral Problems in Youth with Depression: Results from a Pilot RCT 2017 · combined treatment (PEP + omega-3 supplementation) · Children and adolescents aged 7–14 with depressive disorders | 1 g | 12 weeks | 12 |
| Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults 2020 · Fish oil group · Healthy physically active men and women aged 60–75 years | 2 g | 12 weeks | 12 |
| Alleviation of Pain, PAIN Interference, and Oxidative Stress by a Novel Combination of Hemp Oil, Calamari Oil, and Broccoli: A Randomized, Double-Blind, Placebo-Controlled Trial 2023 · intervention group · Adults aged 37–74 with chronic pain at two locations | 230 mg | 12 weeks | 12 |
| Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study 1992 · fish oil · 11 patients with mild to moderate active ulcerative colitis | 4.2 g | 240 days | 11 |
| Psychoeducational Psychotherapy and Omega-3 Supplementation Improve Co-Occurring Behavioral Problems in Youth with Depression: Results from a Pilot RCT 2017 · omega-3 monotherapy · Children and adolescents aged 7–14 with depressive disorders | 1 g | 12 weeks | 11 |
| 4-week eicosapentaenoic acid-rich fish oil supplementation partially protects muscular damage following eccentric contractions 2021 · EPA and DHA group · Healthy recreationally untrained men; age range not stated | 3 g | 33 days | 11 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 2 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 2 g | 12 weeks | 11 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 4 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 4 g | 12 weeks | 11 |
| Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions 2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition | 600 mg | 62 days | 10 |
| The effect of fish oil supplementation on resistance training-induced adaptations 2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease | 2.28 g | 10 weeks | 10 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Omega-3 + USRPT (OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 680 mg | 8 weeks | 10 |
| Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids 2004 · n-3 fatty acid enriched oral nutritional supplement · Adults with unresectable pancreatic cancer, age 65–70 on average, with weight loss and cachexia | 2.2 g | 8 weeks | 9 |
| Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma 2006 · fish oil diet · Asthmatic patients with documented exercise-induced bronchoconstriction; age and sex not reported | 5.2 g | 3 weeks | 8 |
| Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study 2017 · ω-3 EFA supplements · Adults with moderate dry eye disease; age and sex not reported | 1 g | 90 days | 8 |
| Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors 2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training | 600 mg | 62 days | 8 |
| Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers 2008 · PUFA group, six-month follow-up subset · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders | 250 mg | 90 days | 6 |
| Effects of Omega-3 Fatty Acids on Resting Cerebral Perfusion in Patients with Mild Cognitive Impairment: A Randomized Controlled Trial 2018 · omega group · Adults aged 50–80 with amnestic mild cognitive impairment | 2.2 g | 26 weeks | 5 |
| Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids 2001 · dietary n-3FA therapy · Patients with sickle cell disease; age and sex not stated | 100 mg/kg | 30 days | — |
| Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial 2002 · lipid extract group · Patients with steroid-naïve atopic asthma; age and sex not reported | 100 mg | 8 weeks | — |
| Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial 1992 · fish oil · Patients with ulcerative colitis, including patients entering in relapse and patients in remission | 4.5 g | 1 year | — |
| Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis 1992 · Group 2 · Patients with active rheumatoid arthritis | 3.8 g | 16 weeks | — |
| Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis 1992 · Group 3 · Patients with active rheumatoid arthritis | 3.8 g | 16 weeks | — |
| Supplementation of fish oil and olive oil in patients with rheumatoid arthritis 2005 · G3 · Adults with rheumatoid arthritis; 34 women and 9 men across the study, mean age 49 years | 3 g | 24 weeks | — |
| Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study 2007 · omega-3 fatty acids · Children aged 5 to 17 years with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior | 1.5 g | 6 weeks | — |
| Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial 2006 · omega-3 fatty acid-treated group · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified | 600 mg | 26 weeks | — |
| Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial 2006 · placebo group after crossover to omega-3 fatty acid supplementation · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified | 600 mg | 26 weeks | — |
| Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers 2007 · fish oil supplementation · Healthy men aged 26.0 ± 3.1 years | 1.8 g | 4 weeks | — |
| Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia 2007 · Australia DHA+EPA only · Children aged 6–10 years in Australia, described as well-nourished | 110 mg | 1 year | — |
| Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia 2007 · Indonesia DHA+EPA only · Children aged 6–10 years in Indonesia, described as marginally nourished | 110 mg | 1 year | — |
| Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers 2008 · PUFA group · Men admitted to substance-abuse outpatient clinics, with polysubstance abuse and suboptimal dietary intake of long-chain n-3 PUFAs | 2.5 g | 90 days | — |
| Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study 2007 · fish oil group · Women with type 2 diabetes without hypertriglyceridemia | 1.8 g | 60 days | — |
| Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids 2008 · PL-n-3 group · Children aged 8–13 years with impaired visual sustained attention performance | 250 mg | 90 days | — |
| The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study 2011 · drug group · Adults aged 65 years or older with mild to moderate depression | 300 mg | 26 weeks | — |
| Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age 2011 · fish-oil group · healthy pregnant women | 150 mg | — | — |
| Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age 2011 · combined fish-oil and 5-MTHF group · healthy pregnant women | 150 mg | — | — |
| Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study 2012 · n-3 group · Patients with advanced inoperable non-small-cell lung cancer undergoing chemotherapy | 510 mg | 66 days | — |
| Fish oil supplementation improves neutrophil function during cancer chemotherapy 2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated | 300 mg | 8 weeks | — |
| The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial 2014 · omega-3 group · Maintenance hemodialysis patients; age range and sex not reported | 540 mg | 120 days | — |
| Effects of omega-3 fatty acids on tobacco craving in cigarette smokers: A double-blind, randomized, placebo-controlled pilot study 2014 · omega-3 fatty acid supplementation · Regular cigarette smokers | 2.71 g | 30 days | — |
| Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss 2015 · EPA+α-lipoic acid · Healthy overweight or obese women following an energy-restricted diet | 1.3 g | 10 weeks | — |
| Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder 2015 · ADHD Active · Boys aged 8–14 with ADHD | 650 mg | 16 weeks | — |
| Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder 2015 · RG Active · Typically developing boys matched to the ADHD participants for age, hand preference, and BMI | 650 mg | 16 weeks | — |
| Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study 2016 · EPA-enriched mix · Adults aged 18–80 with major depressive disorder | 1.06 g | 8 weeks | — |
| Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study 2016 · DHA-enriched mix · Adults aged 18–80 with major depressive disorder | 180 mg | 8 weeks | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 650 mg | 5 years | — |
| Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements 2016 · omega3 supplements arm · Participants with severe physical injury; age and sex not reported | 147 mg | 12 weeks | — |
| Effect of an acute dose of omega-3 fish oil following exercise-induced muscle damage 2017 · Low EPA · Physically active males, mean age 26 ± 4 years, after exercise-induced muscle damage | 250 mg | 1 day | — |
| Effect of an acute dose of omega-3 fish oil following exercise-induced muscle damage 2017 · High EPA · Physically active males, mean age 26 ± 4 years, after exercise-induced muscle damage | 750 mg | 1 day | — |
| Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial 2018 · MCP and omega-3 fatty acid group · Colorectal cancer patients on chemotherapy | 2 g | 8 weeks | — |
| Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial 2018 · omega-3 supplementation · Community-dwelling adults aged 70 years or older with subjective memory complaints | 1.03 g | 3 years | — |
| Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial 2018 · omega-3 plus multidomain intervention · Community-dwelling adults aged 70 years or older with subjective memory complaints | 1.03 g | 3 years | — |
| ω-3 and ω-6 Fatty Acid Supplementation May Reduce Autism Symptoms Based on Parent Report in Preterm Toddlers 2018 · Omega-3-6-9 Junior treatment · Children aged 18–38 months born at 29 weeks’ gestation or earlier, exhibiting early signs of ASD | 338 mg | 90 days | — |
| Effect of vitamin D and omega-3 on nocturnal enuresis of 7-15-year-old children 2018 · Group C · Children aged 7–15 with nocturnal enuresis | 1 g | 60 days | — |
| Adding omega-3 fatty acids to a protein-based supplement during pre-season training results in reduced muscle soreness and the better maintenance of explosive power in professional Rugby Union players 2018 · FO · Professional Rugby Union players undergoing pre-season training; age and sex not stated | 3.09 g | 5 weeks | — |
| Low-Dose Omega-3 Fatty Acid and Vitamin D for Anthropometric, Biochemical Blood Indices and Respiratory Function. Does it work? 2020 · experimental group · Office workers aged 40–60 years; sex and health condition not stated | 330 mg | 16 weeks | — |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: A randomised clinical trial 2022 · omega-3 supplementation (G3) · Children with ADHD; age and sex not specified | 775 mg | 8 weeks | — |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: A randomised clinical trial 2022 · Mediterranean diet plus omega-3 supplementation (G4) · Children with ADHD; age and sex not specified | 775 mg | 8 weeks | — |
| Re-esterified DHA improves ventilatory threshold 2 in competitive amateur cyclists 2020 · DHA · Male amateur cyclists older than 18 years, competing at regional level and training 2–4 sessions per week | 1.22 g | 30 days | — |
| Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women 2021 · omega-3 group (n-3) · Women aged 55–70 who were overweight or obese and postmenopausal | 1.95 g | 16 weeks | — |
| Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women 2021 · omega-3 + resistance training group (n-3+RT) · Women aged 55–70 who were overweight or obese and postmenopausal | 1.95 g | 16 weeks | — |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial 2022 · omega-3 supplementation · children with ADHD | 775 mg | 8 weeks | — |
| Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial 2022 · Mediterranean diet plus omega-3 supplementation · children with ADHD | 775 mg | 8 weeks | — |
| Nutritional Status Predicts Fatty Acid Uptake from Fish and Soybean Oil Supplements for Treatment of Cancer-Related Fatigue: Results from a Phase II Nationwide Study 2021 · 3 g fish oil + 3 g soybean oil · Adult female breast cancer survivors aged 18 or older, with stage 0–III cancer, 4–36 months post-treatment and self-reported fatigue | 3 g | 6 weeks | — |
| Effects of an Omega-3 Supplemented, High-Protein Diet in Combination with Vibration and Resistance Exercise on Muscle Power and Inflammation in Old Adults: A Pilot Randomized Controlled Trial 2022 · high-protein, omega-3-enriched · Community-dwelling adults aged 65–85 years | 2.2 g | 8 weeks | — |
| Effectiveness of a Novel Food Composed of Leucine, Omega-3 Fatty Acids and Probiotic Lactobacillus paracasei PS23 for the Treatment of Sarcopenia in Elderly Subjects: A 2-Month Randomized Double-Blind Placebo-Controlled Trial 2022 · intervention group (OLEP) · men and women aged 55 years or older with sarcopenia | 500 mg | 60 days | — |
| Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipids Improve Endurance Performance 2023 · STG group · Sedentary, untrained healthy men; age range not reported | 5.24 g | 58 days | — |
| Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipids Improve Endurance Performance 2023 · PM group · Sedentary, untrained healthy men; age range not reported | 5.24 g | 58 days | — |
| The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial 2025 · ω3+VitD group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported | 600 mg | 9 weeks | — |
| Omega and heart rate variability in overweight and obese schoolchildren 2025 · interventional (cases) · Children aged 5–12 years, both sexes, with overweight or simple obesity | 600 mg | 90 days | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s, without SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 1 g | 3 years | — |
| Effects of vitamin D3, omega-3 fatty acids and a simple home exercise program on change in physical activity among generally healthy and active older adults: The 3-year DO-HEALTH trial 2025 · Vitamin D3 and omega-3s with SHEP · Generally healthy, community-dwelling adults aged 70 years or older; men and women | 1 g | 3 years | — |
| Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study 1994 · 1.3 gm of omega 3 + 3 gm of olive oil · People with active rheumatoid arthritis; age and sex not stated | 1.3 g | 1 year | — |
| Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study 1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported | 1.71 g | 1 year | — |
| Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis 1993 · fish-oil group · Patients with moderate-to-severe psoriasis; age and sex not specified | 5 g | 120 days | — |
| High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study 2018 · phase 1: EPA · Adults with abdominal obesity and subclinical inflammation at risk of cardiovascular disease; 48 men and 106 women enrolled | 2.7 g | 10 weeks | 154 |
| Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial 2021 · n-3 PUFA supplements · Adult kidney transplant recipients with stable kidney function in the early post-transplant phase | 2.6 g | 44 weeks | 66 |
| Effects of omega-3 on metabolic markers in postmenopausal women with metabolic syndrome 2015 · diet plus omega-3 supplementation · Postmenopausal Brazilian women aged 45 years or older with metabolic syndrome | 900 mg | 26 weeks | 44 |
| Blood pressure-lowering effects of long chain n-3 fatty acids from meals enriched with liquid fish oil and from microencapsulated powder 2016 · Group 1 · Community-dwelling adults older than 50 years | 1.5 g | 4 weeks | 38 |
| The effects of low doses of n-3 fatty acid supplementation on blood pressure in hypertensive subjects. A randomized controlled trial 1991 · n-3 fatty acid supplementation · Adults with mild hypertension; age and sex not specified | 2.04 g | 12 weeks | 33 |
| Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia 2011 · prescription omega-3-acid ethyl esters (POM3) · men and women with primary, isolated hypercholesterolemia (LDL-C 130–220 mg/dL and triglycerides less than 150 mg/dL) | 4 g | 6 weeks | 31 |
| Blood pressure-lowering effects of long chain n-3 fatty acids from meals enriched with liquid fish oil and from microencapsulated powder 2016 · Group 2 · Community-dwelling adults older than 50 years | 1.5 g | 4 weeks | 30 |
| Blood pressure lowering in elderly subjects: a double-blind crossover study of omega-3 and omega-6 fatty acids 1991 · fish oil · Elderly subjects aged 60 years or older with hypertension | 9 g | 8 weeks | 22 |
| Ethyl EPA and ethyl DHA cause similar and differential changes in plasma lipid concentrations and lipid metabolism in subjects with low-grade chronic inflammation 2022 · EPA supplementation · Adults aged 50–75 with low-grade chronic inflammation and at least one characteristic of metabolic syndrome; women were postmenopausal | 3 g | 10 weeks | 21 |
| Effects of fish oil, nifedipine and their combination on blood pressure and lipids in primary hypertension 1993 · fish oil treatment · 18 males with primary hypertension (WHO stage I–II) and elevated lipid levels | 4.55 g | 4 weeks | 18 |
| The Effects of Omega-3 Supplementation Combined with Strength Training on Neuro-Biomarkers, Inflammatory and Antioxidant Responses, and the Lipid Profile in Physically Healthy Adults 2025 · experimental group (omega-3 supplementation group) · healthy, resistance-trained males aged 18–30 years | 3.15 g | 8 weeks | 15 |
| Effect of sodium restriction and fish oil supplementation on BP and thrombotic risk factors in patients treated with ACE inhibitors 1994 · Low sodium with fish oil · Patients with hypertension treated with captopril or enalapril | 5 g | 6 weeks | 14 |
| Effect of sodium restriction and fish oil supplementation on BP and thrombotic risk factors in patients treated with ACE inhibitors 1994 · Normal sodium with fish oil · Patients with hypertension treated with captopril or enalapril | 5 g | 6 weeks | 14 |
| Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients 1997 · omega-3 fatty acids treatment group · heart transplant recipients, from the fourth postoperative day | 4 g | 26 weeks | 14 |
| n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects 1990 · group 1 · Hypertriglyceridemic subjects; age range and sex not reported | 2.2 g | 20 weeks | 10 |
| Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation 1993 · omega-3 fatty acids treatment group · Hypertensive cardiac transplant recipients treated with cyclosporine | 3 g | 12 weeks | 10 |
| Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans 1999 · purified EPA · overweight, mildly hyperlipidemic men | 4 g | 6 weeks | — |
| Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients 2001 · omega-3 fatty acids · Hypertensive heart transplant recipients, studied 1–12 years after transplantation | 3.4 g | 1 year | — |
| Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia 2005 · omega-3 FA + placebo · Patients with type II hypercholesterolaemia | 2 g | 8 weeks | — |
| The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial 2009 · omega3FA · Nondiabetic patients with stage 3–4 chronic kidney disease | 4 g | 8 weeks | — |
| n-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants 1990 · EPA plus DHA diet · Normotensive and mildly hypercholesterolemic men | 3.4 g | 6 weeks | — |
| Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy 2010 · P-OM3 · Men and women with high triglycerides (200 to 499 mg/dl) and mixed dyslipidemia receiving diet plus simvastatin therapy | 4 g | 8 weeks | — |
| Preliminary evidence that acute long-chain omega-3 supplementation reduces cardiovascular reactivity to mental stress: a randomized and placebo controlled trial 2012 · omega-3 fatty acids · young, healthy individuals | 1.4 g | 3 weeks | — |
| Untitled 2012 · fish oil group · Women with metabolic syndrome; mean age 47.9 years | 3 g | 90 days | — |
| Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients 2013 · 1.8 g/d ω-3 PUFA group · Non-dialyzed patients with stage IV/V chronic kidney disease; age and sex not stated | 1.8 g | 10 weeks | — |
| Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults 2014 · 0.45 g/d EPA and DHA · Healthy adults; age range and sex not stated | 450 mg | 1 year | — |
| Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults 2014 · 0.9 g/d EPA and DHA · Healthy adults; age range and sex not stated | 900 mg | 1 year | — |
| Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults 2014 · 1.8 g/d EPA and DHA · Healthy adults; age range and sex not stated | 1.8 g | 1 year | — |
| Lipidomic changes of LDL in overweight and moderately hypercholesterolemic subjects taking phytosterol- and omega-3-supplemented milk 2015 · ω3-milk · Overweight and moderately hypercholesterolemic subjects; age and sex not specified | 375 mg | 4 weeks | — |
| Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives 1998 · daily fish meal · Overweight adults with medication-treated hypertension | 3.65 g | 16 weeks | — |
| Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives 1998 · fish meal plus weight reduction · Overweight adults with medication-treated hypertension | 3.65 g | 16 weeks | — |
| The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial 2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition | 1 g | 18 weeks | 134 |
| Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial 2015 · omega-3 group · Children aged 8–16 years living in the community | 2 g | 26 weeks | 100 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 100 mg | 12 weeks | 96 |
| Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial 2017 · PCSO-524® · Children and adolescents aged 6–14 years with elevated ADHD symptoms, including participants with and without an ADHD diagnosis | 38.4 mg | 14 weeks | 74 |
| Nutritional supplementation to reduce child aggression: a randomized, stratified, single-blind, factorial trial 2016 · Nutrition + CBT · Children aged 11–12 years at high risk for aggression or antisocial behavior, including full or borderline conduct disorder or oppositional defiant disorder criteria, or elevated proactive or reactive aggression scores | 1 g | 90 days | 73 |
| Effects of a 6-Month Multifaceted Diet and Exercise Intervention on Cognition in Older Adults at Risk of Cognitive Decline: The PONDER Double-Blind, Placebo-Controlled Randomized Trial 2022 · Multimodal exercise program with daily supplement · Community-dwelling older adults with subjective memory impairment; mean age 70.2 years, 70% female | 1.5 g | 26 weeks | 73 |
| Nutritional supplementation to reduce child aggression: a randomized, stratified, single-blind, factorial trial 2016 · Nutrition only · Children aged 11–12 years at high risk for aggression or antisocial behavior, including full or borderline conduct disorder or oppositional defiant disorder criteria, or elevated proactive or reactive aggression scores | 1 g | 90 days | 72 |
| Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial 2016 · n-3 PUFA treatment · Men and women aged 45–80 with stable coronary artery disease participating in cardiac rehabilitation, with or without a depressive episode | 1.9 g | 12 weeks | 46 |
| Association between cognitive function and supplementation with omega-3 PUFAs and other nutrients in ≥ 75 years old patients: A randomized multicenter study 2018 · intervention group · Institutionalized adults aged 75 years or older without dementia, with or without mild cognitive impairment | 870 mg | 1 year | 44 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 1.42 g | 12 weeks | 40 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 100 mg | 24 weeks | 40 |
| TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD 2007 · Sham MCS and nutritional supplement · Adults aged 50–90 with dry age-related macular degeneration in at least one eye | 300 mg | 24 weeks | 37 |
| A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction 2013 · Group B (study oral supplement formulation, Brudysec 1.5 g) · Adults aged 23–85 years, both sexes, diagnosed with meibomian gland dysfunction | 1.27 g | 90 days | 33 |
| Lipid Profile, Lipoprotein Subfractions, and Fluidity of Membranes in Children and Adolescents with Depressive Disorder: Effect of Omega-3 Fatty Acids in a Double-Blind Randomized Controlled Study 2020 · Om3 group · Children and adolescents aged 11–17 years with depressive disorder or mixed anxiety and depressive disorder | 4.15 g | 12 weeks | 29 |
| The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis 2021 · OMEGA group · Adults with relapsing-remitting multiple sclerosis; mean age 38.4 years (SD 7.1) | 4.95 g | 2 years | 27 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 600 mg | 120 days | 26 |
| Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial 2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis | 2.6 g | 26 weeks | 24 |
| The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment 2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment | 810 mg | 26 weeks | 23 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 590 mg | 30 days | 22 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 159 mg | 30 days | 22 |
| Benefits of Krill Oil Supplementation During Alternate-Day Fasting in Adults With Overweight and Obesity: A Randomized Trial 2025 · KO group · Healthy adults aged 25–65 with BMI >25 kg/m² and overweight or obesity; 25 women and 16 men enrolled | 570 mg | 12 weeks | 21 |
| Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial 2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis | 2.6 g | 90 days | 20 |
| Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported. | 810 mg | 913 days | 20 |
| Antioxidant and Anti-Inflammatory Effects of Oral Supplementation with a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients with Keratoconus: A Randomized Controlled Preliminary Study 2023 · DHA group · Adults aged 18 years or older with stage I–III keratoconus | 602 mg | 90 days | 19 |
| 21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo 2015 · N-3 PUFA · Healthy male athletes competing in summer Olympic sports; ages not otherwise specified | 10 g | 3 weeks | 18 |
| An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553] 2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress | 120 mg | 6 weeks | 16 |
| A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study 2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill | 160 mg | 24 weeks | 15 |
| A multicomponent intervention consisting of exercise, proteins and omega-3 supplementation to improve sarcopenia in community-dwelling older adults: Lessons learned from a 5-armed randomized controlled feasibility trial 2026 · Exercise intervention + protein supplementation + omega-3 (group 4) · Adults aged 65 years or older with sarcopenia; women and men | 950 mg | 12 weeks | 12 |
| A Combination of Essential Fatty Acids, Panax Ginseng Extract, and Green Tea Catechins Modifies Brain fMRI Signals in Healthy Older Adults 2018 · Investigational product (Cerbella) · Adults aged 55–75 years who were cognitively healthy and non-demented | 1.58 g | 26 days | 10 |
| Effects of Supplementation with Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins, Combined with High-Intensity Functional Training, on Exercise Performance and Body Composition: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · experimental supplement group (SG) · Healthy young adult women and men, aged approximately 29 years, familiar with high-intensity functional training and with at least 6 months of similar exercise experience | 6.9 g | 8 weeks | 10 |
| Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipid Supplementation Improves Muscular Endurance Exercise Performance and Reduces Muscle Fatigue in Young Healthy Male 2025 · EPA/MCT group · Healthy young men | 600 mg | 8 weeks | 10 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 680 mg | 8 weeks | 10 |
| Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients 1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported | 216 mg | 6 weeks | — |
| Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia 2007 · Australia micronutrient mix plus DHA+EPA · Children aged 6–10 years in Australia, described as well-nourished | 110 mg | 1 year | — |
| Effect of a 12-mo micronutrient intervention on learning and memory in well-nourished and marginally nourished school-aged children: 2 parallel, randomized, placebo-controlled studies in Australia and Indonesia 2007 · Indonesia micronutrient mix plus DHA+EPA · Children aged 6–10 years in Indonesia, described as marginally nourished | 110 mg | 1 year | — |
| Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders 2013 · DEDG+S · Adults aged 23–80 years, both sexes, with mild-to-moderate dry eye disorders | 845 mg | 90 days | — |
| Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders 2013 · CG+S · Healthy adults aged 23–80 years, both sexes | 845 mg | 90 days | — |
| B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial 2014 · B vitamins plus n-3 fatty acids · Adults aged 45–80 with a recent history of myocardial infarction, unstable angina, or ischemic stroke | 600 mg | 1716 days | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 650 mg | 5 years | — |
| Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms 2017 · treatment group · Children aged 18–38 months, born before 30 completed gestational weeks, screened as at risk for ASD | 563 mg | 90 days | — |
| Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial 2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms | 706 mg | 90 days | — |
| EPA and DHA as markers of nutraceutical treatment response in major depressive disorder 2020 · combination nutraceutical · Adults with major depressive disorder; age and sex not reported | 1 g | 8 weeks | — |
| Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass 2022 · supplement (SUPP) · Community-dwelling older adults with low skeletal muscle mass; mean age 74.9 years; 18 men and 19 women in the study overall | 3 g | 26 weeks | — |
| Supplemental Protein and a Multinutrient Beverage Speed Wound Healing after Acute Sleep Restriction in Healthy Adults 2022 · NUT · Generally healthy young adults aged 18–approximately 20 years (18 males and 2 females), after acute sleep restriction | 1 g | 7 days | — |
| Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial 2022 · omega 3-6-9 treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation, with symptoms commonly associated with autism spectrum disorder | 1.04 g | 90 days | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.95 g | 16 weeks | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.95 g | 16 weeks | — |
| Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension 2011 · PS-DHA continuers (open-label extension) · Men and women aged 50–90 years with memory complaints who had received PS-DHA in the double-blind phase | 26 mg | 15 weeks | 61 |
| Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension 2011 · PS-DHA naive group (open-label extension) · Men and women aged 50–90 years with memory complaints who had received placebo during the double-blind phase | 26 mg | 15 weeks | 61 |
| Evaluating the Impact of Omega-3 Fatty Acid (Soloways(TM)) Supplementation on Lipid Profiles in Adults with PPARG Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial 2023 · omega-3 fatty acids group · Adults aged 40–75 with LDL-C levels of 70–190 mg/dL and low-to-moderate cardiovascular risk, including participants with and without PPARG polymorphisms | 1.8 g | 90 days | 51 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · FO concentrate · Obese men and women with BMI >30 | 1.6 g | 12 weeks | 12 |
| Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia 2005 · omega-3 FA + policosanol 5 mg/day · Patients with type II hypercholesterolaemia | 2 g | 8 weeks | — |
| Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia 2005 · omega-3 FA + policosanol 10 mg/day · Patients with type II hypercholesterolaemia | 2 g | 8 weeks | — |
| The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial 2009 · both supplements · Nondiabetic patients with stage 3–4 chronic kidney disease | 4 g | 8 weeks | — |
| Untitled 2012 · fish oil and kinako group · Women with metabolic syndrome; mean age 47.9 years | 3 g | 90 days | — |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 0.7 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 700 mg | 8 weeks | — |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 1.8 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 1.8 g | 8 weeks | — |
| Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial 2018 · ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported | 3.65 g | 12 weeks | — |
| Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial 2018 · LCHP+ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported | 3.65 g | 12 weeks | — |
| Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention 1994 · fish oil group · Normotensive men and women aged 30–54 years | 3 g | 26 weeks | — |
| Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol 2017 · Omega3Q10 treatment group · Adults aged at least 50 years with elevated blood pressure and/or elevated blood cholesterol | 514 mg | 12 weeks | 48 |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects 2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia | 1.7 g | 4 weeks | 21 |
| Reduction in Serum LDL Cholesterol Using a Nutrient Compendium in Hyperlipidemic Adults Unable or Unwilling to Use Statin Therapy: A Double-Blind Randomized Crossover Clinical Trial 2022 · Treatment foods · Adult men and women with hyperlipidemia who were unable or unwilling to use statin therapy | 2 g | 4 weeks | — |
| Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid 2017 · EPA treatment phase · Men and women with abdominal obesity and subclinical inflammation; ages not reported | 2.7 g | 10 weeks | 154 |
| The effects of omega-3 fatty acid supplementation in pregnancy on maternal eicosanoid, cytokine, and chemokine secretion 2009 · omega-3 LCPUFA · Pregnant women with allergic disease in their immediate family | 2.7 g | — | 70 |
| Omega-3 Eicosapentaenoic Acid (EPA) Rich Extract from the Microalga Nannochloropsis Decreases Cholesterol in Healthy Individuals: A Double-Blind, Randomized, Placebo-Controlled, Three-Month Supplementation Study 2020 · active intervention group · Generally healthy men and women over 25 years of age with low omega-3 index | 1 g | 12 weeks | 60 |
| Bioavailability of long-chain n-3 fatty acids from enriched meals and from microencapsulated powder 2015 · Group 1 · Adults aged 50 years or older; no condition stated | 1.5 g | 4 weeks | 38 |
| FADS1 Genetic Variant and Omega-3 Supplementation Are Associated with Changes in Fatty Acid Composition in Red Blood Cells of Subjects with Obesity 2024 · omega-3 group · Men and women aged 30 to 50 years with obesity | 1.5 g | 120 days | 38 |
| Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial 2023 · treatment group (study group) · Full-term neonates with intrauterine growth restriction (IUGR) | 40 mg/kg | 2 weeks | 35 |
| Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda 2018 · ω-3 arm · Adults aged 18 years or older with HIV and HHV-8 coinfection, including participants with early-stage Kaposi sarcoma | 3 g | 12 weeks | 33 |
| Dietary supplementation with seed oil from transgenic Camelina sativa induces similar increments in plasma and erythrocyte DHA and EPA to fish oil in healthy humans 2020 · Camelina sativa seed oil (CSO) · Healthy men and women aged 20–74 years | 450 mg | 8 weeks | 31 |
| Bioavailability of long-chain n-3 fatty acids from enriched meals and from microencapsulated powder 2015 · Group 2 · Adults aged 50 years or older; no condition stated | 1.5 g | 4 weeks | 30 |
| Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents 2010 · n-3 treatment · Obese adolescents, 14 female and 11 male, mean age 15.7 years | 1.2 g | 90 days | 25 |
| Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies(TM) (ALT(®))-based formulation 2017 · SC401 under fasted, low-fat meal, and high-fat meal conditions · 24 healthy subjects | 1.53 g | 1 day | 24 |
| Essential fatty acid status in neonates after fish-oil supplementation during late pregnancy 1995 · fish-oil-supplemented group · Healthy pregnant women, from the 30th week of gestation until delivery | 2.7 g | — | 23 |
| Oral Bioavailability of Omega-3 Fatty Acids and Carotenoids from the Microalgae Phaeodactylum tricornutum in Healthy Young Adults 2021 · Fish oil (FO) capsule · Healthy adults aged 18–50 years, women and men | 310 mg | 2 weeks | 22 |
| Equal bioavailability of omega-3 PUFA from Calanus oil, fish oil and krill oil: A 12-week randomized parallel study 2023 · CO group · Healthy volunteers; mean age 29.7 years; sex not specified | 242 mg | 12 weeks | 21 |
| Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with inflammatory skin diseases 1994 · n-3 fatty acids group · Patients with psoriasis or atopic dermatitis; ages and sex not stated | 6 g | 120 days | 21 |
| Preoperative oral supplementation with long-chain Omega-3 fatty acids beneficially alters phospholipid fatty acid patterns in liver, gut mucosa, and tumor tissue 2005 · PUFA group · Patients with malignancies of the upper gastrointestinal tract undergoing major gastrointestinal surgery; age and sex not specified | 3.7 g | 5 days | 20 |
| Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial 2021 · monoglyceride rich oil (MAG) · Healthy men and women aged 18–60 years | 3 g | 1 day | 20 |
| Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial 2021 · ethyl ester (EE) · Healthy men and women aged 18–60 years | 3 g | 1 day | 20 |
| A novel n-3 glyceride mixture enhances enrichment of EPA and DHA after single dosing in healthy older adults: results from a double-blind crossover trial 2021 · glyceride-EPA + DHA formulation · Healthy adults aged 50–70 years | 2.8 g | 1 day | 20 |
| A novel n-3 glyceride mixture enhances enrichment of EPA and DHA after single dosing in healthy older adults: results from a double-blind crossover trial 2021 · ethyl ester EPA + DHA formulation · Healthy adults aged 50–70 years | 2.8 g | 1 day | 20 |
| Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study 2007 · fish oil group · Haemodialysis patients; age and sex not reported | 1.3 g | 12 weeks | 18 |
| Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study 2014 · n-3 FA supplement group · Patients with mild Alzheimer's disease | 2.3 g | 26 weeks | 18 |
| Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels 2012 · rosuvastatin 10 mg plus omega-3 fatty acids 2 g · Patients with mixed dyslipidemia and LDL cholesterol above 160 mg/dL plus triglycerides above 200 mg/dL | 2 g | 90 days | 17 |
| Effect of Omega-3 and Vitamins E + C Supplements on the Concentration of Serum B-Vitamins and Plasma Redox Aminothiol Antioxidant Status in Elderly Men after Strength Training for Three Months 2016 · group II · Healthy men, mean age 60 ± 6 years, undertaking strength training | 700 mg | 90 days | 17 |
| Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial 2011 · n-3 LC-PUFA (group 1) · Adults aged 18–90 with rheumatoid arthritis or psoriatic arthritis and at least medium disease activity | 3 g | 12 weeks | 15 |
| Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study 2019 · Ω-3LCPUFA group · Boys with Duchenne muscular dystrophy; age range not stated | 2.9 g | 26 weeks | 14 |
| Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers 2019 · 1 g group · healthy volunteers following a Therapeutic Lifestyle Change diet | 1 g | 15 days | 14 |
| Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers 2019 · 2 g group · healthy volunteers following a Therapeutic Lifestyle Change diet | 2 g | 15 days | 14 |
| Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers 2019 · 4 g group · healthy volunteers following a Therapeutic Lifestyle Change diet | 4 g | 15 days | 14 |
| Effect of Food with Low Enrichment of N-3 Fatty Acids in a Two-Month Diet on the Fatty Acid Content in the Plasma and Erythrocytes and on Cardiovascular Risk Markers in Healthy Young Men 2020 · omega-3 group · Healthy men aged 18–25 years | 37 mg | 8 weeks | 14 |
| Incorporation of eicosapentaenioic and docosahexaenoic acids into breast adipose tissue of women at high risk of breast cancer: a randomized clinical trial of dietary fish and n-3 fatty acid capsules 2015 · n-3 PUFA capsules · Women aged 18 years or older at high risk for breast cancer | 1.8 g | 90 days | 13 |
| Erythrocyte eicosapentaenoic acid versus docosahexaenoic acid as a marker for fish and fish oil consumption 1991 · Fish + Oil · Healthy men; age not reported | 5 g | 6 weeks | 12 |
| Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study 2020 · OM3-EE 4 g once daily · Adults aged 18 years or older with severe hypertriglyceridemia and a history of hospitalization for acute hypertriglyceridemia-induced pancreatitis | 4 g | 4 weeks | 12 |
| Erythrocyte eicosapentaenoic acid versus docosahexaenoic acid as a marker for fish and fish oil consumption 1991 · Fish oil alone · Healthy men; age not reported | 5 g | 6 weeks | 11 |
| Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker 2008 · SDA-SBO · Overweight healthy volunteers | 24 mL | 16 weeks | 11 |
| Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker 2008 · EPA ethyl esters · Overweight healthy volunteers | 1 g | 16 weeks | 11 |
| A short-term n-3 DPA supplementation study in humans 2013 · DPA supplementation · Adult female participants; age and health status not specified | 1.14 g | 7 days | 10 |
| A short-term n-3 DPA supplementation study in humans 2013 · EPA supplementation · Adult female participants; age and health status not specified | 1.14 g | 7 days | 10 |
| The impact of non-surgical periodontal treatment on serum levels of long chain-polyunsaturated fatty acids: a pilot randomized clinical trial 2014 · test group · Adults with generalized chronic periodontitis; mean age 44 years (10 participants) | 3 g | 120 days | 10 |
| Use of manufactured foods enriched with fish oils as a means of increasing long-chain n-3 polyunsaturated fatty acid intake 1997 · n-3 enriched · Healthy, normotriacylglycerolaemic men aged 35–60 years | 1.4 g | 22 days | 9 |
| Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119) 2023 · MND-2119 2-g group · Healthy men aged 20–40 years | 2 g | 7 days | 8 |
| Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119) 2023 · MND-2119 4-g group · Healthy men aged 20–40 years | 4 g | 7 days | 8 |
| Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119) 2023 · EPA-E 1.8-g group · Healthy men aged 20–40 years | 1.8 g | 7 days | 8 |
| Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study 2020 · OM3-CA 2 g once daily · Adults aged 18 years or older with severe hypertriglyceridemia and a history of hospitalization for acute hypertriglyceridemia-induced pancreatitis | 2 g | 4 weeks | 6 |
| Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study 2020 · OM3-CA 4 g once daily · Adults aged 18 years or older with severe hypertriglyceridemia and a history of hospitalization for acute hypertriglyceridemia-induced pancreatitis | 4 g | 4 weeks | 6 |
| Bioavailability of n-3 polyunsaturated fatty acids (PUFA) in foods enriched with microencapsulated fish oil 2000 · capsule group · Healthy female volunteers | 900 mg | 4 weeks | — |
| Fatty acid composition of skeletal muscle reflects dietary fat composition in humans 2002 · Fish oil supplementation in the SFA diet group · Healthy adults (25 men and 7 women); exact numbers in this diet group not reported | 3.6 g | 90 days | — |
| Fatty acid composition of skeletal muscle reflects dietary fat composition in humans 2002 · Fish oil supplementation in the MUFA diet group · Healthy adults (25 men and 7 women); exact numbers in this diet group not reported | 3.6 g | 90 days | — |
| The influence of different combinations of gamma-linolenic, stearidonic and eicosapentaenoic acids on the fatty acid composition of blood lipids and mononuclear cells in human volunteers 2004 · STA-rich oil intake (STA alone; amount varied) · Healthy young males | 1 g | 12 weeks | — |
| The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters 2006 · 62.5% concentration · Adults; age and sex not reported; no condition specified | 5.1 g | 2 weeks | — |
| The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters 2006 · 80% concentration · Adults; age and sex not reported; no condition specified | 5.1 g | 2 weeks | — |
| The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters 2006 · 85% concentration · Adults; age and sex not reported; no condition specified | 5.1 g | 2 weeks | — |
| Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors 2007 · n-3-enriched foods · Overweight adults with triacylglycerol levels above 1.6 mmol/L | 1 g | 26 weeks | — |
| Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus 2008 · EPA group · Patients with Barrett's esophagus; age and sex not specified | 1.5 g | 26 weeks | — |
| Regular consumption of n-3 fatty acid-enriched pork modifies cardiovascular risk factors 2009 · n-3-enriched pork · Healthy adult volunteers | 186 mg | 12 weeks | — |
| Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers 2009 · test formulation · healthy subjects | 3 g | 4 weeks | — |
| Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers 2009 · reference formulation · healthy subjects | 3 g | 4 weeks | — |
| The incorporation of marine n-3 PUFA into platelets and adipose tissue in pre- and postmenopausal women: a randomised, double-blind, placebo-controlled trial 2010 · Marine n-3 PUFA (fish oil) · Pre- and postmenopausal women | 2.2 g | 12 weeks | — |
| Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition 2010 · 1 capsule/day · Women at high risk of breast cancer | 840 mg | 26 weeks | — |
| Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition 2010 · 3 capsules/day · Women at high risk of breast cancer | 2.52 g | 26 weeks | — |
| Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition 2010 · 6 capsules/day · Women at high risk of breast cancer | 5.04 g | 26 weeks | — |
| Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition 2010 · 9 capsules/day · Women at high risk of breast cancer | 7.56 g | 26 weeks | — |
| Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content 2012 · SDA 0.43 g/d · Healthy subjects; age and sex not specified | 430 mg | 12 weeks | — |
| Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content 2012 · SDA 1.3 g/d · Healthy subjects; age and sex not specified | 1.3 g | 12 weeks | — |
| Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content 2012 · SDA 2.6 g/d · Healthy subjects; age and sex not specified | 2.6 g | 12 weeks | — |
| Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content 2012 · SDA 5.2 g/d · Healthy subjects; age and sex not specified | 5.2 g | 12 weeks | — |
| Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content 2012 · EPA 0.44 g/d · Healthy subjects; age and sex not specified | 440 mg | 12 weeks | — |
| Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content 2012 · EPA 1.3 g/d · Healthy subjects; age and sex not specified | 1.3 g | 12 weeks | — |
| Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content 2012 · EPA 2.7 g/d · Healthy subjects; age and sex not specified | 2.7 g | 12 weeks | — |
| Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients 2012 · omega-3 FA supplement · Adults with end-stage kidney disease treated with dialysis for at least 1 year; mean age 57.4 years | 3 g | 26 weeks | — |
| A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study 2012 · OM-3 FFA during low-fat consumption period · Overweight adults; age and sex not specified | 4 g | 1 day | — |
| A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study 2012 · OM-3 FFA during high-fat consumption period · Overweight adults; age and sex not specified | 4 g | 1 day | — |
| A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study 2012 · OM-3 EE during low-fat consumption period · Overweight adults; age and sex not specified | 4 g | 1 day | — |
| A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study 2012 · OM-3 EE during high-fat consumption period · Overweight adults; age and sex not specified | 4 g | 1 day | — |
| Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors 2013 · yoghurt enriched with 3 g n-3 LC-PUFA/d · Mildly hypertriacylglycerolemic subjects with TAG ≥ 1.7 mmol/L; age and sex not specified | 3 g | 10 weeks | — |
| Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality 2013 · n-3 PUFA · Patients with chronic heart failure | 1 g | 90 days | — |
| Do fish oil omega-3 fatty acids enhance antioxidant capacity and mitochondrial fatty acid oxidation in human atrial myocardium via PPARγ activation? 2014 · n-3 PUFA-treated patients · Patients undergoing elective cardiac surgery; age and sex not specified | 3.4 g | 3 weeks | — |
| Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation 2015 · Study 2: 850 mg/day EPA + DHA · Adults aged 22–65 years with moderately elevated triglycerides and low habitual oily-fish consumption | 850 mg | 8 weeks | — |
| Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation 2015 · Study 2: 3400 mg/day EPA + DHA · Adults aged 22–65 years with moderately elevated triglycerides and low habitual oily-fish consumption | 3.4 g | 8 weeks | — |
| Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study 2015 · ω3 FA supplementation group · Adults aged 74 ± 9 years with mild to moderate Alzheimer's disease | 2.3 g | 26 weeks | — |
| High levels of omega-3 fatty acids in milk from omega-3 fatty acid-supplemented mothers are related to less immunoglobulin E-associated disease in infancy 2016 · omega-3 LCPUFA group · Pregnant women at risk of having an allergic infant | 2.6 g | — | — |
| Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial 2016 · O3AEE group · Patients with heart failure; age and sex not reported | 1 g | 90 days | — |
| Potential therapeutic impact of omega-3 long chain-polyunsaturated fatty acids on inflammation markers in Duchenne muscular dystrophy: A double-blind, controlled randomized trial 2018 · ω-3 long chain-PUFA · boys with Duchenne muscular dystrophy | 2.9 g | 26 weeks | — |
| Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State 2018 · SMEDS treatment · Healthy men and women; mean age 33.8 years | 500 mg | 1 day | — |
| Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State 2018 · EE treatment · Healthy men and women; mean age 33.8 years | 840 mg | 1 day | — |
| Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial 2019 · EPA group · Adults aged 21.6 ± 2.2 years; no condition stated | 3 g | 12 weeks | — |
| Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study 2020 · EPA · Healthy women; age range not reported | 1 g | 6 days | — |
| Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study 2020 · DPA · Healthy women; age range not reported | 1 g | 6 days | — |
| Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms 2020 · OM3-MAG (clinical trial A) · Healthy adults, both sexes, normal weight, on a low-fat diet | 1 g | 1 day | — |
| Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms 2020 · OM3-ethyl ester (clinical trial A) · Healthy adults, both sexes, normal weight, on a low-fat diet | 1 g | 1 day | — |
| Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms 2020 · OM3-FFA (clinical trial A) · Healthy adults, both sexes, normal weight, on a low-fat diet | 1 g | 1 day | — |
| Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms 2020 · OM3-MAG (clinical trial B) · Overweight or obese healthy adults, both sexes | 380 mg | 1 day | — |
| Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms 2020 · OM3-TAG (clinical trial B) · Overweight or obese healthy adults, both sexes | 380 mg | 1 day | — |
| High Variability in Erythrocyte, Plasma and Whole Blood EPA and DHA Levels in Response to Supplementation 2020 · 0.35 g/day group · Premenopausal women aged 18–39 with mildly elevated triglycerides and regular menstrual cycles | 350 mg | 8 weeks | — |
| High Variability in Erythrocyte, Plasma and Whole Blood EPA and DHA Levels in Response to Supplementation 2020 · 0.7 g/day group · Premenopausal women aged 18–39 with mildly elevated triglycerides and regular menstrual cycles | 700 mg | 8 weeks | — |
| High Variability in Erythrocyte, Plasma and Whole Blood EPA and DHA Levels in Response to Supplementation 2020 · 1.0 g/day group · Premenopausal women aged 18–39 with mildly elevated triglycerides and regular menstrual cycles | 1 g | 8 weeks | — |
| Comparison of the Effect of Omega-3 vs. MCT Supplementation on Iron-Related Indices in Patients Undergoing Dialysis 2025 · omega-3 group · Patients with chronic kidney disease undergoing dialysis; age and sex not reported | 3 g | 8 weeks | — |
| The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial 2025 · EPA-FFA group · High-risk adults undergoing colonoscopy surveillance after removal of multiple colorectal polyps; age and sex not specified | 2 g | 1 year | — |
| The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial 2025 · EPA-TG group · High-risk adults undergoing colonoscopy surveillance after removal of multiple colorectal polyps; age and sex not specified | 2.78 g | 1 year | — |
| Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors - impact on breast adipose oxylipin and DNA methylation patterns 2025 · ∼5 g/d EPA+DHA · Female breast cancer survivors with ERPR-negative stage 0–III cancer, within 5 years of completing standard therapy | 5 g | 1 year | — |
| Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors - impact on breast adipose oxylipin and DNA methylation patterns 2025 · ∼1 g/d EPA+DHA · Female breast cancer survivors with ERPR-negative stage 0–III cancer, within 5 years of completing standard therapy | 1 g | 1 year | — |
| Effects of vitamin D, omega-3 and a simple strength exercise programme in cardiovascular disease prevention: The DO-HEALTH randomized controlled trial 2024 · Omega-3 · Community-dwelling adults aged 70 years and older, generally healthy and active, without major chronic conditions | 1 g | 3 years | 1,073 |
| Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial 2025 · Omega-3 group · Generally healthy, community-dwelling adults aged 70 years and older; Swiss subgroup with DNA methylation measures at baseline and 3 years | 1 g | 3 years | 385 |
| Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial 2022 · ω-3–PL/FFA · Adults aged 18 years or older with severe hypertriglyceridemia (fasting triglycerides 500–1500 mg/dL) | 4 g | 26 weeks | 372 |
| Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial 2020 · n-3 LCPUFA · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified | 2.4 g | 17 weeks | 344 |
| Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies 2013 · ANCHOR IPE 2 g/day · Men and women aged over 18 at high cardiovascular risk, on stable statin therapy, with triglycerides 200–<500 mg/dL and LDL-C 40–<115 mg/dL | 2 g | 12 weeks | 236 |
| Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies 2013 · ANCHOR IPE 4 g/day · Men and women aged over 18 at high cardiovascular risk, on stable statin therapy, with triglycerides 200–<500 mg/dL and LDL-C 40–<115 mg/dL | 4 g | 12 weeks | 233 |
| Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study) 2015 · IPE 4 g/day · Adults at high cardiovascular risk with triglycerides ≥200 and <500 mg/dL despite statin control of LDL cholesterol | 4 g | 12 weeks | 216 |
| Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial 2015 · Statin + OM3-CA 4 g/d · Adults aged 18 years or older, men and non-pregnant, non-lactating women, at high cardiovascular risk with residual hypertriglyceridemia while taking a statin | 4 g | 6 weeks | 216 |
| Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study 2015 · TAK-085 4 g/day · Japanese men and women aged 20 to under 75 with hypertriglyceridemia | 4 g | 12 weeks | 210 |
| Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study 2015 · TAK-085 2 g/day · Japanese men and women aged 20 to under 75 with hypertriglyceridemia | 2 g | 12 weeks | 206 |
| Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study 2013 · EPA-E 0.6 g three times daily · Japanese patients with hypertriglyceridemia (TG ≥150 mg/dL and <750 mg/dL) | 1.8 g | 12 weeks | 195 |
| Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study 2015 · EPA-E 1.8 g/day · Japanese men and women aged 20 to under 75 with hypertriglyceridemia | 1.8 g | 12 weeks | 195 |
| Insulin Resistance Modifies the Effects of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction (from the OMEGA-REMODEL Randomized Clinical Trial) 2020 · O-3FA treatment · Adults with acute myocardial infarction, enrolled 2–4 weeks after the event | 4 g | 180 days | 180 |
| Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study 2013 · IPE 2 g/day · Adults with type 2 diabetes (one participant had type 1 diabetes), residual triglycerides of 200–500 mg/dL, LDL-C of 40–100 mg/dL, and high cardiovascular risk while taking stable statin therapy | 2 g | 12 weeks | 171 |
| Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study 2013 · TAK-085 4 g · Japanese adults with hypertriglyceridemia undergoing lifestyle modification | 4 g | 52 weeks | 171 |
| Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study 2013 · EPA-E 1.8 g · Japanese adults with hypertriglyceridemia undergoing lifestyle modification | 1.8 g | 52 weeks | 167 |
| Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study 2013 · IPE 4 g/day · Adults with type 2 diabetes (one participant had type 1 diabetes), residual triglycerides of 200–500 mg/dL, LDL-C of 40–100 mg/dL, and high cardiovascular risk while taking stable statin therapy | 4 g | 12 weeks | 165 |
| Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study 2013 · TAK-085 2 g · Japanese adults with hypertriglyceridemia undergoing lifestyle modification | 2 g | 52 weeks | 165 |
| A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study 2016 · EPA · Men and women with abdominal obesity and low-grade systemic inflammation, at risk of cardiovascular disease | 2.7 g | 10 weeks | 154 |
| Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study 2022 · MND-2119 2 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL | 2 g | 12 weeks | 145 |
| Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study 2022 · MND-2119 4 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL | 4 g | 12 weeks | 145 |
| Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study 2022 · EPA-E 1.8 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL | 1.8 g | 12 weeks | 145 |
| Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study 2022 · EPA-E 2.7 g/day · Adults with hypertriglyceridemia, with triglyceride levels ≥150 and <500 mg/dL | 2.7 g | 12 weeks | 145 |
| Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study) 2019 · icosapent ethyl 4 g/day · statin-treated patients at increased cardiovascular risk with triglycerides 200 to 499 mg/dL, controlled LDL-C, and baseline hsCRP ≥2.0 mg/L | 4 g | 12 weeks | 126 |
| Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia 2011 · POM3 plus atorvastatin · Men and women with mixed dyslipidemia, non-HDL-C >160 mg/dL and triglycerides 250–599 mg/dL | 4 g | 16 weeks | 118 |
| Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2020 · ATOMEGA group · Adults aged 20–79 years with high cardiovascular risk and residual hypertriglyceridemia while treated with statins; most had type 2 diabetes | 4 g | 8 weeks | 105 |
| The effect of n-3 fatty acids on levels of methylarginines in patients with end-stage renal disease 2010 · n-3 fatty acids · Adults with end-stage renal disease and documented cardiovascular disease | 1.7 g | 90 days | 103 |
| Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents 2013 · ω-3 PUFA group · Obese, insulin-resistant children and adolescents | 1.8 g | 12 weeks | 103 |
| A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study 2022 · EPA+DPA-FFA · Men and women aged 18 years or older with elevated fasting triglycerides of 1.70–5.64 mmol/L (150–499 mg/dL) | 2 g | 4 weeks | 100 |
| A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study 2022 · EPA-EE (icosapent ethyl) · Men and women aged 18 years or older with elevated fasting triglycerides of 1.70–5.64 mmol/L (150–499 mg/dL) | 2 g | 4 weeks | 100 |
| Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial 2014 · OM3-FFA 4 g/d · Men and women with severe hypertriglyceridemia (triglycerides ≥500 mg/dL and <2000 mg/dL) | 4 g | 12 weeks | 99 |
| A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins 2017 · PTV/EPA group · Patients with coronary heart disease who underwent percutaneous coronary intervention and were receiving statin therapy | 1.8 g | 240 days | 97 |
| Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects 2009 · P-OM3 plus FENO during the second open-label extension · Subjects with very high triglyceride levels continuing combination treatment | 4 g | 2 years | 93 |
| Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials) 2017 · ANCHOR icosapent ethyl group · Women with triglyceride levels of 200–2000 mg/dL enrolled in the ANCHOR trial | 4 g | 12 weeks | 91 |
| A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients 2017 · Omacor 2 g/day · Adults aged 20–79 with hypertriglyceridemia | 2 g | 8 weeks | 82 |
| Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects 2009 · P-OM3 plus concomitant FENO · Subjects with very high triglyceride levels (≥500 mg/dL) | 4 g | 8 weeks | 81 |
| Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies 2013 · MARINE IPE 4 g/day · Men and women aged over 18 with triglycerides 500–2000 mg/dL; some had high cardiovascular risk or coronary heart disease | 4 g | 12 weeks | 77 |
| Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial) 2011 · AMR101 4 g/day · Patients with fasting triglycerides of 500–2,000 mg/dl, with or without background statin therapy; age and sex not stated | 4 g | 12 weeks | 76 |
| Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies 2013 · MARINE IPE 2 g/day · Men and women aged over 18 with triglycerides 500–2000 mg/dL; some had high cardiovascular risk or coronary heart disease | 2 g | 12 weeks | 76 |
| Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis 2018 · Icosapent ethyl 4 g/day · Women with type 2 diabetes, elevated triglycerides, and high cardiovascular risk despite stable statin therapy; ages 42–81 years | 4 g | 12 weeks | 74 |
| The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients 2009 · group C · Patients with hyperlipidemia and type II diabetes; age and sex not reported | 1.8 g | 26 weeks | 72 |
| Highly purified eicosapentaenoic acid may increase low-density lipoprotein particle size by improving triglyceride metabolism in patients with hypertriglyceridemia 2013 · EPA group · Hypertriglyceridemic subjects | 1.8 g | 26 weeks | 72 |
| Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group 2000 · eicosapentaenoic acid group · Japanese menopausal women with hyperlipidemia and symptoms | 1.8 g | 48 weeks | 69 |
| Effect of supplementation with omega-3 fatty acids on hypertriglyceridemia in pediatric patients with obesity 2019 · omega-3 fatty acids group · children and adolescents aged 10–16 years with obesity and hypertriglyceridemia | 3 g | 12 weeks | 65 |
| Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study 2022 · MND-2119 2 g/day · Patients with hypertriglyceridemia (triglyceride levels ≥150 and <500 mg/dL) undergoing lifestyle modification | 2 g | 52 weeks | 61 |
| Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study 2022 · MND-2119 4 g/day · Patients with hypertriglyceridemia (triglyceride levels ≥150 and <500 mg/dL) undergoing lifestyle modification | 4 g | 52 weeks | 61 |
| Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study 2025 · OMEGA-3 group · Japanese adults aged 20–79 with dyslipidemia, fasting triglycerides ≥177 mg/dL, and statin treatment | 4 g | 16 weeks | 60 |
| The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides 2006 · DHA + EPA group · Adults with coronary artery disease and triglycerides greater than 200 mg/dL | 1.25 g | 8 weeks | 59 |
| Dietary echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome 2014 · echium oil (EO) group · Adults in normal-weight age groups 20–35 and 49–69 years and overweight adults with metabolic syndrome | 17 g | 8 weeks | 59 |
| Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects 2009 · P-OM3 added to stable FENO during the first open-label extension · Subjects with very high triglyceride levels who had received stable FENO monotherapy | 4 g | 8 weeks | 58 |
| Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease 2015 · Group 1 (PUFA group) · Obese children aged 9–17 years with nonalcoholic fatty liver disease | 1 g | 1 year | 56 |
| The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients 2009 · group B · Patients with hyperlipidemia and type II diabetes; age and sex not reported | 1.8 g | 26 weeks | 55 |
| Impact of Adding Eicosapentaenoic Acid to Statin Therapy on Plasma Pentraxin 3 Level in Patients with Stable Coronary Artery Disease: A 6-Month, Randomized Controlled Study 2017 · EPA group · Patients with stable coronary artery disease receiving statin therapy; age and sex not stated | 1.8 g | 26 weeks | 53 |
| Comparison of the effect of omega-3 supplements and fresh fish on lipid profile: a randomized, open-labeled trial 2017 · omega-3 supplement group · Adults with hyperlipidemia; ages and sex not restricted | 2 g | 60 days | 53 |
| Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia 2012 · omega-3 fatty acids · Patients with hypertriglyceridemia; age and sex not specified | 2 g | 60 days | 50 |
| Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients 2013 · omega-3 group · Hemodialysis patients with end-stage renal disease; age and sex not specified | 3 g | 60 days | 50 |
| Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia 2016 · n-3 FA 2g+fenofibrate 160mg (combination) · Patients with hypertriglyceridemia; age and sex range not reported | 2 g | 60 days | 50 |
| The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy 2017 · EPA group · Adults with stable coronary artery disease receiving statin treatment | 1.8 g | 26 weeks | 50 |
| Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease? 2019 · EPA group · Adults with stable coronary artery disease receiving statin therapy | 1.8 g | 26 weeks | 50 |
| Administration of eicosapentaenoic acid may alter high-density lipoprotein heterogeneity in statin-treated patients with stable coronary artery disease: A 6-month randomized trial 2020 · EPA group · Adults with stable coronary artery disease receiving statin therapy; age and sex not stated | 1.8 g | 26 weeks | 50 |
| A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease 2021 · omega-3 fatty acid group · Patients with chronic kidney disease and urine albumin excretion of at least 30 mg/g creatinine | 3.67 g | 90 days | 50 |
| Supplementation of n3 long-chain polyunsaturated fatty acid synergistically decreases insulin resistance with weight loss of obese prepubertal and pubertal children 2011 · n3-LCPUFA group · Overweight, insulin-resistant children aged 9–18 years; prepubertal and pubertal; otherwise healthy | 900 mg | 30 days | 49 |
| Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound 2016 · EPA group · Patients with coronary artery disease treated with strong statin therapy for at least 6 months; age and sex not reported | 1.8 g | 26 weeks | 48 |
| Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial 2008 · EPA open-label extension · Adults with schizophrenia receiving antipsychotic medication | 2 g | 40 weeks | 47 |
| Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial 2023 · n-3FA group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified | 300 mg | 8 weeks | 47 |
| Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis 2020 · study group (group A) · Patients with chronic kidney disease undergoing hemodialysis | 2.4 g | 12 weeks | 46 |
| Omega-3 supplementation and stress reactivity of cellular aging biomarkers: an ancillary substudy of a randomized, controlled trial in midlife adults 2021 · 1.25 g/d omega-3 group · Adults aged 40–85 who were sedentary and overweight or at risk of overweight, without metabolic, autoimmune, or inflammatory disease | 1.25 g | 120 days | 46 |
| Omega-3 supplementation and stress reactivity of cellular aging biomarkers: an ancillary substudy of a randomized, controlled trial in midlife adults 2021 · 2.496 g/d omega-3 group · Adults aged 40–85 who were sedentary and overweight or at risk of overweight, without metabolic, autoimmune, or inflammatory disease | 2.5 g | 120 days | 46 |
| Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression 2016 · n-3 PUFA treatment · Adults with non-alcoholic fatty liver disease; mean age 51.5 years, 57.6% men | 4 g | 548 days | 45 |
| Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia 2014 · n-3 FA 1 g (O1) · Adults with hypertriglyceridemia, including some with metabolic syndrome or type 2 diabetes mellitus; age and sex not specified | 1 g | 60 days | 44 |
| Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia 2014 · n-3 FA 2 g (O2) · Adults with hypertriglyceridemia, including some with metabolic syndrome or type 2 diabetes mellitus; age and sex not specified | 2 g | 60 days | 44 |
| Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia 2014 · n-3 FA 4 g (O4) · Adults with hypertriglyceridemia, including some with metabolic syndrome or type 2 diabetes mellitus; age and sex not specified | 4 g | 60 days | 44 |
| Beneficial Effects of n-3 Fatty Acids on Cardiometabolic and Inflammatory Markers in Type 2 Diabetes Mellitus: A Clinical Trial 2017 · n-3 PUFA group · Patients with type 2 diabetes mellitus; age and sex not specified | 2.7 g | 10 weeks | 44 |
| Lipid extract from blue mussel (Mytilus edulis) improves glycemic traits in Chinese type 2 diabetic mellitus patients: a double-blind randomized controlled trial 2023 · BMLE group · Chinese adults with type 2 diabetes mellitus | 1.6 g | 60 days | 44 |
| Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): is related with lower levels of creatine kinase-MB (CK-MB) and troponin I? 2013 · Group A (omega-3 PUFAs) · Patients planned to undergo percutaneous coronary intervention (PCI) | 3 g | 1 day | 43 |
| Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid 2014 · EPA-FFA · Patients undergoing liver resection surgery for colorectal cancer liver metastases | 2 g | 30 days | 43 |
| Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis 2016 · EPA-FFA · Adults with colorectal cancer liver metastases awaiting liver resection surgery | 2 g | 30 days | 43 |
| Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids 2018 · ω-3 PUFAs group · Individuals aged 13–25 years at ultra-high risk for psychosis | 1.2 g | 12 weeks | 41 |
| Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study 2020 · EPA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted | 1.8 g | 1 year | 40 |
| One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome 2016 · ω-3 fatty acid supplementation · Overweight schoolchildren with metabolic syndrome; girls and boys | 2.4 g | 30 days | 39 |
| Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial 2021 · OM3EE monotherapy in severe HTG (sHTG cohort) · Adults aged 18 years or older with severe hypertriglyceridemia (baseline triglycerides ≥500 and <1000 mg/dL) | 2 g | 12 weeks | 39 |
| Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells 2009 · 0.4 g EPA+DHA/d · Healthy Dutch elderly subjects | 400 mg | 26 weeks | 37 |
| The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia 2011 · omega-3 fatty acids · Men and women aged 35–70 with primary isolated hypertriglyceridemia; patients with triglycerides 200–500 mg/dL, total cholesterol below 200 mg/dL, and LDL cholesterol below 130 mg/dL | 2 g | 12 weeks | 37 |
| Impact of EPA ingestion on COX- and LOX-mediated eicosanoid synthesis in skin with and without a pro-inflammatory UVR challenge--report of a randomised controlled study in humans 2014 · EPA supplementation group · Women aged 18–60 years with a history of nickel contact allergy and sun-reactive skin type I or II; healthy, without active contact dermatitis | 5 g | 12 weeks | 37 |
| The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial 2022 · FO group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease | 2.34 g | 90 days | 37 |
| Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells 2009 · 1.8 g EPA+DHA/d · Healthy Dutch elderly subjects | 1.8 g | 26 weeks | 36 |
| Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial 2016 · omega-3 fatty acids · HIV-seropositive adults aged 20–55 years receiving antiretroviral therapy, with elevated triglycerides or LDL cholesterol | 2.4 g | 180 days | 35 |
| The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes 2017 · omega-3 fatty acids + vitamin D placebo · Patients with gestational diabetes; age and sex not otherwise specified | 2 g | 6 weeks | 35 |
| Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus 2010 · n-3 FAs · Subjects with type 2 diabetes mellitus | 2 g | 6 weeks | 34 |
| Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial 2011 · omega-3 PUFA group · First- and second-year medical students aged 21–29, men and women, without a stated chronic illness | 2.5 g | 12 weeks | 34 |
| Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers in Type 2 Diabetes Mellitus Patients 2017 · fish oil group (FOG) · Men and women aged 25–60 years with type 2 diabetes mellitus, without other specified chronic diseases, BMI ≤29.9, and not receiving insulin treatment | 520 mg | 24 weeks | 34 |
| Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study 2010 · omega-3 ethyl esters · Patients with stable coronary artery disease undergoing percutaneous coronary intervention; age and sex not specified | 1 g | 30 days | 33 |
| Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers 2020 · Epeleuton 2 g/day · Adults aged 18–75 with nonalcoholic fatty liver disease, BMI 25–40, and elevated alanine aminotransferase | 2 g | 16 weeks | 33 |
| Influence of fish oil on blood lipids in coronary artery disease 1991 · 2.4 g EPA/DHA phase · Patients with coronary artery disease and dyslipidaemia | 2.4 g | — | 32 |
| Influence of fish oil on blood lipids in coronary artery disease 1991 · 3.6 g EPA/DHA open phase · Patients with coronary artery disease and dyslipidaemia | 3.6 g | — | 32 |
| Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial 2013 · EPA group · Overweight patients with type 2 diabetes mellitus; age and sex not specified | 2 g | 90 days | 32 |
| Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers 2020 · Epeleuton 1 g/day · Adults aged 18–75 with nonalcoholic fatty liver disease, BMI 25–40, and elevated alanine aminotransferase | 1 g | 16 weeks | 32 |
| Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability 2011 · Combination treatment group · Patients with mixed dyslipidemia, high triglyceride levels (200–499 mg per 100 ml) and total cholesterol >200 mg per 100 ml | 4 g | 6 weeks | 31 |
| The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial 2013 · n-3 PUFA supplementation period · Adults older than 21 years with adult-onset diabetes and trace or greater proteinuria | 4 g | 6 weeks | 31 |
| Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer 2017 · ω-3-rich EN · Patients undergoing neoadjuvant chemotherapy for esophageal cancer | 900 mg | 15 days | 31 |
| Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids 2018 · P-OM3 treatment · Adults with metabolic syndrome; age range and sex not specified | 4 g | 16 weeks | 31 |
| Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial 2020 · IPE group · Adults aged 30–85 with coronary atherosclerosis and elevated fasting triglycerides (135–499 mg/dL), receiving statin therapy | 4 g | 548 days | 31 |
| Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes 2007 · EPA treated group · Japanese adults with type 2 diabetes | 1.8 g | 767 days | 30 |
| Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot) 2011 · 1 g/day n-3 PUFA · Adults with stable coronary artery disease undergoing percutaneous coronary intervention | 1 g | 30 days | 30 |
| The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia 2011 · rosuvastatin 10 mg plus omega 3 fatty acids (group RΩ) · Patients with mixed dyslipidemia; age and sex not specified | 2 g | 90 days | 30 |
| Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation 2012 · n3-FA · Non-diabetic patients with documented coronary artery disease | 4 g | 3 weeks | 30 |
| Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome 2012 · Omega-3 fatty acids group · Women aged 20–35 with polycystic ovary syndrome and BMI 25–40 kg/m² | 1.2 g | 8 weeks | 30 |
| Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina 2014 · omega-3 PUFA · Patients with stable coronary artery disease undergoing percutaneous coronary intervention | 1 g | 30 days | 30 |
| The effects of vitamin E and omega-3 PUFAs on endothelial function among adolescents with metabolic syndrome 2014 · omega-3 group · Adolescents aged 10–18 years with metabolic syndrome | 2.4 g | 8 weeks | 30 |
| Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial 2017 · omega-3 fatty acid from flaxseed oil · Patients with diabetic nephropathy | 1 g | 12 weeks | 30 |
| Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Cytokines and Advanced Glycation End Products in Patients With Diabetic Nephropathy: a Randomized Controlled Trial 2016 · omega-3 fatty acid group · Patients with diabetic nephropathy; age and sex not specified | 1 g | 12 weeks | 30 |
| Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer 2017 · ω-3-poor EN support · Patients undergoing neoadjuvant chemotherapy for esophageal cancer | 250 mg | 15 days | 30 |
| Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis 2018 · EPA-FFA group · Adults with ulcerative colitis in clinical remission, elevated fecal calprotectin, and stable therapy | 1 g | 26 weeks | 30 |
| A comparison between the effects of flaxseed oil and fish oil supplementation on cardiovascular health in type 2 diabetic patients with coronary heart disease: A randomized, double-blinded, placebo-controlled trial 2019 · fish oil group · Adults with type 2 diabetes and coronary heart disease; age and sex not specified | 2 g | 12 weeks | 30 |
| A comparison between the effects of flaxseed oil and fish oil supplementation on cardiovascular health in type 2 diabetic patients with coronary heart disease: A randomized, double-blinded, placebo-controlled trial 2019 · flaxseed oil group · Adults with type 2 diabetes and coronary heart disease; age and sex not specified | 2 g | 12 weeks | 30 |
| Improvement of NRF2 gene expression and antioxidant status in patients with type 2 diabetes mellitus after supplementation with omega-3 polyunsaturated fatty acids: A double-blind randomised placebo-controlled clinical trial 2020 · n-3 PUFAs group · Adults with type 2 diabetes mellitus | 2.7 g | — | 30 |
| Administration of eicosapentaenoic acid may alter lipoprotein particle heterogeneity in statin-treated patients with stable coronary artery disease: A pilot 6-month randomized study 2020 · EPA group · Adults with stable coronary artery disease receiving statin therapy; age and sex not specified | 1.8 g | 26 weeks | 30 |
| Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: A randomized, controlled trial 2021 · ω-3 therapy · Adults with acute myocardial infarction after successful percutaneous coronary intervention; age and sex not specified | 2 g | 90 days | 30 |
| Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD 2022 · n-3-PUFA group · Adults with NAFLD and metabolic syndrome; ages 51.8 ± 12 years on average; 80% male | 1.8 g | 1 year | 30 |
| Omega-3 fatty acids effectively mitigate high-sensitivity C-reactive protein (hs-CRP) biomarker of inflammation in acute myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial 2025 · omega-3 PUFAs · Adults with acute myocardial infarction | 2 g | 30 days | 30 |
| Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides 2025 · OP (ω-3 PUFA + placebo) · Pregnant women with a family history of allergies who intended to breastfeed for the first 3 months; maternal age median about 30.5 years | 3.84 g | 230 days | 30 |
| Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome 2014 · PUFAs · Adults with metabolic syndrome; mean age 44 ± 12 years, 15 male | 2 g | 12 weeks | 29 |
| Effects of omega-3 fatty acid supplementation on insulin metabolism and lipid profiles in gestational diabetes: Randomized, double-blind, placebo-controlled trial 2015 · omega-3 fatty acid group · Pregnant women with gestational diabetes | 1 g | 6 weeks | 28 |
| Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia 1995 · Encapsulated K85 · People with combined hyperlipidaemia who continued to meet the serum triglyceride and total cholesterol inclusion criteria after a 10-week dietary run-in | 4 g | 12 weeks | 28 |
| Long-term effects of n-3 fatty acids on serum lipids and glycaemic control 1994 · n-3 PUFA group · Non-diabetic patients with moderate hypertriglyceridaemia undergoing coronary artery bypass grafting; age and sex not stated | 3.4 g | 26 weeks | 28 |
| Omega-3 fatty acid supplementation affects pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial 2016 · omega-3 fatty acid group · pregnant women with gestational diabetes | 1 g | 6 weeks | 27 |
| Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial 2016 · n-3 group · Patients with biopsy-proven non-alcoholic steatohepatitis (NASH); age and sex not stated | 945 mg | 26 weeks | 27 |
| Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia 2011 · 0.85 g/d EPA+DHA · 23 men and 3 postmenopausal women with moderate hypertriglyceridemia (150–500 mg/dL) | 850 mg | 8 weeks | 26 |
| Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia 2011 · 3.4 g/d EPA+DHA · 23 men and 3 postmenopausal women with moderate hypertriglyceridemia (150–500 mg/dL) | 3.4 g | 8 weeks | 26 |
| Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia 2015 · low dose · Middle-aged healthy nonsmoking men and post-menopausal women with triglycerides 150–500 mg/dL | 850 mg | 8 weeks | 25 |
| Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia 2015 · high dose · Middle-aged healthy nonsmoking men and post-menopausal women with triglycerides 150–500 mg/dL | 3.4 g | 8 weeks | 25 |
| Effect of Omega-3 Fatty Acids on Serum Lipid Profile and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized Placebo-Controlled Study 2017 · omega-3 group · Pediatric patients with end-stage renal disease on regular hemodialysis | 1 g | 16 weeks | 25 |
| Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study 2018 · OM-3CA · Overweight or obese patients with non-alcoholic fatty liver disease and hypertriglyceridemia | 4 g | 12 weeks | 25 |
| Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome 2012 · Rω group · Patients with mixed dyslipidaemia and metabolic syndrome | 2 g | 12 weeks | 24 |
| Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients 2013 · active treatment group · Adults aged 18 years or older with HIV infection, CD4 count above 200 cells/μL, and triglycerides above 200 mg/dL | 3.6 g | 8 weeks | 24 |
| Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study 2016 · R+O group · Patients with mixed dyslipidaemia | 2 g | 90 days | 24 |
| Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia 2016 · R + O group · Adults with mixed dyslipidaemia | 2 g | 90 days | 24 |
| Effects of Omega-3 Supplementation on Ki-67 and VEGF Expression Levels and Clinical Outcomes of Locally Advanced Breast Cancer Patients Treated with Neoadjuvant CAF Chemotherapy: A Randomized Controlled Trial Report 2019 · intervention group · Women aged 25–60 with locally advanced stage IIIB breast cancer receiving neoadjuvant CAF chemotherapy | 1 g | 51 days | 24 |
| Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study 2020 · Omega-3 treatment · Patients with dyslipidemia receiving statins; age and sex not reported | 4 g | 8 weeks | 24 |
| [Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances] 2010 · continued omega-3 group · Adults with stable coronary heart disease, ejection fraction above 45%, and ventricular arrhythmias; mean age 66.2 years | 1 g | 60 days | 23 |
| The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial 2012 · PUFA group · Adults with HIV infection, hypertriglyceridemia, and receiving HAART; nearly all were male. | 4 g | 12 weeks | 23 |
| A comparison of the changes in cardiac output and systemic vascular resistance during exercise following high-fat meals containing DHA or EPA 2012 · EPA meal · Healthy adult males | 4.7 g | 1 day | 22 |
| Effects of administration of omega-3 fatty acids with or without vitamin E supplementation on adiponectin gene expression in PBMCs and serum adiponectin and adipocyte fatty acid-binding protein levels in male patients with CAD 2015 · OP (omega-3 fatty acid & placebo) · Adult men with coronary artery disease and more than 50% stenosis | 4 g | 8 weeks | 22 |
| Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study 2018 · OM-3CA + dapagliflozin · Adults aged 40–75 with type 2 diabetes, overweight or obesity, and NAFLD | 4 g | 12 weeks | 22 |
| The effect of n-3 fatty acids on neutrophil chemiluminescence 1995 · 4 g n-3 PUFA group · Healthy adults; ages and sex not reported | 4 g | 6 weeks | 22 |
| Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids 2020 · ω3 + placebo · Pregnant women included at gestational week 20, with at least one parent or sibling with allergic disease history or symptoms | 1.28 g | 130 days | 21 |
| EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study 2021 · EPA supplementation · Men and postmenopausal women aged 50–75 years with chronic inflammation | 3 g | 10 weeks | 21 |
| Investigating the Neuroprotective Effect of Oral Omega-3 Fatty Acid Supplementation in Type 1 Diabetes (nPROOFS1): A Randomized Placebo-Controlled Trial 2021 · n-3 · Participants with type 1 diabetes; age and sex not reported | 1.8 g | 180 days | 21 |
| Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation 2024 · EPA supplementation phase · Adults aged 50–75 years with low-grade chronic inflammation and at least one metabolic syndrome characteristic; postmenopausal women and men | 3 g | 10 weeks | 21 |
| Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study 1998 · E (n-3 PUFA) · Kidney graft recipients; age and sex range not reported | 6 g | 1 year | 21 |
| Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia 2004 · omega-3 fatty acids group · Patients with coronary heart disease or CHD risk equivalents and mixed dyslipidemia whose LDL cholesterol had reached goal on simvastatin | 3 g | 60 days | 20 |
| Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease 2008 · Group DP · Adults with nonalcoholic fatty liver disease | 2 g | 26 weeks | 20 |
| Low-dose aspirin and omega-3 fatty acids improve uterine artery blood flow velocity in women with recurrent miscarriage due to impaired uterine perfusion 2009 · Omega(3) · Women with unexplained recurrent miscarriage and impaired uterine perfusion | 4 g | 60 days | 20 |
| Low-dose aspirin and omega-3 fatty acids improve uterine artery blood flow velocity in women with recurrent miscarriage due to impaired uterine perfusion 2009 · LDA plus Omega(3) · Women with unexplained recurrent miscarriage and impaired uterine perfusion | 4 g | 60 days | 20 |
| Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects 2012 · n-3 long chain polyunsaturated fatty acids (fish oil) · Overweight and obese adults; age range and sex not stated | 3.7 g | 6 weeks | 20 |
| [Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances] 2010 · omega-3 group that stopped after one month · Adults with stable coronary heart disease, ejection fraction above 45%, and ventricular arrhythmias; mean age 66.2 years | 1 g | 30 days | 20 |
| Effects of Ω-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study 2013 · Ω-3 fatty acids · Healthy smokers; age and sex not specified | 2 g | 12 weeks | 20 |
| Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers 2013 · ω-3 fatty acid supplementation · Male cigarette smokers; age not stated; described as healthy smokers | 2 g | 6 weeks | 20 |
| Beneficial effects of omega-3 and vitamin E coadministration on gene expression of SIRT1 and PGC1α and serum antioxidant enzymes in patients with coronary artery disease 2016 · Group 1 (OP) · Male patients with coronary artery disease; age range not reported | 4 g | 60 days | 20 |
| The effects of fish oil on gene expression in patients with polycystic ovary syndrome 2018 · omega-3 fatty acids from fish oil · Women aged 18–40 years with polycystic ovary syndrome (PCOS) | 2 g | 12 weeks | 20 |
| Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study 2018 · OM-3CA monotherapy · Adults aged 40–75 with type 2 diabetes, overweight or obesity, and NAFLD | 4 g | 12 weeks | 20 |
| [Influence of Omega-3 PUFA on Non-invasive factors determining the risk of arrhYthmias eXcess and sudden cardiac death in patients with HFpEF with ischemic etiology (ONYX)] 2020 · Omacor 2 g/day treatment group · Adults with ischemic heart failure with reduced left ventricular ejection fraction (HFrEF) receiving optimal drug therapy; age and sex not reported | 2 g | 1 year | 20 |
| Comparative Analysis of the Effects of Fish Oil and Fenofibrate on Plasma Metabolomic Profiles in Overweight and Obese Individuals 2022 · fish oil intervention · Overweight and obese adults (BMI ≥27 kg/m²), men and women | 3.7 g | 6 weeks | 20 |
| Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia 2023 · ω3FA treatment period · Adults aged 18–70 years with familial hypercholesterolemia, 10 men and 10 women, receiving statin with or without ezetimibe | 4 g | 8 weeks | 20 |
| The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man 1997 · highly purified EPA · healthy men | 3.8 g | 7 weeks | 20 |
| n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease 2016 · n-3 fatty acids · Men and women aged 25–75 years with chronic renal impairment (eGFR >15 and <60 mL/min/1.73 m²) | 4 g | 8 weeks | 19 |
| Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides 2019 · icosapent ethyl 4 g/day · Adults with stage 3 chronic kidney disease, high triglycerides, and increased cardiovascular risk despite statin treatment | 4 g | 12 weeks | 19 |
| Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridemia 1997 · Drug treated group · Patients with severe hypertriglyceridemia; age and sex not reported | 4 g | 6 weeks | 19 |
| Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials) 2017 · MARINE icosapent ethyl group · Women with triglyceride levels of 200–2000 mg/dL enrolled in the MARINE trial | 4 g | 12 weeks | 18 |
| Effect of Eicosapentaenoic acid (EPA) supplementation on cardiovascular markers in patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial 2018 · EPA · Patients with type 2 diabetes mellitus | 2 g | 8 weeks | 18 |
| Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial 2012 · P-OM3 · Adults aged 40–69 with metabolic syndrome | 4 g | 16 weeks | 17 |
| Effect of omega-3 ethyl esters on the triglyceride-rich lipoprotein response to endotoxin challenge in healthy young men 2023 · P-OM3 · Healthy young men | 3.4 g | 12 weeks | 17 |
| Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function 2008 · Group II · People with peripheral arterial disease (PAD); age and sex not reported | 2 g | 90 days | 16 |
| Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study 2021 · Females: EPA + DHA (n-3) · Females with abdominal obesity | 3 g | 7 weeks | 16 |
| Functional and metabolic effects of omega-3 polyunsaturated fatty acid supplementation and the role of β-hydroxy-β-methylbutyrate addition in chronic obstructive pulmonary disease: A randomized clinical trial 2024 · EPA/DHA · Patients with COPD, GOLD stages II–IV; age and sex not stated | 2 g | 10 weeks | 16 |
| Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma 2014 · EPA + statin · Patients with untreated dyslipidemia; age and sex not reported | 1.8 g | 270 days | 15 |
| Untargeted metabolomic on urine samples after α-lipoic acid and/or eicosapentaenoic acid supplementation in healthy overweight/obese women 2018 · EPA group · Healthy sedentary overweight/obese women, mean age 37.3 years; following a hypocaloric diet | 1.3 g | 10 weeks | 15 |
| Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome 2024 · P-OM3 · Adults aged 40–69 with metabolic syndrome | 4 g | 16 weeks | 15 |
| Supplementation with n3 fatty acid ethyl esters increases large and small artery elasticity in obese adults on a weight loss diet 2013 · WL+FAEE · Obese adults on a weight-loss diet | 4 g | 12 weeks | 13 |
| Effect of ω-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state 2014 · Hypocaloric diet plus ω-3 FAEE supplementation · Obese subjects on a weight-loss diet; age and sex not specified | 4 g | 12 weeks | 13 |
| Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds 2014 · Omega-3 FA group · Youth aged 10–19 years with fasting triglycerides of 150–1000 mg/dL and moderate to severe hypertriglyceridemia | 3.36 g | 26 weeks | 13 |
| The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans 2002 · EPA · Dyslipidemic subjects | 3 g | 7 weeks | 12 |
| Effect of dietary supplementation with n-3 polyunsaturated fatty acids on physical properties and metabolism of low density lipoprotein in humans 1992 · n-3 fatty acid group · Humans; age, sex, and health condition not specified | 6 g | 120 days | 12 |
| Interaction of exercise training and n-3 fatty acid supplementation on postprandial lipemia 2007 · n-3 FA supplementation plus exercise training (FO+ExTr) · Previously sedentary, overweight adults; 12 women and 10 men across the study, BMI 26.6 ± 0.7 kg/m² | 4 g | 4 weeks | 12 |
| Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study 2017 · EPA+DHA · Adults with non-alcoholic fatty liver disease (NAFLD); age range and sex not specified | 4 g | 78 weeks | 12 |
| Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure 2018 · 1 g/day n3-PUFA · Adults with advanced chronic heart failure of nonischaemic origin, NT-proBNP >2000 pg/mL, NYHA class III or IV, and LVEF <35% | 1 g | 12 weeks | 12 |
| Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure 2018 · 4 g/day n3-PUFA · Adults with advanced chronic heart failure of nonischaemic origin, NT-proBNP >2000 pg/mL, NYHA class III or IV, and LVEF <35% | 4 g | 12 weeks | 12 |
| Improvement of coronary vasomotion with eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina 1995 · EPA-treated group · Patients with variant angina | 1.8 g | 120 days | 12 |
| (n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal 1999 · (n-3) fatty acid period (FOP) · Adults with moderately elevated fasting triacylglycerides | 5.2 g | 6 weeks | 11 |
| High Dose Omega-3 Fatty Acid Administration and Skeletal Muscle Protein Turnover in Maintenance Hemodialysis Patients 2016 · ω-3 · Adults receiving maintenance hemodialysis with systemic inflammation | 2.9 g | 12 weeks | 11 |
| The Effects of Omega-3 and Branched-Chain Amino Acids Supplementation on Serum Apoptosis Markers Following Acute Resistance Exercise in Old Men 2019 · Omega-3 supplementation · Men aged 62.8 ± 2.2 years undergoing acute resistance exercise | 2.7 g | 7 days | 11 |
| Leukocyte Activation and Antioxidative Defense Are Interrelated and Moderately Modified by n-3 Polyunsaturated Fatty Acid-Enriched Eggs Consumption-Double-Blind Controlled Randomized Clinical Study 2020 · n-3 PUFA group · Healthy men and women aged 18–30 years with normal BMI, blood pressure and serum lipids | 407 mg | 3 weeks | 11 |
| Interaction of exercise training and n-3 fatty acid supplementation on postprandial lipemia 2007 · n-3 FA supplementation alone (FO) · Previously sedentary, overweight adults; 12 women and 10 men across the study, BMI 26.6 ± 0.7 kg/m² | 4 g | 4 weeks | 10 |
| Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia 2011 · Omacor 1 g/day · Adults with documented stable coronary artery disease and triglycerides over 250 mg/dl, treated with aspirin and statins | 1 g | 2 weeks | 10 |
| Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia 2011 · Omacor 2 g/day · Adults with documented stable coronary artery disease and triglycerides over 250 mg/dl, treated with aspirin and statins | 2 g | 2 weeks | 10 |
| Impact of Cranberry Juice Enriched with Omega-3 Fatty Acids Adjunct with Nonsurgical Periodontal Treatment on Metabolic Control and Periodontal Status in Type 2 Patients with Diabetes with Periodontal Disease 2018 · omega-3 (I1) · Adults aged 35–67 years with type 2 diabetes and periodontal disease | 2 g | 8 weeks | 10 |
| [Influence of Omega-3 PUFA on Non-invasive factors determining the risk of arrhYthmias eXcess and sudden cardiac death in patients with HFpEF with ischemic etiology (ONYX)] 2020 · Omacor 1 g/day treatment group · Adults with ischemic heart failure with reduced left ventricular ejection fraction (HFrEF) receiving optimal drug therapy; age and sex not reported | 1 g | 1 year | 10 |
| ω-3 polyunsaturated fatty acid supplementation improves postabsorptive and prandial protein metabolism in patients with chronic obstructive pulmonary disease: a randomized clinical trial 2022 · high dose · Normal-weight patients with moderate to severe COPD; age and sex not stated | 3.5 g | 4 weeks | 10 |
| ω-3 polyunsaturated fatty acid supplementation improves postabsorptive and prandial protein metabolism in patients with chronic obstructive pulmonary disease: a randomized clinical trial 2022 · low dose · Normal-weight patients with moderate to severe COPD; age and sex not stated | 2 g | 4 weeks | 10 |
| Impact of polyunsaturated fatty acids on human colonic bacterial metabolism: an in vitro and in vivo study 1995 · EPA-EE · 10 healthy volunteers | 18 g | 7 days | 10 |
| Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial 2005 · omega-3 group · Healthy young adults, men and women, with no chronic stress | 762 mg | 60 days | 9 |
| Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia 1990 · Himega, Study 1, 2 g/day n-3 fatty acid subgroup · Adults with primary hypertriglyceridaemia | 2 g | 12 weeks | 9 |
| Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia 1990 · Triglyceride-based fish oil, Study 1, 2 g/day n-3 fatty acid subgroup · Adults with primary hypertriglyceridaemia | 2 g | 12 weeks | 9 |
| Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia 1990 · Himega, Study 2 · Adults with primary hypercholesterolaemia | 2 g | 9 weeks | 9 |
| Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia 1993 · 3.0 g EPA+DHA per day · Patients with familial combined hyperlipidemia; age and sex not specified | 3 g | 4 weeks | 9 |
| Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia 1993 · 4.5 g EPA+DHA per day · Patients with familial combined hyperlipidemia; age and sex not specified | 4.5 g | 4 weeks | 9 |
| Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals 1991 · 4.0 g/day omega-3-PUFA, patients with recent-onset IDDM · Patients with recent-onset insulin-dependent diabetes mellitus; age and sex not reported | 4 g | 7 weeks | 8 |
| A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients 1991 · fish oil · adult men with non-insulin-dependent diabetes | 10 g | 2 weeks | 8 |
| Functions and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid 1990 · EPA group · Elderly people; sex and specific condition not stated | 100 mg | 60 days | 8 |
| ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study 2013 · ω-3 fatty acids · Patients with cardiac syndrome X; age and sex not reported | 1.44 g | 120 days | 8 |
| Effect of Icosapent Ethyl on Gynoid Fat and Bone Mineral Health in the Metabolic Syndrome: A Preliminary Report 2020 · IPE treatment group · Adult men and women with metabolic syndrome | 4 g | 270 days | 8 |
| n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects 1990 · group 2 · Hypertriglyceridemic subjects; age range and sex not reported | 1.1 g | 20 weeks | 7 |
| Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes 1993 · n-3 fatty acid concentrate group · Human volunteers; age, sex, and health condition not specified | 7 g | 6 weeks | 7 |
| Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia 1998 · EPA group · Healthy volunteers; age and sex not specified | 4 g | 5 weeks | 7 |
| Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men 2003 · increased EPA+DHA intake · Healthy men, mean age 52 (SD 12) years | 1.5 g | 8 weeks | 5 |
| Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia 1990 · Himega, Study 1, 4 g/day n-3 fatty acid subgroup · Adults with marked primary hypertriglyceridaemia | 4 g | 12 weeks | 4 |
| Effects of an ethyl ester preparation of fish oils (Himega) on lipids and lipoproteins in hyperlipidaemia 1990 · Triglyceride-based fish oil, Study 1, 4 g/day n-3 fatty acid subgroup · Adults with marked primary hypertriglyceridaemia | 4 g | 12 weeks | 4 |
| Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients 1999 · EPA · Dialysis patients with relatively high plasma levels of remnant lipoproteins and ox-LDL | 1.8 g | 90 days | — |
| Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects 1999 · daily fish meal · Overweight adults treated for hypertension | 3.65 g | 16 weeks | — |
| Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects 1999 · fish meal plus weight-loss regimen · Overweight adults treated for hypertension | 3.65 g | 16 weeks | — |
| Effect of supplementation with dietary seal oil on selected cardiovascular risk factors and hemostatic variables in healthy male subjects 1999 · seal oil group · Healthy, normocholesterolemic male subjects | 20 g | 6 weeks | — |
| Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia 2000 · simvastatin+omega-3 fatty acids · Patients with combined hyperlipemia | 3.36 g | 5 weeks | — |
| Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses 2000 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age and sex not specified | 3.4 g | 8 weeks | — |
| Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men 2000 · EPA group · Overweight, nonsmoking, mildly hyperlipidemic men; age range not reported | 4 g | 6 weeks | — |
| The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia 2000 · Omacor · Patients with primary hypertriglyceridemia | 4 g | 12 weeks | — |
| Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: effects on lipolysis and lipid oxidation 2000 · EPA-EE supplementation · Weight-losing cancer patients of different tumor types and healthy subjects | 6 g | 7 days | — |
| An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia 2001 · Omacor active-treatment group · Patients with coronary heart disease and triglycerides >2.3 mmol/L despite simvastatin treatment; age and sex not reported | 4 g | 48 weeks | — |
| Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia 2001 · omega-3 FA group · Adults with combined hyperlipemia | 1.68 g | 5 weeks | — |
| Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients 2001 · omega-3 group · Long-time survivors of heart transplantation | 3.4 g | 1 year | — |
| Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients 2003 · EPA group · Treated-hypertensive men and postmenopausal women with type 2 diabetes | 4 g | 6 weeks | — |
| Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women 2003 · 4:0 (control group) · Women; age and health status not further specified | 4 g | 4 weeks | — |
| Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance 2003 · EPA group · Healthy subjects; age and sex not reported | 4 g | 4 weeks | — |
| Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects 2003 · 0.8 g EPA+DHA/d · Moderately hyperlipidemic subjects; age and sex not specified | 800 mg | 26 weeks | — |
| Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects 2003 · 1.7 g EPA+DHA/d · Moderately hyperlipidemic subjects; age and sex not specified | 1.7 g | 26 weeks | — |
| Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation 2003 · fish oil supplements · Men and women, mean age 49 years, participating in a controlled study; no specific condition reported | 3.6 g | 90 days | — |
| Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients 2003 · n-3FAs group · Hyperlipidemic patients with total cholesterol and triglycerides greater than 200 mg/dL; age and sex not specified | 1 g | 10 weeks | — |
| Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia 2003 · omega-3 fatty acids · Patients with combined hyperlipemia and elevated serum triglycerides and cholesterol | 1.68 g | 5 weeks | — |
| Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation 2003 · EPA+DHA 0.3 g/day course · Healthy men | 300 mg | 4 weeks | — |
| Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation 2003 · EPA+DHA 1.0 g/day course · Healthy men | 1 g | 4 weeks | — |
| Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation 2003 · EPA+DHA 2.0 g/day course · Healthy men | 2 g | 4 weeks | — |
| Influence of supplementation with N-3 fatty acids on different coronary risk factors in men--a placebo controlled study 1992 · 1.12 g n-3 FA/day · healthy men who were monks; age not reported | 1.12 g | 1 year | — |
| Influence of supplementation with N-3 fatty acids on different coronary risk factors in men--a placebo controlled study 1992 · 2.24 g n-3 FA/day · healthy men who were monks; age not reported | 2.24 g | 1 year | — |
| Influence of supplementation with N-3 fatty acids on different coronary risk factors in men--a placebo controlled study 1992 · 3.37 g n-3 FA/day · healthy men who were monks; age not reported | 3.37 g | 1 year | — |
| Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects 2003 · purified EPA · Adults with treated hypertension and type 2 diabetes; mean age 61.2 years | 4 g | 6 weeks | — |
| Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids 1992 · n-3 fatty acids (fish oil) · Patients with active rheumatoid arthritis | 3.6 g | 12 weeks | — |
| Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids 2004 · eicosapentaenoic acid (EPA) · healthy subjects; age and sex not stated | 4 g | 4 weeks | — |
| Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein 2004 · EPA-rich oil · Healthy human volunteers; age and sex not specified | 9 g | 4 weeks | — |
| Influence of eicosapentaenoic acid, an omega-3 fatty acid, on ultraviolet-B generation of prostaglandin-E2 and proinflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 in human skin in vivo 2004 · EPA · Healthy humans; age and sex not specified | 4 g | 90 days | — |
| Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids 2004 · n-3 PUFA 6.6 g · Healthy adult volunteers; age and sex distribution not stated | 6.6 g | 12 weeks | — |
| Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids 2004 · n-3 PUFA 2.0 g · Healthy adult volunteers; age and sex distribution not stated | 2 g | 12 weeks | — |
| Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia 2005 · n-3 PUFA supplementation (no dietary counseling) · Elderly men with long-standing hyperlipidemia | 2.4 g | 3 years | — |
| Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia 2005 · Dietary counseling and n-3 PUFA supplementation · Elderly men with long-standing hyperlipidemia | 2.4 g | 3 years | — |
| Fish oil treatment and apolipoprotein(a) 1992 · 3.5 g omega-3 fatty acids/day group · Subjects with apolipoprotein(a) values between 34 and 1062 U/l | 3.5 g | 4 weeks | — |
| Fish oil treatment and apolipoprotein(a) 1992 · 7.1 g omega-3 fatty acids/day group · Subjects with apolipoprotein(a) values between 34 and 1062 U/l | 7.1 g | 4 weeks | — |
| Fish oil treatment and apolipoprotein(a) 1992 · 10.6 g omega-3 fatty acids/day group · Subjects with apolipoprotein(a) values between 34 and 1062 U/l | 10.6 g | 4 weeks | — |
| Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals 1991 · 2.0 g/day omega-3-PUFA, healthy individuals · Healthy individuals; age and sex not reported | 2 g | 7 weeks | — |
| Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals 1991 · 4.0 g/day omega-3-PUFA, healthy individuals · Healthy individuals; age and sex not reported | 4 g | 7 weeks | — |
| Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans 2006 · fish-oil supplementation · Healthy men and women | 3.6 g | 90 days | — |
| Trans, and n-3 polyunsaturated fatty acids and vascular function-a yin yang situation? 2006 · 4 g n-3 PUFA group · Healthy males | 4 g | 8 weeks | — |
| Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder 2007 · ethyl-EPA treatment group · Female outpatients with bipolar disorder and moderate depressive symptoms | 2 g | 12 weeks | — |
| Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia 2006 · omega-3 PUFA supplementation (no dietary counselling) · elderly men with long-standing hyperlipidaemia | 2.4 g | 3 years | — |
| Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia 2006 · dietary counselling and omega-3 PUFA supplementation · elderly men with long-standing hyperlipidaemia | 2.4 g | 3 years | — |
| A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy 2006 · omega-3 fatty acid arm · HIV-infected males with hypertriglyceridemia receiving stable HAART | 9 g | 8 weeks | — |
| Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas 2007 · EPA supplementation · Patients with a history of colorectal adenomas | 2 g | 90 days | — |
| [Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia] 2006 · SR group · Patients with primary hyperlipidaemia; age and sex not reported | 3.6 g | 1 year | — |
| Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study 2007 · P-OM3 plus simvastatin · Adults with persistent hypertriglyceridemia receiving stable statin therapy | 4 g | 8 weeks | — |
| The effect of low dose omega-3 on plasma lipids in hemodialysis patients 2007 · Omega-3 group · Hemodialysis patients with serum triglycerides above 200 mg/dl and total cholesterol above 220 mg/dl | 2 g | 12 weeks | — |
| The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women 2008 · (n-3) LCPUFA alone · Men and women with hyperlipidemia; age range not reported | 1.4 g | 3 weeks | — |
| Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients 2008 · purified omega-3 fatty acids · people with type 2 diabetes | 2 g | 10 weeks | — |
| Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia 2008 · P-OM3 + simvastatin · Men and women, average age 58 years, with mixed dyslipidemia (triglycerides 200–600 mg/dl and non-HDL cholesterol above treatment goals) | 4 g | 6 weeks | — |
| Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial 2008 · EPA group (blinded phase) · Adults with schizophrenia receiving antipsychotic medication | 2 g | 12 weeks | — |
| Effect of n-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge 2009 · n-3 PUFA-enriched fat blend · House dust mite-allergic asthmatics aged 22–29 years | 690 mg | 5 weeks | — |
| Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans 2009 · EPA group · Healthy normolipidemic men and women aged 19–43 years | 2.2 g | 6 weeks | — |
| The effect of the plasma n-3/n-6 polyunsaturated fatty acid ratio on the dietary LDL phenotype transformation - insights from the LIPGENE study 2009 · LFHCC n-3 · Patients with metabolic syndrome | 1.24 g | 12 weeks | — |
| The efficacy of omega-3 fatty acid supplementation on plasma homocysteine and malondialdehyde levels of type 2 diabetic patients 2010 · treatment group · patients with type 2 diabetes; age and sex not specified | 3 g | 60 days | — |
| Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men 2009 · n-3 PUFA supplementation · elderly high-risk men | 2.4 g | 3 years | — |
| Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men 2009 · dietary counseling plus n-3 PUFA supplementation · elderly high-risk men | 2.4 g | 3 years | — |
| Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy 2009 · omega-3 fatty acids · Women with polycystic ovary syndrome; mean age 32.7 years | 4 g | 8 weeks | — |
| Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV 2009 · intervention group · Adults with HIV and elevated serum triglycerides and/or abnormal Quantitative Insulin Sensitivity Check Index values | 6 g | 13 weeks | — |
| The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial 2010 · treatment group · Postmenopausal women with osteoporosis | 900 mg | 26 weeks | — |
| The bleeding time effects of a single dose of aspirin in subjects receiving omega-3 fatty acid dietary supplementation 1991 · omega-3 fatty acid supplementation · 12 healthy adults | 8 g | 3 weeks | — |
| Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients 2010 · Switchers · Patients with hypertriglyceridemia (triglycerides 200–500 mg/dL) and LDL-C no greater than 10% above the treatment goal; adults, age and sex not stated | 4 g | 2 years | — |
| Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients 2010 · Non-switchers · Patients with hypertriglyceridemia (triglycerides 200–500 mg/dL) and LDL-C no greater than 10% above the treatment goal; adults, age and sex not stated | 4 g | 2 years | — |
| Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure 2010 · n-3 PUFA · Patients with NYHA class II–III chronic heart failure | 900 mg | 24 weeks | — |
| n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study 2010 · intervention dairy products · Adults with mild hypertriacylglycerolemia (TAG ≥1.5 mmol/L), 25 women and 26 men | 3 g | 15 weeks | — |
| The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions 2010 · EPA · Overweight, dyslipidaemic men (Study A) and treated-hypertensive patients with type 2 diabetes (Study B) | 4 g | 6 weeks | — |
| Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial 2010 · omega-3 ethyl esters 90 · Patients with type 2 diabetes | 2 g | 120 days | — |
| Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial 2010 · atorvastatin and omega-3 ethyl esters 90 · Patients with type 2 diabetes | 2 g | 120 days | — |
| Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation 2011 · n-3 PUFA only · Either-sex patients undergoing on-pump cardiac surgery | 2 g | — | — |
| Omega-3 fatty acids supplementation attenuates inflammatory markers after eccentric exercise in untrained men 2011 · experimental group · Men who had not participated in a training program for 60 days before the study; age and health condition not specified | 1.8 g | — | — |
| Dose-response effects of fish-oil supplementation in healthy volunteers 1990 · 1.5 g group · Healthy normotriglyceridemic men | 1.5 g | 12 weeks | — |
| Dose-response effects of fish-oil supplementation in healthy volunteers 1990 · 3 g group · Healthy normotriglyceridemic men | 3 g | 12 weeks | — |
| Dose-response effects of fish-oil supplementation in healthy volunteers 1990 · 6 g group · Healthy normotriglyceridemic men | 6 g | 12 weeks | — |
| The effect of n-3 polyunsaturated fatty acids on leukotriene B₄ and leukotriene B₅ production from stimulated neutrophil granulocytes in patients with chronic kidney disease 2011 · n-3 PUFA · Patients with CKD stage 2–5 | 2.4 g | 8 weeks | — |
| Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial) 2011 · AMR101 2 g/day · Patients with fasting triglycerides of 500–2,000 mg/dl, with or without background statin therapy; age and sex not stated | 2 g | 12 weeks | — |
| Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients 2011 · marine omega-3 fatty acid group · Hemodialysis patients; age and sex not specified | 2.08 g | 10 weeks | — |
| Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients 2012 · n-3 PUFA group · Haemodialysis patients with cardiovascular disease | 1.7 g | 90 days | — |
| Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure 2011 · 1 g/day n3-PUFA · Patients with severe non-ischaemic chronic heart failure under optimised therapy | 1 g | 12 weeks | — |
| Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure 2011 · 4 g/day n3-PUFA · Patients with severe non-ischaemic chronic heart failure under optimised therapy | 4 g | 12 weeks | — |
| Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients 2011 · ω-3 fatty acids · Subjects with isolated hypertriglyceridemia | 2 g | 12 weeks | — |
| Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients 2011 · omega-3 fatty acids group · Hemodialysis patients; age range and sex not stated | 2.08 g | 10 weeks | — |
| [Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients] 2011 · RSI (oral powder supplement enriched with eicosapentaenoic acid) · Adults older than 18 years with cancer | 1.5 g | 30 days | — |
| Untitled 2012 · 1.25 g/d omega-3 group · Adults aged 40–85, men and women, healthy but overweight and sedentary | 1.25 g | 120 days | — |
| Untitled 2012 · 2.496 g/d n-3 group (high-dose group) · Adults aged 40–85, men and women, healthy but overweight and sedentary | 2.5 g | 120 days | — |
| Margarines fortified with α-linolenic acid, eicosapentaenoic acid, or docosahexaenoic acid alter the fatty acid composition of erythrocytes but do not affect the antioxidant status of healthy adults 2012 · EPA margarine group · Healthy men and women; age range and sex-specific numbers not reported | 2.2 g | 6 weeks | — |
| Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) 2012 · AMR101 4 g/day · High-risk statin-treated patients with triglycerides ≥200 and <500 mg/dl despite controlled LDL cholesterol of ≥40 and <100 mg/dl | 4 g | 12 weeks | — |
| Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) 2012 · AMR101 2 g/day · High-risk statin-treated patients with triglycerides ≥200 and <500 mg/dl despite controlled LDL cholesterol of ≥40 and <100 mg/dl | 2 g | 12 weeks | — |
| Untitled 2012 · AMR101 4 g/day · Patients with very high triglyceride levels (≥500 mg/dl) | 4 g | 12 weeks | — |
| Untitled 2012 · AMR101 2 g/day · Patients with very high triglyceride levels (≥500 mg/dl) | 2 g | 12 weeks | — |
| Untitled 2012 · n-3 PUFA group · Severely obese, nondiabetic patients scheduled to undergo elective bariatric surgery | 3.36 g | 8 weeks | — |
| Untitled 2013 · n-3PUFA group · Patients with chronic heart failure of any cause and severity | 1 g | 1 year | — |
| Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement 2013 · 0.45 g/day group · Healthy subjects; age and sex not specified | 450 mg | 26 weeks | — |
| Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement 2013 · 0.9 g/day group · Healthy subjects; age and sex not specified | 900 mg | 26 weeks | — |
| Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement 2013 · 1.8 g/day group · Healthy subjects; age and sex not specified | 1.8 g | 26 weeks | — |
| Untitled 2013 · supplement group · Overweight and obese participants; age and sex not specified | 1.8 g | 4 weeks | — |
| Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study) 2012 · IPE 4 g/day · Patients with very high triglyceride levels (≥500 mg/dL); age and sex not reported | 4 g | 12 weeks | — |
| Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study) 2012 · IPE 2 g/day · Patients with very high triglyceride levels (≥500 mg/dL); age and sex not reported | 2 g | 12 weeks | — |
| Effect of dietary intervention to reduce the n-6/n-3 fatty acid ratio on maternal and fetal fatty acid profile and its relation to offspring growth and body composition at 1 year of age 2013 · dietary intervention · Healthy pregnant women, from the 15th week of gestation through 4 months of lactation | 1.2 g | — | — |
| Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients 2013 · 3.6 g/d ω-3 PUFA group · Non-dialyzed patients with stage IV/V chronic kidney disease; age and sex not stated | 3.6 g | 10 weeks | — |
| Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis 2014 · ω-3 PUFA group · Young people at ultra-high risk for transition to psychosis | 1.2 g | 12 weeks | — |
| Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals 2013 · 0.45 g/d group · Healthy men and women aged 45–70 years | 450 mg | 1 year | — |
| Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals 2013 · 0.9 g/d group · Healthy men and women aged 45–70 years | 900 mg | 1 year | — |
| Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals 2013 · 1.8 g/d group · Healthy men and women aged 45–70 years; the reported increase was in participants older than 58 years with the +45 TT genotype | 1.8 g | 1 year | — |
| Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men 2013 · n-3 fatty acids only, 2 g/day · Healthy men; age range not reported. | 2 g | 12 weeks | — |
| A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial) 2013 · OM3-FFA 4 g/d · Adults with fasting triglycerides ≥200 mg/dL and <500 mg/dL, treated with a maximally tolerated statin or statin plus ezetimibe, and at high cardiovascular risk | 4 g | 6 weeks | — |
| Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men 2014 · ATV plus ω-3 FAEEs · insulin-resistant obese men; the abstract does not report an age range | 4 g | 6 weeks | — |
| Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance 2014 · P-OM3 alone · Men and women aged 40–69 years with overweight or obesity, insulin resistance, and dyslipidemia | 4 g | 16 weeks | — |
| Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance 2014 · Combination (P-OM3 plus ERN) · Men and women aged 40–69 years with overweight or obesity, insulin resistance, and dyslipidemia | 4 g | 16 weeks | — |
| DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial 2014 · FlaxSaff · Volunteers with abdominal obesity | 60 g | 4 weeks | — |
| Effects of supplementation with omega-3 on insulin sensitivity and non-esterified free fatty acid (NEFA) in type 2 diabetic patients 2014 · Group A · People with type 2 diabetes; age range and sex not reported | 4 g | 10 weeks | — |
| Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults 2014 · 300 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements | 300 mg | 150 days | — |
| Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults 2014 · 600 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements | 600 mg | 150 days | — |
| Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults 2014 · 900 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements | 900 mg | 150 days | — |
| Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults 2014 · 1800 mg/d EPA+DHA group · Healthy adults aged 20–45 years, BMI 20–30 kg/m², with no or low habitual oily fish consumption and not taking n-3 PUFA supplements | 1.8 g | 150 days | — |
| A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia 2014 · DHA-O · Adults with mild-to-moderate hypertriglyceridemia (TAG 150–499 mg/dL) | 2.4 g | 14 weeks | — |
| Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation 2014 · n-3 fatty acids plus aspirin · healthy human volunteers; age and sex not specified | 2.4 g | 7 days | — |
| Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation 2014 · n-3 fatty acids plus placebo · healthy human volunteers; age and sex not specified | 2.4 g | 7 days | — |
| Benefits of foods supplemented with vegetable oils rich in α-linolenic, stearidonic or docosahexaenoic acid in hypertriglyceridemic subjects: a double-blind, randomized, controlled trail 2015 · Stearidonic acid (SDA) group · Hypertriglyceridemic subjects with triglycerides ≥ 1.5 mmol/L; age and sex not stated | 2 g | 10 weeks | — |
| [Effect of Omega 3 fatty acids on body female obese composition] 2013 · Group 2 · Premenopausal obese women (BMI >30 kg/m²) | 1 g | 90 days | — |
| [Effect of Omega 3 fatty acids on body female obese composition] 2013 · Group 3 · Premenopausal obese women (BMI >30 kg/m²) | 2 g | 90 days | — |
| n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial 2015 · AG-PUFA group · Subjects with non-fasting plasma triacylglycerol levels of 1.7–5.65 mmol/L (150–500 mg/dL) | 3 g | 8 weeks | — |
| n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial 2015 · EE-PUFA group · Subjects with non-fasting plasma triacylglycerol levels of 1.7–5.65 mmol/L (150–500 mg/dL) | 3 g | 8 weeks | — |
| Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome 2015 · IPE 4 grams/day · Patients with metabolic syndrome and high or very high triglyceride levels, with or without stable statin therapy | 4 g | — | — |
| A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease 2016 · n-3 fatty acids · Patients with chronic kidney disease; age and sex not specified. | 4 g | 8 weeks | — |
| Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol 2015 · P-OM3 · Overweight patients with elevated triglyceride/HDL-C ratios; age and sex not specified | 4 g | 16 weeks | — |
| Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis 2015 · PUFA therapy group · Patients with pathologically diagnosed nonalcoholic steatohepatitis (NASH) | 50 mL | 26 weeks | — |
| n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease 2015 · n-3 fatty acids · Patients with chronic kidney disease | 4 g | 8 weeks | — |
| Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: A randomised study 2016 · marine n-3 PUFA · Healthy pre- and postmenopausal women | 2.2 g | 12 weeks | — |
| ω-3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: A randomized placebo-controlled study 2016 · group A · Children and adolescents with acute lymphoblastic leukemia in the maintenance phase of chemotherapy, receiving methotrexate | 1 g | 26 weeks | — |
| Insulin resistance determines a differential response to changes in dietary fat modification on metabolic syndrome risk factors: the LIPGENE study 2015 · LFHCC diet supplemented with long-chain n-3 polyunsaturated fatty acids · Adults with metabolic syndrome; age and sex not specified | 1.2 g | 12 weeks | — |
| Short term omega-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; A randomized clinical trial 2016 · omega 3-PUFA supplementation · Adults with chronic compensated systolic heart failure due to ischemic or dilated cardiomyopathy, NYHA class I–III | 1 g | 26 weeks | — |
| Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial 2016 · icosabutate · Men and women with very high triglycerides (500–1500 mg/dL); age not reported | 600 mg | 12 weeks | — |
| Effect of ω-3 supplementation on placental lipid metabolism in overweight and obese women 2016 · DHA plus EPA (n–3 FAs) · Healthy overweight and obese pregnant women | 2 g | — | — |
| Omega-3 LCPUFA supplement: a nutritional strategy to prevent maternal and neonatal oxidative stress 2017 · supplemented group FO · Pregnant women receiving supplementation during pregnancy and lactation | 400 mg | — | — |
| Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies 2016 · MARINE icosapent ethyl 4 g/day · Adults with very high triglyceride levels (≥500 and ≤2000 mg/dL) | 4 g | 12 weeks | — |
| Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies 2016 · ANCHOR icosapent ethyl 4 g/day · Adults with high triglyceride levels (≥200 and <500 mg/dL) despite statin control of LDL-C | 4 g | 12 weeks | — |
| ω-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia 2016 · ω-3 FAEE supplementation · Familial hypercholesterolemia patients receiving standard cholesterol-lowering treatment; age range and sex not stated | 4 g | 8 weeks | — |
| Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies 2016 · MARINE icosapent ethyl 4 g/day · Adults with triglycerides ≥500 and ≤2000 mg/dL | 4 g | 12 weeks | — |
| Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies 2016 · MARINE icosapent ethyl 2 g/day · Adults with triglycerides ≥500 and ≤2000 mg/dL | 2 g | 12 weeks | — |
| Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies 2016 · ANCHOR icosapent ethyl 4 g/day · Adults with triglycerides ≥200 and <500 mg/dL despite statin-controlled LDL-C | 4 g | 12 weeks | — |
| Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies 2016 · ANCHOR icosapent ethyl 2 g/day · Adults with triglycerides ≥200 and <500 mg/dL despite statin-controlled LDL-C | 2 g | 12 weeks | — |
| Potential Effects of Omega-3 Fatty Acids on Insulin Resistance and Lipid Profile in Maintenance Hemodialysis Patients: a Randomized Placebo-Controlled Trial 2016 · omega-3 fatty acids group · Adults receiving maintenance hemodialysis | 1.8 g | 120 days | — |
| Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial 2016 · EPA 600mg/d · Healthy, normolipidemic subjects; age and sex not specified | 600 mg | 6 weeks | — |
| Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial 2016 · EPA 1800mg/d · Healthy, normolipidemic subjects; age and sex not specified | 1.8 g | 6 weeks | — |
| The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia 2016 · OM3-CA 2 g/d · Subjects with fasting triglycerides of 500 to 2000 mg/dL (age and sex not specified) | 2 g | 12 weeks | — |
| The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia 2016 · OM3-CA 3 g/d · Subjects with fasting triglycerides of 500 to 2000 mg/dL (age and sex not specified) | 3 g | 12 weeks | — |
| The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia 2016 · OM3-CA 4 g/d · Subjects with fasting triglycerides of 500 to 2000 mg/dL (age and sex not specified) | 4 g | 12 weeks | — |
| Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study 2017 · EPA · Men and women with abdominal obesity and low-grade inflammation, at risk for cardiometabolic diseases | 2.7 g | 10 weeks | — |
| Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia 2017 · second group (statin + omega-3 PUFA) · People with combined dyslipidemia and elevated TAG levels; age and sex not reported | 2.52 g | 90 days | — |
| Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial 2017 · n-3 PUFA intervention group · Patients aged 16–35 with first-episode schizophrenia | 2.2 g | 26 weeks | — |
| Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia 2017 · MAT9001 · Men and women aged 18–70 years with hypertriglyceridemia (fasting triglycerides 200–400 mg/dL) | 4 g | 2 weeks | — |
| Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia 2017 · EPA-EE (Vascepa, icosapent ethyl) · Men and women aged 18–70 years with hypertriglyceridemia (fasting triglycerides 200–400 mg/dL) | 4 g | 2 weeks | — |
| A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota 2018 · soft-gel capsule intervention · Healthy middle-aged volunteers | 4 g | 8 weeks | — |
| A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota 2018 · Smartfish drink intervention · Healthy middle-aged volunteers | 4 g | 8 weeks | — |
| The Effect of Eicosapentaenoic Acid on the Serum Levels and Enzymatic Activity of Paraoxonase 1 in the Patients With Type 2 Diabetes Mellitus 2017 · EPA supplement group · Patients with type 2 diabetes; age and sex not specified | 2 g | 8 weeks | — |
| Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial 2017 · n-3 fatty acid group · Atopic pregnant women | 3.7 g | — | — |
| Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial 2018 · ROSUMEGA group · Adults with residual hypertriglyceridemia despite statin treatment | 4 g | 8 weeks | — |
| Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial 2018 · n-3 PUFA intervention group · patients aged 16–35 with first-episode schizophrenia | 2.2 g | 26 weeks | — |
| Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight 2018 · n-3 PUFA · Patients with NASH; age and sex not specified | 945 mg | 26 weeks | — |
| Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial 2018 · OM3-CA 2 g daily · Adults with severe hypertriglyceridemia and qualifying serum triglycerides of at least 500 mg/dL and below 2500 mg/dL (below 2000 mg/dL in Canada) | 2 g | 12 weeks | — |
| The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease 2018 · n-3 FA · Patients with chronic kidney disease (CKD) | 4 g | 8 weeks | — |
| A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study 2018 · ω-3 group · Patients with episodic migraine | 2.5 g | 60 days | — |
| Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial 2019 · marine n-3 FA group · Norwegian renal transplant recipients | 2.6 g | 44 weeks | — |
| Effect of Low Dose Docosahexaenoic Acid-Rich Fish Oil on Plasma Lipids and Lipoproteins in Pre-Menopausal Women: A Dose⁻Response Randomized Placebo-Controlled Trial 2018 · 0.35 g/day n-3 LCPUFA group · Healthy premenopausal women aged 18–40 with mildly elevated triglycerides (>1.0 mmol/L) and regular menstrual cycles | 350 mg | 8 weeks | — |
| Effect of Low Dose Docosahexaenoic Acid-Rich Fish Oil on Plasma Lipids and Lipoproteins in Pre-Menopausal Women: A Dose⁻Response Randomized Placebo-Controlled Trial 2018 · 0.7 g/day n-3 LCPUFA group · Healthy premenopausal women aged 18–40 with mildly elevated triglycerides (>1.0 mmol/L) and regular menstrual cycles | 700 mg | 8 weeks | — |
| Effect of Low Dose Docosahexaenoic Acid-Rich Fish Oil on Plasma Lipids and Lipoproteins in Pre-Menopausal Women: A Dose⁻Response Randomized Placebo-Controlled Trial 2018 · 1.0 g/day n-3 LCPUFA group · Healthy premenopausal women aged 18–40 with mildly elevated triglycerides (>1.0 mmol/L) and regular menstrual cycles | 1 g | 8 weeks | — |
| The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients 2019 · ω3FA treatment group · Nondiabetic patients with Stage 3–4 chronic kidney disease | 4 g | 8 weeks | — |
| Comparing the serum TAG response to high-dose supplementation of either DHA or EPA among individuals with increased cardiovascular risk: the ComparED study 2019 · EPA · Men and women with increased cardiovascular risk | 2.7 g | 10 weeks | — |
| Four Weeks of Preoperative Omega-3 Fatty Acids Reduce Liver Volume: a Randomised Controlled Trial 2019 · Omega-3 fatty acids with a normal diet · Morbidly obese women undergoing laparoscopic Roux-en-Y gastric bypass surgery | 2 g | 4 weeks | — |
| EPA+DHA, but not ALA, Improved Lipids and Inflammation Status in Hypercholesterolemic Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · 1.8 g/d DHA+EPA · Adults with hypercholesterolemia; age range and sex not specified | 1.8 g | 12 weeks | — |
| EPA+DHA, but not ALA, Improved Lipids and Inflammation Status in Hypercholesterolemic Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · 3.6 g/d EPA+DHA · Adults with hypercholesterolemia; age range and sex not specified | 3.6 g | 12 weeks | — |
| Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients 2020 · omega-3 fatty acid group · Colorectal cancer patients | 660 mg | 8 weeks | — |
| Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial 2019 · intensive therapy group · Patients with non-obstructive neoatherosclerotic plaques detected on OCT | 1.8 g | 1 year | — |
| EPA and DHA have divergent effects on serum triglycerides and lipogenesis, but similar effects on lipoprotein lipase activity: a randomized controlled trial 2019 · EPA group · Young, healthy normolipidemic men and women | 3 g | 12 weeks | — |
| Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study 2020 · 2 g AZD0585 group · Japanese patients with dyslipidemia, LDL-C controlled regardless of statin use, and triglyceride levels of 150–499 mg/dL | 2 g | 52 weeks | — |
| Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study 2020 · 4 g AZD0585 group · Japanese patients with dyslipidemia, LDL-C controlled regardless of statin use, and triglyceride levels of 150–499 mg/dL | 4 g | 52 weeks | — |
| Effects of Vitamin D and Omega-3 Fatty Acids Co-Supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2020 · omega-3 fatty acid · Patients with stage II or III colorectal cancer undergoing chemotherapy | 660 mg | 8 weeks | — |
| Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results 2021 · icosapent ethyl (IPE) · Adults with coronary atherosclerosis, persistently high triglycerides, and stable statin therapy | 4 g | 548 days | — |
| Concomitant Use of Rosuvastatin and Eicosapentaenoic Acid Significantly Prevents Native Coronary Atherosclerotic Progression in Patients With In-Stent Neoatherosclerosis 2020 · intensive therapy · Patients with in-stent neoatherosclerosis and native coronary plaques | 1.8 g | 1 year | — |
| Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning 2020 · omega-3 · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment | 2 g | 1 year | — |
| Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning 2020 · atorvastatin + omega-3 · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment | 2 g | 1 year | — |
| Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning 2020 · omega-3 + action planning · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment | 2 g | 1 year | — |
| Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning 2020 · atorvastatin + omega-3 + action planning · Adults with type 2 diabetes and no known cardiovascular events, managed in UK primary care and not thought to require immediate lipid-lowering treatment | 2 g | 1 year | — |
| The prebiotic effects of omega-3 fatty acid supplementation: A six-week randomised intervention trial 2021 · omega-3 intervention · Adults over 18 years with BMI 20–39.9 kg/m² and habitual fiber consumption below 15 g/day; no particular disease or trait selected | 500 mg | 6 weeks | — |
| Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects 2021 · EPA · healthy volunteers | 4 g | 30 days | — |
| An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study 2021 · Low LCn3 and low PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion | 1.5 g | 8 weeks | — |
| An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study 2021 · High LCn3 and low PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion | 4 g | 8 weeks | — |
| An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study 2021 · Low LCn3 and high PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion | 1.4 g | 8 weeks | — |
| An Oily Fish Diet Improves Subclinical Inflammation in People at High Cardiovascular Risk: A Randomized Controlled Study 2021 · High LCn3 and high PP · Adults aged 35–70 years with overweight or obesity, high waist circumference, and at least one additional metabolic syndrome criterion | 4 g | 8 weeks | — |
| Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study 2021 · UI-018 fixed-dose combination atorvastatin/Ω-3 fatty acid · Patients with residual hypertriglyceridemia who responded poorly to atorvastatin 40 mg monotherapy | 4 g | 8 weeks | — |
| Omega 3-rich Camelina sativa oil in the context of a weight loss program improves glucose homeostasis, inflammation and oxidative stress in patients with NAFLD: A randomised placebo-controlled clinical trial 2021 · Camelina sativa oil (CSO) group · Patients with non-alcoholic fatty liver disease (NAFLD); age and sex not reported | 20 g | 12 weeks | — |
| Omega-3 polyunsaturated fatty acids supplementation improve clinical symptoms in patients with Covid-19: A randomised clinical trial 2021 · intervention group · Adult men and women diagnosed with Covid-19 | 2 g | 2 weeks | — |
| Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial 2021 · OM3EE monotherapy in moderate HTG (mHTG cohort) · Adults aged 18 years or older with moderate hypertriglyceridemia (baseline triglycerides ≥200 and <500 mg/dL) | 2 g | 12 weeks | — |
| Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial 2021 · OM3EE with existing statin therapy (combination cohort) · Adults aged 18 years or older with hypertriglyceridemia receiving stable existing statin therapy | 2 g | 12 weeks | — |
| Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease 2021 · omega-3 free carboxylic acids (OM-3CA) · Overweight patients with non-alcoholic fatty liver disease and hypertriglyceridemia | 4 g | 12 weeks | — |
| A Randomized Trial of ω-3 Fatty Acid Supplementation and Circulating Lipoprotein Subclasses in Healthy Older Adults 2022 · n-3-PUFA ethyl esters · Men and women aged 65–85 years without cardiovascular disease or hypertriglyceridemia | 3.9 g | 26 weeks | — |
| Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial 2022 · EPA 1 g/d · Adults with DSM-5 major depressive disorder, BMI >25 kg/m², and plasma hs-CRP ≥3.0 mg/L; mean age 45.5 years; 75% female | 1 g | 12 weeks | — |
| Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial 2022 · EPA 2 g/d · Adults with DSM-5 major depressive disorder, BMI >25 kg/m², and plasma hs-CRP ≥3.0 mg/L; mean age 45.5 years; 75% female | 2 g | 12 weeks | — |
| Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial 2022 · EPA 4 g/d · Adults with DSM-5 major depressive disorder, BMI >25 kg/m², and plasma hs-CRP ≥3.0 mg/L; mean age 45.5 years; 75% female | 4 g | 12 weeks | — |
| Increases in plasma n-3 tetracosapentaenoic acid and tetracosahexaenoic acid following 12 weeks of EPA, but not DHA, supplementation in women and men 2022 · EPA supplemented group · Women and men aged 19–30 years | 3 g | 12 weeks | — |
| Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial 2022 · Marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization | 1 g | 1935 days | — |
| Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial 2023 · EPA alone · Trial participants in the seAFOod polyp prevention trial; age and sex are not specified in the abstract | 2 g | 1 year | — |
| Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial 2023 · Aspirin and EPA · Trial participants in the seAFOod polyp prevention trial; age and sex are not specified in the abstract | 2 g | 1 year | — |
| Omega-3 fatty acids supplementation improves early-stage diabetic nephropathy and subclinical atherosclerosis in pediatric patients with type 1 diabetes: A randomized controlled trial 2023 · intervention group · Pediatric patients with type 1 diabetes and diabetic nephropathy; mean age 15.2 ± 1.96 years | 1 g | 26 weeks | — |
| Monocyte transcriptomic profile following EPA and DHA supplementation in men and women with low-grade chronic inflammation 2024 · EPA supplementation · Men and postmenopausal women aged 50–75 years with chronic low-grade inflammation and at least one cardiometabolic risk characteristic | 3 g | 10 weeks | — |
| The effect of eight weeks combined training with omega-3 supplementation on the levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in older women 2024 · omega-3 supplement · Older women, mean age 66.7 ± 4.13 years | 2 g | 8 weeks | — |
| The effect of eight weeks combined training with omega-3 supplementation on the levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in older women 2024 · training + omega-3 · Older women, mean age 66.7 ± 4.13 years | 2 g | 8 weeks | — |
| APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial 2024 · EPA supplementation · Participants undergoing colonoscopy surveillance after removal of colorectal polyps | 2 g | 26 weeks | — |
| Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial 2024 · Diet + Supplementation · Patients with psoriatic arthritis; age and sex not specified | 1.81 g | 12 weeks | — |
| The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial 2025 · omega-3 fatty acid (ω3) group · Women newly diagnosed with breast cancer receiving chemotherapy; age range not reported | 600 mg | 9 weeks | — |
| Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial 2025 · Marine n-3 fatty acids only · Females aged 55 years or older and males aged 50 years or older; no specific condition stated | 1 g | 5 years | — |
| Supplementation of Omega-3 Increases Serum Levels of Brain-Derived Neurotrophic Factor and Decreases Depression Status in Patients With Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2025 · omega-3 supplements · Men with bipolar disorder; age not stated | 2 g | 60 days | — |
| The anti-inflammatory effects of three different dietary supplement interventions 2025 · Omega 3 arm · Adults aged 60 years and older with BMI 20–39.9 and habitual fibre consumption below 15 g/day | 500 mg | 6 weeks | — |
| Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial 1995 · Fish oil group · Adults with untreated hypertension recruited from a population survey; age and sex not reported | 4 g | 16 weeks | — |
| Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients 1995 · EPA-E administration · People with non-insulin-dependent diabetes mellitus and nephropathy | 900 mg | 1 year | — |
| The effect of n-3 fatty acids on neutrophil chemiluminescence 1995 · 0.65 g n-3 PUFA group · Adults; ages, sex, and health status not reported | 650 mg | 6 weeks | — |
| Prolonged inhibition of platelet aggregation after n-3 fatty acid ethyl ester ingestion by healthy volunteers 1995 · Low-dose n-3 fatty acid group · Healthy volunteers; age and sex not specified | 3 g | 18 weeks | — |
| n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes 1994 · n-3 fatty acid ethyl esters, healthy volunteers · Healthy volunteers; age and sex not reported | 3 g | 18 weeks | — |
| n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes 1994 · n-3 fatty acid ethyl esters, hypertriglyceridemic patients · Hypertriglyceridemic patients; age and sex not reported | 3 g | 24 weeks | — |
| The acute effects of a single very high dose of n-3 fatty acids on plasma lipids and lipoproteins in healthy subjects 1994 · n-3 PUFA group · Healthy volunteers; age and sex not specified | 20 g | 1 day | — |
| Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates 1993 · fish oil (n-3 fatty acids) · Eight normal volunteers | 64 mg/kg | 4 weeks | — |
| Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM 1993 · 900-mg group · Adults with non-insulin-dependent diabetes mellitus (NIDDM); age and sex not stated | 900 mg | 8 weeks | — |
| Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM 1993 · 1800-mg group · Adults with non-insulin-dependent diabetes mellitus (NIDDM); age and sex not stated | 1.8 g | 8 weeks | — |
| Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate 1995 · Ethyl icosapentatenoate (EPA) treatment · Non-insulin-dependent diabetic patients; age and sex not reported | 1.8 g | 4 weeks | — |
| Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease 1996 · n-3 PUFA · Patients with chronic atherosclerotic disease | 3 g | 16 weeks | — |
| Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans 1996 · EPA · Normolipidemic subjects; age and sex not reported | 3 g | 3 weeks | — |
| Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans 1996 · DHA · Normolipidemic subjects; age and sex not reported | 3 g | 3 weeks | — |
| Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans 1997 · Menhaden oil without vitamin E · Healthy men; age not stated | 6.26 g | 6 weeks | — |
| Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants 1997 · omega-3 FAs · male smokers with combined hyperlipidemia | 5 g | 6 weeks | — |
| Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia 1998 · omega-3 fatty acids · Adults with combined hyperlipidemia | 4 g | 5 weeks | — |
| Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia 1998 · simvastatin plus omega-3 fatty acids · Adults with combined hyperlipidemia | 4 g | 5 weeks | — |
| One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations 1998 · n-3 fatty acid ethyl ester group · Patients with hypertriglyceridemia and additional cardiovascular risk factors, including glucose intolerance, NIDDM and/or arterial hypertension | 2 g | 26 weeks | — |
| Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers 1998 · n-3 fatty acids without antioxidants · adult male smokers with hyperlipidaemia | 4.8 g | 6 weeks | — |
| Safety and efficacy of Omacor in severe hypertriglyceridemia 1997 · Omacor · 42 patients with severe hypertriglyceridemia; age and sex not reported | 4 g | 120 days | — |
| Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study 1999 · omega-3 fatty acids · Volunteers; no age, sex, or health condition specified | 7 g | 4 weeks | — |
| Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective? 2023 · O3FA group · Symptomatic visual display terminal users with dry eye; mean age 26.5 years; men and women | 360 mg | 180 days | 470 |
| Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN) 2018 · MF4637 omega-3 concentrate · Adults aged 18 years or older with suspected non-alcoholic fatty liver disease (NAFLD) | 1.38 g | 24 weeks | 87 |
| Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Bone Turnover in Older Women 2014 · n-3 LCPUFA group · Postmenopausal women, mean age 75±7 years | 1.2 g | 26 weeks | 85 |
| Consumption of echium oil increases EPA and DPA in blood fractions more efficiently compared to linseed oil in humans 2016 · Echium oil (EO) · Adults aged 20–69 years, women and men, including normal-weight and overweight participants; no chronic disease reported | 17 g | 8 weeks | 60 |
| Supplementation of EPA and DHA in pregnant women with type 1 diabetes mellitus 2021 · intervention group · Pregnant women aged 17–35 with type 1 diabetes mellitus and well-controlled glycaemia; supplementation began at 11–12 gestational weeks | 120 mg | — | 42 |
| Habitual diets rich in dark-green vegetables are associated with an increased response to ω-3 fatty acid supplementation in Americans of African ancestry 2014 · EPA + DHA supplementation · Participants of African ancestry; age and sex not stated | 2 g | 6 weeks | 41 |
| Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index 2010 · n-3 fatty acid drink · Adults with atherosclerotic disease and an n-3 index below 5% | 200 mg | 8 weeks | 40 |
| Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults 2025 · microalgal oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL | 656 mg | 14 weeks | 37 |
| Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans 2014 · 2 continuous portions (2C) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition | 429 mg | 1 year | 35 |
| A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction 2014 · rTG concentrated triglyceride fish oil · Healthy adults aged 19–60 years, women and men, without diagnosed illness | 1.1 g | 4 weeks | 35 |
| A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction 2014 · EE ethyl ester fish oil · Healthy adults aged 19–60 years, women and men, without diagnosed illness | 984 mg | 4 weeks | 35 |
| Comparative Pharmacokinetic of Curcuminoids Formulations with an Omega-3 Fatty Acids Monoglyceride Carrier: A Randomized Cross-Over Triple-Blind Study 2022 · Curcuminoids extract emulsified in MAG-OM3 oil · Healthy males and females aged 18–50 years | 760 mg | 1 day | 31 |
| Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans 2014 · 2 intermittent portions (2I) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition | 429 mg | 1 year | 30 |
| Women have higher levels of CoQ(10) than men when supplemented with a single dose of CoQ(10) with monoglycerides omega-3 or rice oil and followed for 48 h: a crossover randomised triple blind controlled study 2022 · CoQ10 + MAG-OM3 · Healthy men and women aged 18–50 years | 1 g | 1 day | 30 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Soup · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 13.6 mg | 1 day | 27 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Extruded rice snack · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 13.8 mg | 1 day | 27 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Gel capsule (control) · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 14.7 mg | 1 day | 27 |
| Treatment with n-3 polyunsaturated fatty acids overcomes the inverse association of vitamin D deficiency with inflammation in severely obese patients: a randomized controlled trial 2013 · n-3 PUFA group · Severely obese, non-diabetic adults; sex and age range not specified | 3.36 g | 8 weeks | 26 |
| A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency 2014 · Multi · Healthy adults aged 18–32 years | 190 mg | 120 days | 25 |
| Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study 2023 · krill oil (KO) · Healthy adult men and women | 206 mg | 1 day | 24 |
| Bioavailability of Dietary Omega-3 Fatty Acids Added to a Variety of Sausages in Healthy Individuals 2017 · verum group · Healthy adults aged 20–60 years with Omega-3 Index below 5% | 250 mg | 8 weeks | 22 |
| Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial 2021 · MAG (monoglyceride) · Healthy adults aged 18–50 years, men and women | 1.21 g | 1 day | 22 |
| Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial 2021 · EE (ethyl ester) · Healthy adults aged 18–50 years, men and women | 1.21 g | 1 day | 22 |
| Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial 2021 · TG (triglyceride) · Healthy adults aged 18–50 years, men and women | 1.21 g | 1 day | 22 |
| Circulating levels of endocannabinoids and oxylipins altered by dietary lipids in older women are likely associated with previously identified gene targets 2016 · fish oil supplement · Postmenopausal women, mean age 75±7 years | 1.2 g | 180 days | 20 |
| Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study) 2025 · ω-3 supplement · Healthy young adults aged 18–30 years, male and female, low habitual fish consumers with ω-3 index <6% | 400 mg | 8 weeks | 20 |
| Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption 2016 · Calanus Oil condition · Healthy adults; age and sex not specified | 4 g | 1 day | 18 |
| Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial 2011 · n-3 LC-PUFA + GLA (group 3) · Adults aged 18–90 with rheumatoid arthritis or psoriatic arthritis and at least medium disease activity | 1.58 g | 12 weeks | 15 |
| A randomized controlled trial of the effect of fish oil supplementation in late pregnancy and early lactation on the n-3 fatty acid content in human breast milk 2004 · FO(pregn/lact) · Healthy pregnant Danish women, starting in the third trimester and continuing during early lactation | 2.2 g | — | 12 |
| A randomized controlled trial of the effect of fish oil supplementation in late pregnancy and early lactation on the n-3 fatty acid content in human breast milk 2004 · FO(pregn) · Healthy pregnant Danish women, starting in the third trimester; women stopped supplementation at delivery | 2.2 g | — | 11 |
| Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk 2018 · 675+270 mg/day group · Pregnant women | 270 mg | — | 11 |
| Omega-3 fatty acid supplementation affects tryptophan metabolism during a 12-week endurance training in amateur runners: a randomized controlled trial 2024 · O-3 + SEDEN · Physically inactive men, mean age 38 years | 3.16 g | 12 weeks | 11 |
| Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk 2018 · 225+90 mg/day group · Pregnant women | 90 mg | — | 9 |
| Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk 2018 · 450+180 mg/day group · Pregnant women | 180 mg | — | 9 |
| The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study 2015 · Cholecalciferol with omega-3 FA group · Hemodialysis patients with baseline 25(OH)D levels below 30 ng/mL; mean age 62.1 years; 33.3% men | 2.4 g | 12 weeks | 8 |
| In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA 2021 · Lys-FFA · Eight female volunteers | 500 mg | 1 day | 8 |
| In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA 2021 · EE · Eight female volunteers | 504 mg | 1 day | 8 |
| Fish oil supplemental dose needed to reach 1g% DHA+EPA in mature milk 2018 · 900+360 mg/day group · Pregnant women | 360 mg | — | 7 |
| Perioperative immunonutrition in well-nourished patients undergoing surgery for head and neck cancer: evaluation of inflammatory and immunologic outcomes 2013 · Immunonutrition (IMN) group · Patients aged 17 years and older with normal nutritional status undergoing radical resection for oral cavity, pharyngeal or laryngeal cancer | 6.1 g | 11 days | 4 |
| Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients 2003 · VitC + n-3FAs group · Hyperlipidemic patients with total cholesterol and triglycerides greater than 200 mg/dL; age and sex not specified | 1 g | 10 weeks | — |
| The influence of different combinations of gamma-linolenic, stearidonic and eicosapentaenoic acids on the fatty acid composition of blood lipids and mononuclear cells in human volunteers 2004 · STA plus GLA oil blend · Healthy young males | 1 g | 12 weeks | — |
| Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids 2006 · fish oil · 20 study participants; age, sex, and health condition not specified | 1.3 g | 8 weeks | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO · Pregnant women from gestation week 22 until delivery | 150 mg | — | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery | 150 mg | — | — |
| Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations? 2008 · omega-3 FA supplementation · Patients with epilepsy; age and sex not reported | 1 g | 12 weeks | — |
| Dietary intake of stearidonic acid-enriched soybean oil increases the omega-3 index: randomized, double-blind clinical study of efficacy and safety 2010 · EPA group · Overweight adults; age and sex not reported | 1 g | 12 weeks | — |
| Consumption of salmon v. salmon oil capsules: effects on n-3 PUFA and selenium status 2011 · 2 salmon oil capsules/d · Healthy volunteers; age and sex not specified | 240 mg | 8 weeks | — |
| Consumption of salmon v. salmon oil capsules: effects on n-3 PUFA and selenium status 2011 · 4 salmon oil capsules/d · Healthy volunteers; age and sex not specified | 470 mg | 8 weeks | — |
| Consumption of salmon v. salmon oil capsules: effects on n-3 PUFA and selenium status 2011 · 6 salmon oil capsules/d · Healthy volunteers; age and sex not specified | 690 mg | 8 weeks | — |
| Consumption of stearidonic acid-rich oil in foods increases red blood cell eicosapentaenoic acid 2013 · positive control · Healthy men and women aged 21 to 65 years | 1.5 g | 12 weeks | — |
| Consumption of stearidonic acid-rich oil in foods increases red blood cell eicosapentaenoic acid 2013 · active · Healthy men and women aged 21 to 65 years | 7 g | 12 weeks | — |
| Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats 2015 · Butter meal · Healthy adult men and women | 300 mg | 1 day | — |
| Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats 2015 · Sunflower seed oil meal · Healthy adult men and women | 300 mg | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · unmodified fish oil TAG (uTAG) · Healthy men in the postprandial crossover study | 1.1 g | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · re-esterified TAG · Healthy men in the postprandial crossover study | 1.1 g | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · free fatty acids (FFA) · Healthy men in the postprandial crossover study | 1.1 g | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · ethyl esters (EE) · Healthy men in the postprandial crossover study | 1.1 g | 1 day | — |
| Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions 2016 · MAG-enriched oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion | 500 mg | 3 weeks | — |
| Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions 2016 · TAG fish oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion | 500 mg | 3 weeks | — |
| Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies 2017 · Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder | 1.67 g | 12 weeks | — |
| Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies 2017 · PEP plus Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder | 1.67 g | 12 weeks | — |
| Maternal Pre-Pregnancy Obesity Attenuates Response to Omega-3 Fatty Acids Supplementation During Pregnancy 2018 · n-3 PUFA supplementation group · Pregnant women with a history of at least one prior singleton preterm delivery, enrolled at 16 to 21 6/7 weeks; lean, overweight, and obese women were included | 1.2 g | 8 weeks | — |
| n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial 2019 · n-3 PUFA supplementation · Adults with small abdominal aortic aneurysm (AAA), diameter 3.0–4.5 cm | 1.8 g | 12 weeks | — |
| Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth? 2020 · DHA supplementation group · Pregnant Australian women enrolled before 20 weeks of gestation; age and condition range not specified | 100 mg | — | — |
| Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation 2021 · EPA 1 g/day · Overweight or obese adults with major depressive disorder and chronic inflammation | 1.3 g | 12 weeks | — |
| Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation 2021 · EPA 2 g/day · Overweight or obese adults with major depressive disorder and chronic inflammation | 2.6 g | 12 weeks | — |
| Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation 2021 · EPA 4 g/day · Overweight or obese adults with major depressive disorder and chronic inflammation | 5.2 g | 12 weeks | — |
| Intake of Docosahexaenoic Acid-Enriched Milk Beverage Prevents Age-Related Cognitive Decline and Decreases Serum Bone Resorption Marker Levels 2021 · docosahexaenoic acid-enriched milk beverage · Healthy elderly Japanese individuals with a Mini-Mental State Examination score of 28 or higher at baseline | 137 mg | 1 year | — |
| Effects of EPA+DHA and Corn Oil Supplementation on PUFA Concentrations across Plasma Lipid Pools and on Downstream Oxylipins: Exploratory Results from a Randomized Controlled Trial in Healthy Humans 2026 · EPA+DHA concentrate · Healthy adults aged 35–49 years; 20 women and 1 man in the available-sample analysis | 1.1 g | 12 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · ethyl ester (EE) · healthy normolipaemic men | 2.2 g | 7 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · triglyceride (TG) · healthy normolipaemic men | 2.2 g | 7 weeks | — |
| Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men 1997 · fish diet group · Healthy men aged 19–32 years | 380 mg | 14 weeks | — |
| Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men 1997 · fish oil group · Healthy men aged 19–32 years | 1.33 g | 14 weeks | — |
| Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors 2013 · yoghurt enriched with 0.8 g n-3 LC-PUFA/d · Mildly hypertriacylglycerolemic subjects with TAG ≥ 1.7 mmol/L; age and sex not specified | 800 mg | 10 weeks | — |
| Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial 2023 · Marine omega-3 only · Generally healthy, robust, community-dwelling adults aged 70 years or older | 1 g | 3 years | — |
| Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease 1995 · fish-oil group · Patients with coronary artery disease; age range and sex not stated | 3.4 g | 39 weeks | 260 |
| Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial 2015 · Statin + OM3-CA 2 g/d plus olive oil 2 g/d · Adults aged 18 years or older, men and non-pregnant, non-lactating women, at high cardiovascular risk with residual hypertriglyceridemia while taking a statin | 2 g | 6 weeks | 215 |
| Supplementation-induced increase in circulating omega-3 serum levels is not associated with a reduction in depressive symptoms: Results from the MooDFOOD depression prevention trial 2020 · Supplement without F-BA · Adults aged 18–75 who were overweight (BMI 25–40) and had at least mild depressive symptoms but no current major depressive episode | 1.41 g | 1 year | 174 |
| Supplementation-induced increase in circulating omega-3 serum levels is not associated with a reduction in depressive symptoms: Results from the MooDFOOD depression prevention trial 2020 · Supplement with F-BA · Adults aged 18–75 who were overweight (BMI 25–40) and had at least mild depressive symptoms but no current major depressive episode | 1.41 g | 1 year | 169 |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 1.86 g | 1 year | 147 |
| Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial 2017 · Omega-3 ethyl-ester group · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk features; predominantly men | 3.36 g | 913 days | 143 |
| Effects of EPA, γ-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial 2013 · group 1 (n-3 fatty acids) · Healthy men with serum PSA ≤ 2.5 ng/ml | 4.48 g | 12 weeks | 126 |
| Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial 2014 · OM3-FFA 3 g/d (plus OO 1 g/d) · Men and women with severe hypertriglyceridemia (triglycerides ≥500 mg/dL and <2000 mg/dL) | 3 g | 12 weeks | 101 |
| Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial 2014 · OM3-FFA 2 g/d (plus OO 2 g/d) · Men and women with severe hypertriglyceridemia (triglycerides ≥500 mg/dL and <2000 mg/dL) | 2 g | 12 weeks | 100 |
| Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study 2013 · n - 3/n - 3 group · Older adults with Alzheimer's disease; mean age 75 years; 57% women | 600 mg | 1 year | 89 |
| Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial 2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery | 2 g | 7 days | 74 |
| Effects of enriched seafood sticks (heat-inactivated B. animalis subsp. lactis CECT 8145, inulin, omega-3) on cardiometabolic risk factors and gut microbiota in abdominally obese subjects: randomized controlled trial 2022 · SIAP2 · Adults older than 18 years with abdominal obesity | 370 mg | 12 weeks | 57 |
| Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes 2016 · omega-3 group · Adults over 18 years with diagnosed dry eye disease, meibomian gland dysfunction stage 1 or 2, and elevated tear osmolarity | 1.68 g | 12 weeks | 54 |
| The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial 2021 · Low-calorie diet + n-3 PUFA · Adults aged 25–65 with overweight or obesity and abdominal obesity | 1.8 g | 90 days | 50 |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 650 mg | 1 year | 50 |
| Joint effects of one year of marine omega-3 fatty acid supplementation and participant dietary fish intake upon circulating lipid mediators of inflammation resolution in a randomized controlled trial 2024 · n-3 fatty acid supplementation · Women aged 55 years or older and men aged 50 years or older; participants selected from the VITAL trial by baseline fish intake, without a stated diagnosis | 1 g | 1 year | 50 |
| Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study 2020 · EPA+DHA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted | 930 mg | 1 year | 48 |
| Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial 2023 · D+ group · Jordanian participants with vitamin D deficiency and no other medical conditions; age and sex not specified | 300 mg | 8 weeks | 47 |
| Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids 2013 · n-3 PUFA / fish oil treatment · Adults with type 2 diabetes and hypertension, and adults with hypertension without diabetes; age- and sex-matched groups | 460 mg | 8 weeks | 45 |
| The Effect of Caloric Restriction with and without n-3 PUFA Supplementation on Bone Turnover Markers in Blood of Subjects with Abdominal Obesity: A Randomized Placebo-Controlled Trial 2021 · Isocaloric diet + n-3 PUFA · Adults aged 25–65 with overweight or obesity and abdominal obesity | 1.8 g | 90 days | 45 |
| Omega-3 Fatty Acid Supplementation is Associated With Oxidative Stress and Dyslipidemia, but Does not Contribute to Better Lipid and Oxidative Status on Hemodialysis Patients 2017 · n-3 PUFA group · Adults aged 18 years or older receiving hemodialysis for at least 6 months | 1.28 g | 12 weeks | 43 |
| A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha 2002 · 300 mg DHA + 70 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported | 70 mg | 4 weeks | 40 |
| A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha 2002 · 600 mg DHA + 140 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported | 140 mg | 4 weeks | 40 |
| Untitled 2013 · low dose fish oil arm · Men and women aged 40–85; overweight or obese, without the listed excluded medical conditions; not selected for a diagnosed disease or nutrient deficiency. | 1.25 g | 120 days | 40 |
| Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication | 4.4 g | 30 days | 40 |
| Hyaluronic acid is associated with organ dysfunction in acute respiratory distress syndrome 2017 · fish oil treatment · Adults with acute respiratory distress syndrome in intensive care | 16.5 g | 2 weeks | 38 |
| Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines 2018 · EPA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history | 1.06 g | 14 weeks | 37 |
| The effects of fish oil plus vitamin D(3) intervention on non-alcoholic fatty liver disease: a randomized controlled trial 2022 · FO + D group · Adults aged 56.0 ± 15.9 years with non-alcoholic fatty liver disease | 2.34 g | 90 days | 37 |
| Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes 2017 · n-3 PUFAs · Adults, mean age 65.6 years, men and women, with type 2 diabetes and established atherosclerotic cardiovascular disease | 1 g | 90 days | 36 |
| Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines 2018 · DHA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history | 180 mg | 14 weeks | 36 |
| Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides 2025 · OL (ω-3 PUFA + L. reuteri) · Pregnant women with a family history of allergies who intended to breastfeed for the first 3 months; maternal age median about 30 years | 3.84 g | 230 days | 36 |
| A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction 2014 · PL phospholipid krill oil · Healthy adults aged 19–60 years, women and men, without diagnosed illness | 240 mg | 4 weeks | 35 |
| A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction 2014 · TG salmon oil triglyceride · Healthy adults aged 19–60 years, women and men, without diagnosed illness | 400 mg | 4 weeks | 35 |
| The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes 2017 · vitamin D + omega-3 fatty acids · Patients with gestational diabetes; age and sex not otherwise specified | 2 g | 6 weeks | 35 |
| A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial 2019 · Omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation | 1.4 g | 12 weeks | 35 |
| The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome 2017 · omega-3 fatty acids and vitamin E · Women aged 18–40 years with polycystic ovary syndrome diagnosed according to the Rotterdam criteria | 1 g | 12 weeks | 34 |
| The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · omega-3 fatty acids and vitamin E co-supplementation · Women aged 18–40 years with polycystic ovary syndrome | 1 g | 12 weeks | 34 |
| Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome 2012 · omega-3 fatty acids · Overweight or obese women aged 20–35 years with polycystic ovary syndrome | 1.2 g | 8 weeks | 32 |
| Phytosterols and Omega 3 Supplementation Exert Novel Regulatory Effects on Metabolic and Inflammatory Pathways: A Proteomic Study 2017 · ω3-supplemented milk · Healthy adults aged 25–70 with overweight or grade 1 obesity (BMI 25–35) | 375 mg | 4 weeks | 32 |
| A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes 2016 · omega-3 fatty acids plus vitamin E group · Women with gestational diabetes who were not taking oral hypoglycemic agents | 1 g | 6 weeks | 30 |
| A Randomized Controlled Clinical Trial Investigating the Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Biomarkers of Oxidative Stress, Inflammation and Pregnancy Outcomes in Gestational Diabetes 2017 · omega-3 fatty acids plus vitamin E · Women with gestational diabetes who were not taking oral hypoglycemic agents | 1 g | 6 weeks | 30 |
| The Effects of Omega-3 Fatty Acids Supplementation on Gene Expression Involved in the Insulin and Lipid Signaling Pathway in Patients with Polycystic Ovary Syndrome 2017 · omega-3 fatty acids from flaxseed oil · Women aged 18–40 diagnosed with polycystic ovary syndrome according to the Rotterdam criteria | 2 g | 12 weeks | 30 |
| The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome 2018 · Vitamin D and omega-3 co-supplementation · Women aged 18–40 years with polycystic ovary syndrome (PCOS) | 2 g | 12 weeks | 30 |
| Long-term vitamin D and high-dose n-3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD 2019 · Vitamin D and n-3 fatty acids co-supplementation · Vitamin D-deficient patients with type 2 diabetes and coronary heart disease; age and sex not reported | 2 g | 26 weeks | 30 |
| The effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomised, double-blind, placebo-controlled trial 2020 · n-3 fatty acids from flaxseed oil · Women with gestational diabetes mellitus | 2 g | 6 weeks | 30 |
| Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia 1999 · n-3 fatty acids · Adults with combined (type IIb) hyperlipidaemia who had not responded to a therapeutic diet | 4 g | 12 weeks | 28 |
| Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers 2014 · Lovaza 1/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years | 465 mg | 7 weeks | 28 |
| Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial 2017 · ω-3 supplement group · Children and adolescents aged 7–14 years with mood disorders, including bipolar disorder, major depressive disorder, or dysthymic disorder | 2.4 g | 12 weeks | 28 |
| Metabolic Response to Omega-3 Fatty Acids and Vitamin E Co-Supplementation in Patients with Fibrocystic Breast Disease: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · omega-3 fatty acids plus vitamin E · Patients with fibrocystic breast disease | 1 g | 12 weeks | 28 |
| Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression 2015 · EPA group · Men and postmenopausal women aged 21–70 with mildly elevated plasma Lp-PLA2 | 1.8 g | 6 weeks | 27 |
| Maternal AA/EPA Ratio and Triglycerides as Potential Biomarkers of Patients at Major Risk for Pharmacological Therapy in Gestational Diabetes 2022 · intervention group · Pregnant women aged 18 or older at 24–28 weeks’ gestation with gestational diabetes | 2.4 g | 10 weeks | 26 |
| Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO) 2025 · marine-derived ω-3 · Adults aged 25–59 years with obesity or abdominal obesity, without major health complications | 1.8 g | 8 weeks | 26 |
| Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study 2002 · group 2 (Maxigard group) · Adults with type 2 diabetes and BMI <27 kg/m²; age and sex not specified | 1.2 g | 6 weeks | 25 |
| Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives 2014 · fish oil group (treatment) · Healthy adults aged 30–54 years, employed at least 25 hours per week, with dietary EPA and DHA consumption below 300 mg/day | 1 g | 120 days | 24 |
| Omega-3 Fatty Acid Could Increase One of Myokines in Male Patients with Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · Omega-3 · Men with coronary artery disease and more than 50% stenosis in at least one major coronary vessel | 720 mg | 8 weeks | 24 |
| Cytokine distribution in mothers and breastfed children after omega-3 LCPUFAs supplementation during the last trimester of pregnancy and the lactation period: A randomized, controlled trial 2017 · FO group · Pregnant women recruited at week 28 of pregnancy and followed through lactation | 72 mg | — | 24 |
| Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism 2020 · omega-3 FA group · Men aged 35–55 years with fasting plasma TAG concentrations of at least 1.5 mmol/L; nondiabetic and free from known disease | 1.84 g | 8 weeks | 24 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · flaxseed oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 3.27 g | 6 weeks | 23 |
| Omega-3 fatty acids, inflammatory status and biochemical markers of patients with systemic lupus erythematosus: a pilot study 2017 · omega-3 group · Women with systemic lupus erythematosus (SLE), median age 37 years; low disease activity | 1.28 g | 12 weeks | 22 |
| Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids 2020 · ω3 + L. reuteri · Pregnant women included at gestational week 20, with at least one parent or sibling with allergic disease history or symptoms | 1.28 g | 137 days | 22 |
| Effect of chia seeds or concentrated fish oil on cardiometabolic risk markers in subjects with hypertriglyceridaemia: a parallel clinical trial 2024 · low-calorie diet with concentrated fish oil · Patients with hypertriglyceridaemia; age and sex not specified | 1.8 g | 8 weeks | 22 |
| Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes 2025 · Probiotic-Omega group · Adults aged 18–75 with type 2 diabetes and pancreatic beta-cell dysfunction | 250 mg | 8 weeks | 22 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 2.15 g | 6 weeks | 21 |
| Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study 2017 · intervention group · Adults older than 18 years with chronic Chagas cardiomyopathy, stages B, C or D | 3 g | 8 weeks | 21 |
| Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults 2021 · EPA+DHA Group · Adults aged 50–85 with chronic inflammatory conditions, including nonhealing venous leg ulcers; overweight or obese older adults | 1.5 g | 8 weeks | 21 |
| Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men 2014 · LC n-3 PUFA supplementation · Men aged 24–48 years: 10 normolipidemic and 10 with mild combined hyperlipidemia | 2.52 g | 12 weeks | 20 |
| Effects of administration of omega-3 fatty acids with or without vitamin E supplementation on adiponectin gene expression in PBMCs and serum adiponectin and adipocyte fatty acid-binding protein levels in male patients with CAD 2015 · OE (omega-3 fatty acid & vitamin E) · Adult men with coronary artery disease and more than 50% stenosis | 4 g | 8 weeks | 20 |
| Beneficial effects of omega-3 and vitamin E coadministration on gene expression of SIRT1 and PGC1α and serum antioxidant enzymes in patients with coronary artery disease 2016 · Group 2 (OE) · Male patients with coronary artery disease; age range not reported | 4 g | 60 days | 20 |
| The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2019 · omega-3 fatty acids plus vitamin E · Patients with Parkinson's disease; age range and sex not reported | 1 g | 12 weeks | 20 |
| N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial 2022 · n-3 FA · Caucasian men and women aged 50–79 with combined hyperlipidemia, taking stable atorvastatin | 3 g | 8 weeks | 20 |
| The effect of omega-3 fatty acids supplementation on inflammatory biomarkers in subjects with migraine: a randomized, double-blind, placebo-controlled trial 2023 · omega-3 supplementation group · Patients prone to episodic migraines | 1.8 g | 60 days | 20 |
| Effects of Long Chain Omega-3 Polyunsaturated Fatty Acids on Brain Function in Mildly Hypertensive Older Adults 2018 · LCn-3PUFA group · Adults aged 40–85 with borderline or mild hypertension and low fish/seafood intake | 2 g | 20 weeks | 19 |
| Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study 2023 · high-dose EPA/DHA group · Adults aged 20 years or older receiving hemodialysis and diagnosed with dyslipidemia | 1.86 g | 90 days | 19 |
| Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation 2025 · ω-3VDCa group · Children aged 5–17 years with acute lymphoblastic leukemia in the maintenance phase | 100 mg/kg | 6 weeks | 19 |
| The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man 1997 · highly purified DHA · healthy men | 3.6 g | 7 weeks | 19 |
| Dietary supplementation with fish oil in ulcerative colitis 1992 · fish oil · Adults with active ulcerative colitis | 3.24 g | 120 days | 18 |
| Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial 2012 · oxidised fish oil · Healthy adults aged 18–50 years | 1.6 g | 7 weeks | 18 |
| n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease 2016 · n-3 fatty acids + CoQ · Men and women aged 25–75 years with chronic renal impairment (eGFR >15 and <60 mL/min/1.73 m²) | 4 g | 8 weeks | 18 |
| Dietary supplementation with omega-3 fatty acids and oleate enhances exercise training effects in patients with metabolic syndrome 2016 · Ω-3 + OLE · Patients with metabolic syndrome; age range and sex not reported | 275 mg | 24 weeks | 18 |
| Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial 2012 · fish oil · Healthy adults aged 18–50 years | 1.6 g | 7 weeks | 17 |
| Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach 2014 · FO group · Healthy men and women aged 18–50 years | 700 mg | 7 weeks | 17 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · FO (fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 1.2 g | 12 weeks | 17 |
| Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans 2015 · n-3 (EPA+DHA) · Overweight insulin-resistant, nondiabetic adults; 8 men and 23 women were randomized, ages not stated | 1.5 g | 26 weeks | 16 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · CC-FO (curcumin plus fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 1.2 g | 12 weeks | 16 |
| Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study 2023 · low-dose EPA/DHA group · Adults receiving hemodialysis and diagnosed with dyslipidemia who continued after the initial control period | 930 mg | 90 days | 16 |
| Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes 2000 · Fish oil · Postmenopausal women | 2 g | — | 15 |
| Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate 2001 · fish oil (FO) · Postmenopausal women; ages and health conditions not specified | 2 g | — | 15 |
| Omega-3 fatty acids effect on wound healing 2008 · EPA/DHA supplement group · Healthy men and women aged 18–45 years | 1.6 g | 5 weeks | 15 |
| Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial 2014 · Omega-3 fatty acid capsules · Adults aged 40–60 of both sexes with BMI >25, apparently healthy and overweight | 300 mg | 6 weeks | 15 |
| Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial 2014 · Omega-3 capsule + VSL#3 capsule · Adults aged 40–60 of both sexes with BMI >25, apparently healthy and overweight | 300 mg | 6 weeks | 15 |
| Dietary supplementation with low-dose omega-3 fatty acids reduces salivary tumor necrosis factor-α levels in patients with chronic periodontitis: a randomized controlled clinical study 2017 · test group · Systemically healthy patients with chronic periodontitis; age and sex not reported | 6.25 mg | 26 weeks | 15 |
| Untargeted metabolomic on urine samples after α-lipoic acid and/or eicosapentaenoic acid supplementation in healthy overweight/obese women 2018 · EPA + α-LA · Healthy sedentary overweight/obese women, mean age 37.3 years; following a hypocaloric diet | 1.3 g | 10 weeks | 15 |
| Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study 2018 · fish oil (FO) · Healthy men and women aged 18–45 years with BMI below 30 kg/m² | 550 mg | 1 day | 15 |
| Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study 2018 · curcumin + fish oil (CC-FO) · Healthy men and women aged 18–45 years with BMI below 30 kg/m² | 550 mg | 1 day | 15 |
| Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial 2020 · DHA + EPA · Healthy male amateur endurance athletes aged 18–45 years | 240 mg | 10 weeks | 15 |
| An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia 2004 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age range and sex not reported | 1.88 g | 8 weeks | 14 |
| Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen 2004 · PFA group · Patients with severe IgA nephropathy, including patients with advanced renal disease | 850 mg | 4 years | 14 |
| Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study 2009 · EPA/DHA · Exercise-trained men; ages 25.5 ± 4.8 years; no stated cardiovascular or metabolic disorders | 2.22 g | 6 weeks | 14 |
| Effect of long-chain omega-3 polyunsaturated fatty acids on cardiometabolic factors in children with acute lymphoblastic leukemia undergoing treatment: a secondary analysis of a randomized controlled trial 2023 · ω3-LCPUFAs · Children aged 6.1 ± 2.3 years on average with newly diagnosed acute lymphoblastic leukemia undergoing chemotherapy | 100 mg/kg | 90 days | 14 |
| Omega-3 fatty acid supplementation affects tryptophan metabolism during a 12-week endurance training in amateur runners: a randomized controlled trial 2024 · O-3 + TRAIN · Male amateur endurance runners, mean age 37 years, without chronic disease | 3.16 g | 12 weeks | 14 |
| Functional and metabolic effects of omega-3 polyunsaturated fatty acid supplementation and the role of β-hydroxy-β-methylbutyrate addition in chronic obstructive pulmonary disease: A randomized clinical trial 2024 · EPA/DHA + HMB · Patients with COPD, GOLD stages II–IV; age and sex not stated | 2 g | 10 weeks | 14 |
| Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects 1999 · EPA/DHA diet, elderly subjects · Adults older than 60 years, healthy elderly subjects | 1.05 g | 6 weeks | 13 |
| Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial 2012 · Combination · Adults aged 40–69 with metabolic syndrome | 4 g | 16 weeks | 13 |
| Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial 2012 · EPA group · Adults aged 18–75 years with type 1 or type 2 diabetes mellitus and major depressive disorder | 1 g | 12 weeks | 13 |
| Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial 2020 · n-3 PUFA group · Adults aged 19 years or older, both sexes, with ultrasound-confirmed non-alcoholic fatty liver disease | 306 mg | 26 weeks | 13 |
| Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome 2024 · Combination · Adults aged 40–69 with metabolic syndrome | 4 g | 16 weeks | 13 |
| Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes 2008 · fish oil · Adults with normotriglyceridemic type II diabetes who were not receiving insulin treatment | 5.9 g | 9 weeks | 12 |
| Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study 2014 · EPA group · Adults older than 65 years with mild cognitive impairment | 1.67 g | 26 weeks | 12 |
| Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study 2014 · DHA group · Adults older than 65 years with mild cognitive impairment | 400 mg | 26 weeks | 12 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · High DHA-FO concentrate · Obese men and women with BMI >30 | 400 mg | 12 weeks | 12 |
| The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners 2021 · ω-3 PUFA group · Healthy physically active male recreational marathon runners, with no stated disease; age range not reported | 2.45 g | 3 weeks | 12 |
| Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial 2025 · EPA-rich fish oil · Adults aged 18–65 with non-severe burns covering less than 20% of total body surface area | 2.1 g | 3 weeks | 12 |
| Effect of 21-Day Omega-3 Polyunsaturated Fatty Acid Supplementation on Exercise-Induced Secretory Factors and Inflammation Status in Young Men: A Randomized Double-Blind Trial 2026 · supplementation group · Physically active, healthy men aged approximately 22 years | 3.25 g | 3 weeks | 12 |
| Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids 1999 · Group I · Patients with atherosclerosis; age and sex not reported | 5.1 g | 30 weeks | 11 |
| Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women 2012 · n-3 PUFA-enriched juice · Healthy women; ages not reported | 250 mg | 2 weeks | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 4.4 g | 90 days | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 4.4 g | 90 days | 11 |
| Enrichment of n-3 containing ether phospholipids in plasma after 30 days of krill oil compared with fish oil supplementation 2022 · krill oil group · Healthy women aged 18–45 years | 1.27 g | 30 days | 11 |
| Enrichment of n-3 containing ether phospholipids in plasma after 30 days of krill oil compared with fish oil supplementation 2022 · fish oil group · Healthy women aged 18–45 years | 1.44 g | 30 days | 11 |
| The influence of low intake of n-3 fatty acids on platelets in elderly people 1999 · n-3 PUFA group · healthy elderly people; age range and sex not stated | 600 mg | 6 weeks | 10 |
| n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes 2016 · n-3 PUFA (fish oil) supplementation · Men with type 2 diabetes; mean age 54.7 ± 7.6 years | 3 g | 8 weeks | 10 |
| Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults 2016 · n-3 PUFA group · Healthy men and women aged 60–85 years | 3.36 g | 26 weeks | 10 |
| Impact of Cranberry Juice Enriched with Omega-3 Fatty Acids Adjunct with Nonsurgical Periodontal Treatment on Metabolic Control and Periodontal Status in Type 2 Patients with Diabetes with Periodontal Disease 2018 · cranberry juice enriched with omega-3 (I3) · Adults aged 35–67 years with type 2 diabetes and periodontal disease | 2 g | 8 weeks | 10 |
| Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study 1996 · Fish oil (FO) · Patients with hyperlipidemic non-insulin-dependent diabetes mellitus; age and sex not reported | 4.6 g | 2 weeks | 10 |
| Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study 2010 · omega-3 group (fish oil) · Patients with Alzheimer disease; age and sex not reported | 2.3 g | 26 weeks | 9 |
| Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds 2011 · Active Group (EPA + DHA supplement) · Healthy adults aged 18–45 years, both sexes | 1.6 g | 4 weeks | 9 |
| Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study 1994 · fish oil group · Adults with non-insulin-dependent diabetes mellitus (NIDDM) | 2.5 g | 6 weeks | 9 |
| [Effect of short-term use of omega-3-type polyunsaturated fatty acids in subjects with hypertriglyceridemia] 1992 · fish oil · Patients with hypertriglyceridemia; age and sex not reported | 1.8 g | 12 weeks | 8 |
| Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acids 1992 · n-3 PUFA supplementation · Healthy adults aged 24–37 years, three men and three women | 5.3 g | 43 days | 6 |
| Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients 2005 · EPA group · Patients with chronic hepatitis C receiving interferon alpha-2b and ribavirin; age and sex not reported | 1.8 g | 24 weeks | 5 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · EPA and DHA (3.4 g/day) · Healthy men aged 29–32 years | 1.84 g | 8 weeks | 3 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · 1800 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group | 1.1 g | 150 days | 2 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · 900 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group | 550 mg | 150 days | 1 |
| Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics 1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract | 1.4 g | 12 days | — |
| Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion 1999 · fish oil supplement group · Human volunteers; age, sex, and health status not specified | 3.6 g | 15 days | — |
| Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion 1999 · soy lecithin supplement group · Human volunteers; age, sex, and health status not specified | 500 mg | 15 days | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 2.1 g | 12 weeks | — |
| Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women 2003 · 4:1 · Women; age and health status not further specified | 4 g | 4 weeks | — |
| Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women 2003 · 4:2 · Women; age and health status not further specified | 4 g | 4 weeks | — |
| n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans 2003 · n-3 FA group · Volunteers with serum triglyceride concentrations of 100–300 mg/dL; age and sex not specified | 860 mg | 12 weeks | — |
| Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects 2003 · 10 g PLT 3514 emulsion group · Healthy adults; age range and sex not specified. | 500 mg | 2 weeks | — |
| Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects 2003 · 20 g PLT 3514 emulsion group · Healthy adults; age range and sex not specified. | 1 g | 2 weeks | — |
| Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects 2003 · 100 g PLT 3514 emulsion group · Healthy adults; age range and sex not specified. | 5 g | 2 weeks | — |
| Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial 2003 · 10 g PLT 3514 emulsion · Patients with mild to moderate atopic asthma; age not specified | 500 mg | 4 weeks | — |
| Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial 2003 · 15 g PLT 3514 emulsion · Patients with mild to moderate atopic asthma; age not specified | 750 mg | 4 weeks | — |
| Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study 2004 · n-3 PUFA group · Healthy adult males | 4 g | 8 weeks | — |
| Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins 2006 · 500 mg DHA + 150 mg eicosapentaenoic acid · Healthy pregnant women during the second half of gestation | 150 mg | — | — |
| Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults 2007 · group A (anti-inflammatory blend) · healthy adult volunteers | 169 mg | 2 weeks | — |
| The effect of n - 3 PUFA/gamma-cyclodextrin complex on serum lipids in healthy volunteers--a randomized, placebo-controlled, double-blind trial 2007 · n-3 group · Adults aged 35–66; mostly healthy volunteers, including some with hypertriglyceridemia | 940 mg | 8 weeks | — |
| Influence of a concentrated ethylester compound of n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery 1991 · n-3 fatty acids · Patients eligible for coronary bypass surgery with fasting triglyceride levels of at least 1.6 mmol/L | 3.15 g | 26 weeks | — |
| The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients 2008 · low dose (Trial 1) · Atopic adults with mild-to-moderate asthma | 500 mg | 4 weeks | — |
| The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients 2008 · high dose (Trial 1) · Atopic adults with mild-to-moderate asthma | 750 mg | 4 weeks | — |
| The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women 2008 · Combination of phytosterols and (n-3) LCPUFA · Men and women with hyperlipidemia; age range not reported | 1.4 g | 3 weeks | — |
| Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals 2009 · n-3 PUFA capsules with plant sterols · Hyperlipidemic participants; age and sex not specified | 1.4 g | 3 weeks | — |
| Effect of n-3 oral supplements on the n-6/n-3 ratio in young adults 2010 · experimental group · healthy young adults | 1.6 g | 4 weeks | — |
| Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal ω-3 fatty acid supplementation during pregnancy and lactation 2011 · ω-3 fatty acid supplementation · Pregnant women at risk of having an allergic infant | 1.6 g | — | — |
| Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation 2011 · n-3 PUFA plus antioxidant vitamins · Either-sex patients undergoing on-pump cardiac surgery | 2 g | — | — |
| Effects of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and postexercise 2011 · LCPUFA supplementation alone · Judoists; age and sex not reported; no diagnosed condition stated | 1 g | 6 weeks | — |
| Effect of mixed flavonoids, n-3 fatty acids, and vitamin C on oxidative stress and antioxidant capacity before and after intense cycling 2011 · QFO · Athletes; age and sex not specified | 400 mg | 17 days | — |
| Untitled 2012 · N3 + placebo · Participants with baseline homocysteine >8.0 µmol/L | 3.2 g | 12 weeks | — |
| Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients 2012 · treatment group · Adults aged 45–85 years with type 2 diabetes mellitus for at least two years | 1.89 g | 8 weeks | — |
| Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 2012 · n-3 PUFAs · Patients with combined dyslipidemia; age and sex not specified | 3 g | 26 weeks | — |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 30 mg | 1 year | — |
| Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men 2013 · n-9 (OSO) 8 g/day with n-3 1 g/day · Healthy men; age range not reported. | 1 g | 12 weeks | — |
| Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men 2013 · n-9 (OSO) 8 g/day with n-3 2 g/day · Healthy men; age range not reported. | 2 g | 12 weeks | — |
| Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men 2013 · n-9 (OSO) 8 g/day with n-3 4 g/day · Healthy men; age range not reported. | 4 g | 12 weeks | — |
| A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial) 2013 · OM3-FFA 2 g/d (plus 2 g/d olive oil) · Adults with fasting triglycerides ≥200 mg/dL and <500 mg/dL, treated with a maximally tolerated statin or statin plus ezetimibe, and at high cardiovascular risk | 2 g | 6 weeks | — |
| Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder 2012 · n-3 group · Children aged 6–12 years with ADHD receiving maintenance therapy | 635 mg | 8 weeks | — |
| Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia 2014 · omega-3 fatty acid treatment · HIV-seropositive adults with hypertriglyceridemia (≥150 mg/dl) on active antiretroviral therapy | 3.4 g | — | — |
| Low doses of eicosapentaenoic acid and docosahexaenoic acid from fish oil dose-dependently decrease serum triglyceride concentrations in the presence of plant sterols in hypercholesterolemic men and women 2014 · Intervention spread with 0.9 g/d EPA+DHA · Hypercholesterolemic men and women aged 25–74 years | 900 mg | 4 weeks | — |
| Low doses of eicosapentaenoic acid and docosahexaenoic acid from fish oil dose-dependently decrease serum triglyceride concentrations in the presence of plant sterols in hypercholesterolemic men and women 2014 · Intervention spread with 1.3 g/d EPA+DHA · Hypercholesterolemic men and women aged 25–74 years | 1.3 g | 4 weeks | — |
| Low doses of eicosapentaenoic acid and docosahexaenoic acid from fish oil dose-dependently decrease serum triglyceride concentrations in the presence of plant sterols in hypercholesterolemic men and women 2014 · Intervention spread with 1.8 g/d EPA+DHA · Hypercholesterolemic men and women aged 25–74 years | 1.8 g | 4 weeks | — |
| Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study 2015 · n-3 FA treatment · Patients with Alzheimer's disease | 600 mg | 26 weeks | — |
| The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses 2015 · PS (2.5 g/day) and EPA+DHA (0.9 g/day) spread · Hypercholesterolemic subjects; age and sex not specified | 900 mg | 4 weeks | — |
| The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses 2015 · PS (2.5 g/day) and EPA+DHA (1.3 g/day) spread · Hypercholesterolemic subjects; age and sex not specified | 1.3 g | 4 weeks | — |
| The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses 2015 · PS (2.5 g/day) and EPA+DHA (1.8 g/day) spread · Hypercholesterolemic subjects; age and sex not specified | 1.8 g | 4 weeks | — |
| Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols 2015 · PDL-0101 · Adults with triacylglycerols 150–499 mg/dL and LDL cholesterol ≥70 mg/dL | 1.8 g | 8 weeks | — |
| n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease 2015 · n-3 fatty acids and CoQ · Patients with chronic kidney disease | 4 g | 8 weeks | — |
| The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions 2015 · 1 portion per week · Healthy non-oily-fish-consuming adults; age range and sex distribution not stated | 214 mg | 1 year | — |
| The effect of 12-wk ω-3 fatty acid supplementation on in vivo thalamus glutathione concentration in patients "at risk" for major depression 2015 · ω-3 FA supplements · Older adults at risk for depression; age range and sex not specified | 4 g | 12 weeks | — |
| A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease 2017 · krill oil · People with mild to moderate dry eye disease; age and sex not reported | 945 mg | 90 days | — |
| A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease 2017 · fish oil · People with mild to moderate dry eye disease; age and sex not reported | 1 g | 90 days | — |
| Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: a randomized, double-blind, placebo-controlled trial 2017 · fish oil group · Adults with type 2 diabetes and abdominal obesity; mean age 65.4 years; 35 men and 64 women completed the study | 2.4 g | 26 weeks | — |
| Changes in relative and absolute concentrations of plasma phospholipid fatty acids observed in a randomized trial of Omega-3 fatty acids supplementation in Uganda 2016 · omega-3 supplement · Adult men and women with HIV and HHV8 infection, with or without Kaposi's sarcoma | 3.09 g | 12 weeks | — |
| Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia 2017 · third group (statin + omega-3 PUFA + CoQ10) · People with combined dyslipidemia and elevated TAG levels; age and sex not reported | 2.52 g | 90 days | — |
| The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease 2018 · n-3 FA plus CoQ · Patients with chronic kidney disease (CKD) | 4 g | 8 weeks | — |
| A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study 2018 · Combination of ω-3 fatty acids plus nano-curcumin · Patients with episodic migraine | 2.5 g | 60 days | — |
| Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects 2020 · Saury oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease | 3.4 g | 8 weeks | — |
| Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects 2020 · Control oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease | 3 g | 8 weeks | — |
| Prenatal dietary supplements influence the infant airway microbiota in a randomized factorial clinical trial 2020 · n-3 LCPUFA plus vitamin D · Pregnant women enrolled at pregnancy week 24; age range and health condition not specified | 2.4 g | 17 weeks | — |
| Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial 2020 · FO group · People with non-alcoholic fatty liver disease (NAFLD); age and sex not reported | 1.95 g | — | — |
| Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial 2020 · PS + FO combination group · People with non-alcoholic fatty liver disease (NAFLD); age and sex not reported | 1.95 g | — | — |
| Omega-3 Supplementation Improves Isometric Strength But Not Muscle Anabolic and Catabolic Signaling in Response to Resistance Exercise in Healthy Older Adults 2021 · ω-3 PUFA (ω-3) supplementation condition · Adults aged 65–83 years, both sexes, healthy and nonsarcopenic older adults | 3.06 g | 14 weeks | — |
| The effect of combined supplementation with vitamin D and omega-3 fatty acids on blood glucose and blood lipid levels in patients with gestational diabetes 2021 · test group · Women aged 18–40 with gestational diabetes | 16 g | 6 weeks | — |
| Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial 2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications | 1.1 g | 12 weeks | — |
| Effects of Vitamin D(3) and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial 2022 · Vitamin D3 and marine n-3 fatty acids active group · Men aged 50 years or older and women aged 55 years or older, without a history of cancer (except non-melanoma skin cancer), myocardial infarction, stroke, transient ischemic attack, or coronary revascularization | 1 g | 1935 days | — |
| Effects of Exercise and Omega-3-Supplemented, High-Protein Diet on Inflammatory Markers in Serum, on Gene Expression Levels in PBMC, and after Ex Vivo Whole-Blood LPS Stimulation in Old Adults 2023 · high-protein, omega-3-enriched (protein + omega-3) · Community-dwelling adults aged 65–85 years without the specified malignant or severe chronic diseases, diabetes, dementia, or severe food allergies | 2.2 g | 8 weeks | — |
| The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial 2024 · EPA+DHA supplementation · Adults with coronary artery disease on statin therapy, with and without diabetes | 1.86 g | 913 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 DHA plus EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 650 mg | 5 years | — |
| Vitamin D(3) and marine ω-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial 2025 · Vitamin D3 plus marine n-3 fatty acids · Females aged 55 years or older and males aged 50 years or older; no specific condition stated | 1 g | 5 years | — |
| Normal subjects consuming physiological levels of 18:3(n-3) and 20:5(n-3) from flaxseed or fish oils have characteristic differences in plasma lipid and lipoprotein fatty acid levels 1996 · Fish oil · Normal adults; sex and age not stated; no stated condition | 35 mg | 90 days | — |
| Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans 1997 · Menhaden oil with vitamin E · Healthy men; age not stated | 6.26 g | 6 weeks | — |
| Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial 2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia | 700 mg | 90 days | 105 |
| A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial 2019 · PS plus omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation | 1.4 g | 12 weeks | 41 |
| Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome 2006 · test group · Patients with metabolic syndrome; age and sex not specified | 200 mg | 90 days | 36 |
| Untitled 2013 · high dose fish oil arm · Men and women aged 40–85; overweight or obese, without the listed excluded medical conditions; not selected for a diagnosed disease or nutrient deficiency. | 4.93 g | 120 days | 35 |
| The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial 2019 · Multinutrient supplementation group · Women aged 19–35 with polycystic ovary syndrome (PCOS) | 500 mg | 90 days | 30 |
| Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial 2019 · Nutraceutical A · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded. | 400 mg | 6 weeks | 24 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 167 mg | 4 weeks | 24 |
| Consumption of Hen Eggs Enriched with n-3 Polyunsaturated Fatty Acids, Selenium, Vitamin E and Lutein Incites Anti-Inflammatory Conditions in Young, Healthy Participants - A Randomized Study 2022 · 4Nutri group · Young, healthy participants; age range and sex not stated | 1.03 g | 3 weeks | 20 |
| Effects of baked products enriched with n-3 fatty acids, folates, β-glucans, and tocopherol in patients with mild mixed hyperlipidemia 2012 · active diet · Adults with mild plasma lipid abnormalities (mild mixed hyperlipidemia) | 1.2 g | 30 days | 16 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 300 mg | 4 weeks | 16 |
| The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial 2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program | 3.6 g | 4 weeks | 11 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 1.05 g | — | 10 |
| Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets 2024 · Omega-3 treatment cohort · Healthy adults; age and sex not specified for this cohort | 1.74 g | 7 days | 6 |
| Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects 2009 · seal oil capsules · Hypertriglyceridaemic volunteers recruited from the Wollongong community; age and sex not reported | 2.02 g | 6 weeks | — |
| Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects 2009 · fish oil capsules · Hypertriglyceridaemic volunteers recruited from the Wollongong community; age and sex not reported | 1.05 g | 6 weeks | — |
| Effects of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and postexercise 2011 · LCPUFA plus antioxidant mixture · Judoists; age and sex not reported; no diagnosed condition stated | 1 g | 6 weeks | — |
| Untitled 2012 · MVit + N3 · Participants with baseline homocysteine >8.0 µmol/L | 3.2 g | 12 weeks | — |
| Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial 2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m² | 640 mg | 8 weeks | — |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 180 mg | 4 weeks | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 650 mg | 5 years | — |
| Multimicronutrient and omega-3 fatty acid supplementation reduces low-grade inflammation in older participants: An exploratory study 2025 · multimicronutrient and n-3 PUFA supplementation · Healthy, physically active older adults; mean age 75.6 ± 3.9 years; sex not specified | 1 g | 12 weeks | — |
| Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants 1997 · omega-3 FAs and antioxidants · male smokers with combined hyperlipidemia | 5 g | 6 weeks | — |
| Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers 1998 · n-3 fatty acids with antioxidants · adult male smokers with hyperlipidaemia | 4.8 g | 6 weeks | — |
| The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial 2024 · Group (2) / EP (EPA plus placebo) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women | 1 g | 12 weeks | 25 |
| The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial 2024 · Group (3) / CE (curcumin plus EPA) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women | 1 g | 12 weeks | 25 |
| Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial 2023 · Vitamin D3 plus marine omega-3s · Generally healthy, robust, community-dwelling adults aged 70 years or older | 1 g | 3 years | — |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 225 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 225 mg | 3 years | 399 |
| Effect of the omega-3 fatty acid plus vitamin E supplementation on subjective global assessment score, glucose metabolism, and lipid concentrations in chronic hemodialysis patients 2016 · omega-3 fatty acid + vitamin E placebo · Chronic hemodialysis patients; age and sex not specified | 1.25 g | 12 weeks | 30 |
| Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides 2019 · icosapent ethyl 2 g/day · Adults with stage 3 chronic kidney disease, high triglycerides, and increased cardiovascular risk despite statin treatment | 2 g | 12 weeks | 30 |
| Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study 2021 · Males: EPA + DHA (n-3) · Males with abdominal obesity | 4 g | 7 weeks | 23 |
| Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals 2009 · n-3 PUFA capsules without plant sterols · Hyperlipidemic participants; age and sex not specified | 1.4 g | 3 weeks | — |
| Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome 2015 · IPE 2 grams/day · Patients with metabolic syndrome and high or very high triglyceride levels, with or without stable statin therapy | 2 g | — | — |
| A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease 2016 · n-3 fatty acids and Coenzyme Q10 · Patients with chronic kidney disease; age and sex not specified. | 4 g | 8 weeks | — |
| Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects 2021 · fish oil (2:1 EPA:DHA) · healthy volunteers | 4 g | 30 days | — |
| Omega-3 Supplementation for the Prevention of Cognitive Decline in Older Adults: Does It Depend on Homocysteine Levels? 2022 · Multidomain intervention combined with n-3 PUFA supplementation · Community-dwelling men and women aged 70 years or older without dementia, with spontaneous memory complaints, slow gait speed, or limitations in instrumental activities of daily living | 513 mg | 3 years | — |
| Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial 2024 · omega-3 fatty acid · Men aged 50 years or older and women aged 55 years or older, free of cardiovascular disease and cancer at baseline | 1 g | 1935 days | — |